Exceptionally sweet - Studies on the bacterial arginine rhamnosyltransferase EarP by Krafczyk, Ralph
 
 
Exceptionally sweet -  
Studies on the bacterial arginine 
rhamnosyltransferase EarP 
 
Dissertation 
Zur Erlangung des Doktorgrades 
der Naturwissenschaften 
(Dr. rer. nat.) 
 
der Fakultät für Biologie 
der Ludwig-Maximilians-Universität München 
vorgelegt von 
 
Ralph Krafczyk 
aus Augsburg 
 
München, Oktober 2018 
 
II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gutachter: 
1. Prof. Dr. Kirsten Jung 
2. Prof. Dr. Dario Leister 
 
 
Datum der Abgabe: 31.10.2018 
Datum der mündlichen Prüfung: 18.12.2018  
  
 
III 
 
Eidesstattliche Erklärung 
Ich versichere hiermit an Eides statt, dass die vorgelegte Dissertation von mir selbstständig 
und ohne unerlaubte Hilfe angefertigt wurde. Des Weiteren erkläre ich, dass ich nicht 
anderweitig ohne Erfolg versucht habe, eine Dissertation einzureichen oder mich der 
Doktorprüfung zu unterziehen. Die folgende Dissertation liegt weder ganz, noch in 
wesentlichen Teilen einer anderen Prüfungskommission vor. 
 
Ralph Krafczyk 
München, 31.10.2018  
 
 
Statutory Declaration 
I declare that I have authored this thesis independently, that I have not used other than the 
declared sources/resources. As well I declare, that I have not submitted a dissertation 
without success and not passed the oral exam. The present dissertation (neither the entire 
dissertation nor parts) has not been presented to another examination board. 
 
Ralph Krafczyk 
Munich, 31.10.2018 
  
 
IV 
 
Contents 
Eidesstattliche Erklärung .......................................................................................................III 
Statutory Declaration .............................................................................................................III 
Contents ............................................................................................................................... IV 
Nomenclature ........................................................................................................................ V 
Abbreviations ....................................................................................................................... VI 
Publications and Manuscripts Originating from this Thesis .................................................. VII 
Contributions to Publications and Manuscripts presented in this Thesis ............................. VIII 
Summary ............................................................................................................................ XIII 
Zusammenfassung ............................................................................................................. XIV 
1 Introduction .................................................................................................................... 1 
1.1 Post-translational modification of proteins ............................................................... 1 
1.2 Glycosylation and glycosyltransferases ................................................................... 3 
1.3 Post-translational protein glycosylation .................................................................... 7 
1.4 Arginine glycosylation .............................................................................................10 
2  Resolving the α-glycosidic linkage of arginine-rhamnosylated translation elongation 
factor  P triggers generation of the first ArgRha specific antibody ....................................12 
3 Structural basis for EarP-mediated arginine glycosylation of translation elongation factor 
EF-P ..............................................................................................................................20 
4 Switching the post-translational modification of elongation factor P ...............................41 
5 A versatile toolbox for the control of protein levels using Nε-acetyl-l-lysine dependent 
amber suppression ........................................................................................................61 
6 Concluding discussion ...................................................................................................73 
6.1 EarP is a GT-B fold glycosyltransferase .................................................................74 
6.2 EarP is an inverting glycosyltransferase .................................................................75 
6.3 Rhamnosyl-arginine is a novel bacterial glycoconjugate .........................................78 
6.4 EF-P-EarP interaction is sequence and structure dependent .................................80 
6.5 The role of glycosylation in EF-P evolution .............................................................82 
6.6 EarP-mediated arginine rhamnosylation and its application in synthetic biology .....83 
6.7 Outlook ...................................................................................................................85 
References for Chapters 1 and 6 ..........................................................................................86 
Supplemental information – Chapter 2 .................................................................................94 
Supplemental information – Chapter 3 ............................................................................... 126 
Supplemental information – Chapter 4 ............................................................................... 134 
Supplemental information – Chapter 5 ............................................................................... 158 
Danksagung ....................................................................................................................... 170 
Curriculum Vitae ................................................................................................................. 171 
 
V 
 
Nomenclature  
Gene products are numbered in a way that the first methionine of the wild type protein is 
designated “1” in the amino acid sequence (if present: independently of the N-terminal affinity 
tag). Amino acid identifiers are given in single letter code followed by the position within the 
primary sequence (Example: D13) 
  
 
VI 
 
Abbreviations  
diNAcBac N,N'-Diacetylbacillosamine 
ER 
EM 
Gal 
GalNAc 
Endoplasmic reticulum 
Electron microscopy 
Galactose 
N-Acetylgalactosamin  
Glc 
GlcNAc 
Glucose 
N-Acetylglucosamin  
GT 
LLO 
LPS 
OST 
PTM 
Rha 
Glycosyltransferase 
Lipid-linked oligosaccharide 
Lipopolysaccharide 
Oligosaccharyltransferase 
Post-translational modification 
Rhamnose 
TDP-Rha TDP-β-L-rhamnose 
 
 
 
 
 
 
 
  
 
VII 
 
Publications and Manuscripts Originating from this Thesis 
 
Chapter 2: 
 
Li X*, Krafczyk R*, Macošek J, Li Y-L, Zou Y, Simon B, Pan X, Wu Q-Y, Yan F, Li S, Hennig 
J, Jung K, Lassak J, Hu H-G. 2016. Resolving the α-glycosidic linkage of arginine-
rhamnosylated translation elongation factor P triggers generation of the first ArgRha specific 
antibody. Chem Sci 7:6995-7001. 
 
Chapter 3: 
 
Krafczyk R*, Macošek J*, Jagtap PKA, Gast D, Wunder S, Mitra P, Jha AK, Rohr J, 
Hoffmann-Röder A, Jung K, Hennig J, Lassak J. 2017. Structural basis for earP-mediated 
arginine glycosylation of translation elongation factor EF-P. mBio 8:e01412-01417. 
 
Chapter 4: 
 
Volkwein W*, Krafczyk R*, Jagtap PKA, Parr M, Mankina E, Macošek J, Guo Z, Fürst MJLJ, 
Pfab M, Frishman D, Hennig J, Jung K & Lassak J. 2018. Switching the post-translational 
modification of elongation factor P. Manuscript. 
 
Chapter 5: 
 
Volkwein W, Maier C, Krafczyk R, Jung K, Lassak J. 2017. A versatile toolbox for the control 
of protein levels using Nε-acetyl-l-lysine dependent amber suppression. ACS Synth Biol 
6:1892-1902. 
 
 
 
*Authors contributed equally 
  
 
VIII 
 
Contributions to Publications and Manuscripts presented in this 
Thesis 
Chapter 2: 
 
Xiang Li performed the organic synthesis, analysis of NMR and single crystal structures of 
small molecules, generated the anti-ArgRha antibody and wrote the manuscript. Ralph 
Krafczyk performed the confirmation of antibody specificity, produced proteins for the NMR-
analysis of rhamnosylated EF-P and wrote parts of the manuscript. Jakub Macošek, Bernd 
Simon and Janosch Hennig performed the NMR determination of the anomeric carbon 
configuration of attached rhamnose and wrote parts of the manuscript. Yu-Lei Li assisted in 
the organic synthesis. Yan Zou, Qiu-Ye Wu and Fang Yan assisted in the organic synthesis 
and antibody generation. Xing Pan and Shan Li assisted in the conformation of antibody 
specificity. Jürgen Lassak performed the conformation of antibody specificity, contributed to 
study design and wrote the manuscript. Kirsten Jung and Hong-Gang Hu contributed to study 
design and assisted in modification of the manuscript. 
 
Chapter 3: 
 
Anja Hoffmann-Röder, Swetlana Wunder, and Daniel Gast performed the organic synthesis 
and NMR analysis of small molecules and wrote the corresponding section of Materials and 
Methods. Ralph Krafczyk performed the confirmation of antibody specificity raised against 
the rhamnosyl-arginine-comprising peptide. Additionally, Ralph Krafczyk constructed the 
EarPPpu - and EF-PPpu -encoding plasmids and purified all proteins used for biochemical 
analyses, NMR studies, and X-ray crystallography. Ralph Krafczyk also performed the 
biochemical in vivo/in vitro characterization of EarPPpu and determined concentrations of 
TDP-β-L-rhamnose in E. coli, P. putida, and P. aeruginosa. TDP-β-L-rhamnose was 
synthesized by Jürgen Rohr, Prithiba Mitra and Amit Kumar Jha. Janosch Hennig, Jakub 
Macošek, and Pravin Kumar Ankush Jagtap performed and analyzed all protein NMR 
experiments. The crystallization screen was set up by Jakub Macošek. Janosch Hennig, 
Jakub Macošek, and Pravin Kumar Ankush Jagtap solved the crystal structure of EarPPpu. 
Jürgen Lassak., Janosch Hennig and Kirsten Jung designed the study. The manuscript was 
written by Ralph Krafczyk, Jakub Macošek, Pravin Kumar Ankush Jagtap, Kirsten Jung, 
Janosch Hennig and Jürgen Lassak.  
  
 
IX 
 
Chapter 4: 
 
Dmitrij Frishman, Marina Parr, Elena Mankina and Jürgen Lassak performed bioinformatic 
analyses. NMR studies were performed by Janosch Henning, Pravin Kumar Ankush Jagtap 
and Jakub Macošek. The corresponding proteins were produced and purified by Wolfram 
Volkwein. Miriam Pfab performed isoelectric focusing experiments. Ralph Krafczyk and 
Zhenghuan Guo performed in vitro rhamnosylation assays. All other biochemical and genetic 
analyses of β3Ωβ4 substitution variants of E. coli and P. putida were conducted by Wolfram 
Volkwein and Ralph Krafczyk. Wolfram Volkwein and Maximilian Josef Ludwig Johannes 
Fürst performed the biochemical analysis with EarP from S. oneidensis with contributions 
from Jürgen Lassak. Jürgen Lassak, Janosch Hennig, Kirsten Jung and Dmitrij Frishman 
designed the study. The manuscript was written by Wolfram Volkwein, Ralph Krafczyk, 
Kirsten Jung, Elena Mankina, Pravin Kumar Ankush Jagtap, Janosch Hennig and Jürgen 
Lassak. 
Chapter 5: 
 
The study was designed by Wolfram Volkwein, Kirsten Jung and Jürgen Lassak and directed 
as well as coordinated by Kirsten Jung and Jürgen Lassak. Wolfram Volkwein and Cristopher 
Maier constructed all strains and performed the enzyme assays. Ralph Krafczyk performed 
the parameter optimization for the Lux reporters. All authors contributed to the writing of the 
manuscript. 
 
 
 
We hereby confirm the above statements: 
 
 
 
 
Ralph Krafczyk        Kirsten Jung 
 
 
  
 
X 
 
Chapter 2: 
 
Ralph Krafczyk supplied affinity purified elongation factor P (EF-P) of Shewanella oneidensis 
that was used for NMR analyses. Based on the resulting information that EF-P exhibits an α-
rhamnosyl-arginine linkage, Xiang Li performed organic synthesis of small molecules and 
analysed them by NMR and X-ray crystallography. He then generated mono-rhamnosyl-
arginine containing glycopeptides and used them to raise and purify the anti-ArgRha antibody. 
Ralph Krafczyk confirmed the specificity of this antibody and showed that it is sensitive 
enough to detect the epitope both in purified protein fractions and bacterial culture. Together, 
Xiang Li and Ralph Krafczyk demonstrated the possibility of generating sensitive and specific 
antibodies against mono-rhamnosyl-arginine that can be utilized in biochemical and 
diagnostic applications.  
 
 
We hereby confirm the above statements: 
 
 
 
Ralph Krafczyk        Xiang Li 
 
  
 
XI 
 
Chapter 3: 
 
During the studies on the structural and biochemical characterization of the 
rhamnosyltransferase EarP, Jakub Macošek performed extensive analyses of NMR and 
X-ray crystallography data of elongation factor P and the corresponding glycosyltransferase 
EarP from Pseudomonas putida respectively. The protein components for these experiments 
were supplied by Ralph Krafczyk. This data allowed the characterization of the overall protein 
structure and unveiled both the localization of the donor substrate and the architecture of the 
corresponding binding site. The biochemical analyses performed by Ralph Krafczyk, 
confirmed the structural data, and led to the identification of two amino acids that are likely to 
be involved in catalyzing the transfer reaction. Thus, Jakub Macošek and Ralph Krafczyk 
both contributed significantly to the successful characterization of a novel mechanism for 
arginine linked glycosylation.  
 
 
We hereby confirm the above statements: 
 
 
 
 
Ralph Krafczyk        Jakub Macošek 
 
 
 
 
Janosch Hennig        Jürgen Lassak 
  
 
XII 
 
Chapter 4: 
 
In order to study the possibility of unnatural elongation factor P (EF-P) activation, Ralph 
Krafczyk generated and applied a novel reporter strain for the sensitive in vivo detection of 
protein-protein interactions. This analysis showed that Pseudomonas putida EarP interacts 
both with its cognate EF-P and the sequentially unrelated homologue from Escherichia coli. 
Based on this information, Wolfram Volkwein performed extensive in vivo functionality 
analyses of single substitution variants. These experiments identified several amino acids 
that are crucial for activity of P. putida EF-P and subsequently enabled in vivo 
rhamnosylation - and thus unnatural activation - of E. coli EF-P. Complemented by in vitro 
rhamnosylation assays that were established and performed by Ralph Krafczyk, the minimal 
sequential requirements for modification and activation of elongation factor P by 
rhamnosylation were determined. Together, Wolfram Volkwein and Ralph Krafczyk managed 
to demonstrate, that the post-translational modification of E. coli EF-P can be switched from 
lysylation to rhamnosylation and that this unnatural modification can activate the elongation 
factor.  
 
 
We hereby confirm the above statements: 
 
 
 
 
Ralph Krafczyk        Wolfram Volkwein 
 
 
 
  
 
XIII 
 
Summary 
Bacterial protein glycosylation affects numerous cellular properties, including physiology 
and pathogenicity. The transfer of carbohydrates to a nitrogen atom is known as 
N-glycosylation and almost exclusively occurs on asparagine side chains. In contrast, EarP 
represents a novel type of arginine-modifying glycosyltransferases. This enzyme uses 
TDP-β-L-rhamnose as a donor substrate to activate the specialized translation elongation 
factor P (EF-P) in about 10 % of sequenced bacteria, including the clinically relevant species 
Pseudomonas aeruginosa and Neisseria meningitidis. The post-translational modification of 
EF-P is crucial for bacterial fitness and also constitutes a prerequisite for virulence. As the 
amido group of asparagine and the arginine guanidinium are chemically distinct, the 
activation of the latter might be based on a so far unsolved molecular mechanism. 
Consequently, the structural characterization of EarP and its products is of clinical and 
functional importance.  
In this regard, NMR analyses unambiguously identified the product of the glycosylation 
reaction as α-rhamnosyl-arginine. Thus, EarP inverts the anomeric configuration of 
rhamnose during the reaction. Anomer-specific mono-rhamnosyl-arginine-containing 
peptides were synthetized and used to raise antibodies against the modified side chain. 
These immunoglobulins were characterized with respect to their sensitivity and specificity 
towards the target epitope and used to determine enzyme kinetics of EarP.  
X-ray crystallography identified EarP as a member of the inverting GT-B superfamily and 
revealed the site for donor binding. Bioinformatic and mutant analyses elucidated the 
functional significance of several amino acids in orienting the nucleotide sugar and 
demonstrated the importance of two highly conserved aspartates for catalysis.  
Additionally, NMR titration experiments revealed that EarP mainly binds the N-terminal 
β-barrel domain of its acceptor substrate EF-P. This information was utilized to generate the 
first synthetic target for EarP-mediated protein modification. The structurally but not 
sequentially related EF-P homologue from E. coli is naturally activated by lysylation of a 
lysine side chain. Successive mutation not only allowed modification but also activation of 
E. coli EF-P by the non-cognate and EarP-mediated rhamnosylation.  
This thesis provides new insights into the structure-function relationship of inverting 
arginine glycosylation. Additionally, it lays the groundwork for the application of EarP in 
synthetic biology and clinical research.   
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Zusammenfassung 
Die Glykosylierung bakterieller Proteine beeinflusst zahlreiche zelluläre Eigenschaften wie 
Physiologie und Pathogenität. Die Übertragung von Kohlenhydraten auf ein Stickstoffatom 
wird als N-Glykosylierung bezeichnet und erfolgt fast ausschließlich an Asparagin-
Seitenketten. Im Gegensatz dazu gehört EarP zu einer neuen Klasse von Arginin-
modifizierenden Glykosyltransferasen. In etwa 10 % der sequenzierten Bakterien, 
einschließlich der klinisch relevanten Spezies Pseudomonas aeruginosa und Neisseria 
meningitidis, verwendet dieses Enzym TDP-β-L-rhamnose als Donorsubstrat zur Aktivierung 
des spezialisierten Translationselongationsfaktors P (EF-P). Die post-translationale 
Modifikation von EF-P ist von entscheidender Bedeutung für die bakterielle Fitness und eine 
Voraussetzung für Virulenz. Da die Amidogruppe von Asparagin und die Guanidinogruppe 
von Arginin chemisch unterschiedlich sind, erfolgt die Aktivierung der letzteren durch einen 
bisher unerforschten molekularen Mechanismus. Folglich ist die strukturelle 
Charakterisierung von EarP und seinen Katalyseprodukten sowohl von medizinischer als 
auch funktioneller Bedeutung.  
Mittels NMR wurde zunächst das Produkt der Glykosylierungsreaktion von EarP eindeutig 
als α-Rhamnosyl-Arginin identifiziert. Somit invertiert EarP die anomere Konfiguration von 
Rhamnose während der Reaktion. Anomer-spezifische mono-Rhamnosyl-Arginin 
enthaltende Peptide wurden synthetisiert und zur Generierung von Antikörpern verwendet. 
Diese Immunglobuline wurden hinsichtlich Sensitivität und Spezifität gegenüber dem Epitop 
charakterisiert und zur Bestimmung der Enzymkinetik von EarP verwendet.  
Die Kristallstrukturanalyse von EarP ermöglichte nicht nur eine Zuordnung des Enzyms 
zur Superfamilie der invertierenden GT-B-Glykosyltransferasen, sondern zeigte auch die 
Position der Donorbindestelle auf. Weitere bioinformatische und Mutagenese-basierte 
Studien führten zur Identifizierung von zwei für die Katalyse wichtigen Aspartaten sowie von 
mehreren Aminosäuren, die für die Orientierung des Nukleotidzuckers von Bedeutung sind.  
NMR-Titrationen ergaben, dass EarP hauptsächlich die N-terminale β-Barreldomäne des 
Akzeptorsubstrates EF-P bindet. Diese Information wurde verwendet, um den ersten 
synthetischen Akzeptor für eine EarP-vermittelte Proteinmodifikation zu generieren. Das 
strukturell, aber nicht sequentiell verwandte EF-P-Homolog von E. coli wird natürlicherweise 
durch Lysylierung einer Lysin-Seitenkette aktiviert. Infolge sukzessiver 
Aminsoäureaustausche wurde nicht nur die Modifikation von E. coli EF-P durch eine 
EarP-vermittelte Rhamnosylierung erreicht, sondern auch die Aktivierung dieses 
Elongationsfaktors.  
Diese Arbeit liefert somit neue Erkenntnisse über die Struktur-Funktionsbeziehung der 
invertierenden Arginin-Glykosylierung. Darüber hinaus legt sie den Grundstein für die 
Anwendung von EarP in der Synthetischen Biologie und der klinischen Forschung. 
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1 Introduction 
1.1 Post-translational modification of proteins 
Proteins are the functional units of living systems and exert most of the biological tasks 
in- and outside of the cell. The process of protein biosynthesis follows the transcription of 
genetic information from DNA to mRNA by the RNA polymerase and is carried out at the 
ribosome. The ribosome is a ribozyme that utilizes the sequential information on the mRNA 
to translate it into a chemically distinct chain of molecules - the peptides and proteins. This 
process is consequently referred to as translation. The building blocks used to assemble 
proteins are amino acids (1, 2). The universal genetic code encodes for 20 proteinogenic 
amino acids, therefore generating an immense pool of possible polypeptide combinations. 
However, only a fraction of protein sequences form functional units with specialized 
biological capabilities (3). This might be due to the limited inventory of usable side chains 
provided by the 20 canonical amino acids (4).  
Selenocysteine and pyrrolysine were identified as the 21st and 22nd proteinogenic amino 
acids and allow an increase in proteome complexity (5, 6) (Figure 1). Specialized tRNAs are 
used to incorporate selenocysteine and pyrrolysine into the nascent peptide chain at the stop 
codons UGA and UAG, respectively (7). While this naturally occurring expansion of the 
genetic code does convey specialized function, it occurs only on a selection of species 
specific proteins (7). The pyrrolysine tRNA and the corresponding tRNA synthetase of the 
methanogens Methanosarcina barkeri and Methanosarcina mazei are orthogonal in bacterial 
cells and eukaryotes (8). The heterologous co-expression of these components mediates 
suppression of the amber stop codon UAG and therefore the site-specific, cotranslational 
incorporation of pyrrolysine (9). Over the years, selective engineering of 
tRNA synthetase - tRNA pairs has greatly increased the number of modified amino acids that 
can be integrated using this system (8-11). The resulting unnatural expansion of the genetic 
code has allowed the study of the structural and biochemical implications of various side 
chain modifications (12).  
A naturally occurring and even more extensive increase in the arsenal of functional side 
chains is provided by the process of post-translational modification (13) (Figure 1). As the 
name suggests, this form of protein processing occurs after biosynthesis at the ribosome and 
can be divided into two groups. The hydrolytic cleavage of proteins is often associated with 
protein localization and modulation of enzyme activity without altering the chemical nature of 
amino acid side chains (4). Instead, specific proteases cleave stretches of amino acids that 
are inter alia used as signaling sequences and removed during secretion (7).  
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Figure 1. Overview of natural strategies to increase proteome complexity. Bacteria employ in principle two 
mechanisms to diversify their proteomes. Incorporation of the non-universally conserved amino acids 
selenocysteine (depicted as ‘U’ in orange circle) and pyrrolysine (depicted as ‘O’ in green circle) at the 
stop-codons UGA and UAG by specialized tRNAs represents an expansion of the universal genetic code. 
Post-translational modification of proteins involves, but is not limited to: acetylation (depicted as structural formula 
of C(O)CH3), glycosylation (depicted as stylized hexose with blue filling), phosphorylation (depicted as ‘P’ in 
orange sphere), methylation (depicted as structural formula of CH3) and hydrolytic cleavage (depicted as stylized 
scissors). 
 
Covalent addition of specific groups on the other hand can dramatically alter the chemical 
properties of an amino acid side chain and thus control protein maturation and function (4, 
14-16). Today, about half of all proteins are proven or predicted to receive at least one of the 
more than 200 known covalent post-translational modifications (13, 17-19). This diversity and 
the associated demand for specialized modification systems corroborate the immense 
functional potential that lies within this enzymatic extension of the genetic code (4). Protein 
phosphorylation represents one of the most thoroughly studied naturally occurring 
modifications (20). Since the initial identification of phosphorylated amino acid side chains in 
1906 (21), numerous studies on its biosynthesis and its diverse physiological roles have 
been published (22, 23). The UniProt Knowledgebase contains annotated data on more than 
550,000 non-redundant protein sequences (24). Over 55,000 of these proteins are 
experimentally verified to receive a phosphate modification and more than 80,000 
phosphoproteins are predicted (17, 24) (Figure 2). Next to phosphorylation, glycosylation is 
the second most reported protein modification in this database (~6,800 reports). The number 
of experimentally verified glycoproteins is therefore an order of magnitude below that of 
phosphoproteins. However, almost 100,000 putative targets for protein glycosylation have 
been identified (17) (Figure 2). This discrepancy indicates an immense functional potential 
that remains yet to be uncovered. The post-translational linkage of carbohydrates to proteins 
has already been shown to affect numerous cellular functions (16). The study of glycosylated 
proteins in basic research, disease and glycoengineering is therefore an important focus in 
current glycobiology (15, 25).  
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Figure 2. Number of experimentally and non-experimentally reported post-translational modifications in 
the UniProt Knowledgebase. Presented are the numbers of the top three experimentally verified (grey) and 
non-experimentally predicted (black) post-translational modifications phosphorylation, glycosylation and 
acetylation. Raw data was downloaded from the Proteome-Wide PTM Statistics Curator (17) 
(status October 2018).  
 
1.2 Glycosylation and glycosyltransferases  
Glycosylation describes the enzymatic transfer of a carbohydrate moiety from an activated 
donor to an acceptor substrate (26). This process leads to the formation of a glycoconjugate 
and is carried out by a group of enzymes (EC 2.4) that are referred to as 
glycosyltransferases (GTs) (27). The targets of glycosylation are highly diverse and comprise 
virtually all important biomolecules including not only proteins but also carbohydrates, lipids 
and nucleic acids (28, 29). Glycosylation is a central process in the biosynthesis of the 
bacterial cell wall (30-32) and the formation of structural and storage components such as 
cellulose and glycogen, respectively (33, 34). The glycosylation of viral DNA has been shown 
to be used as a mechanism by which bacteriophages manage to evade the host defence 
(35-37). Apart from that, bacteria use glycosylation to synthesize important secondary 
metabolites such as aminoglycosides and tetracyclines (38). This substrate and product 
diversity is reflected in the multitude of glycosyltransferase sequences (39). In 1998 the 
carbohydrate active enzymes database (CAZy, http://www.cazy.org/) was established by 
Professor Dr. Bernard Henrissat, Professor Dr. Pedro Coutinho and colleagues. Presently, it 
provides genomic, structural and biochemical information on more than 450,000 
glycosyltransferases. According to sequence similarity, these enzymes have been classified 
into 106 families (referred to as GTX, with X indicating the family number) (27, 40, 41).  
In light of this enormous substrate and sequence diversity, the structural diversity of 
glycosyltransferases appears to be surprisingly limited (28). Four different GT folds 
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(GT-A, GT-B, GT-C, and lysozyme-type) have been identified so far (42) (Figure 3). The vast 
majority of structurally characterized glycosyltransferases exhibit either the GT-A or GT-B 
fold (43). Both of these structural families use nucleotide sugars as activated donor 
substrates and are referred to as Leloir-type glycosyltransferases (44).  
A central open twisted β-sheet that is surrounded by several α-helices defines the overall 
structure of the GT-A fold (Figure 3A). A second structural element is formed by a smaller 
β-sheet and completes the active site of these enzymes. Despite being reminiscent of a 
single domain fold, members of the GT-A family exhibit two functional domains (27, 42). The 
N-terminal domain is dedicated with binding of the sugar donor substrate, while the acceptor 
is bound in the C-terminal domain. GT-A glycosyltransferases contain a conserved and 
functionally important DXD motif. This motif has been shown to facilitate the transfer reaction 
by coordinating a divalent cation that in turn neutralizes the developing negative charge on 
the phosphoryl group (39, 45, 46).  
The GT-B fold (Figure 3B) is characterized by two opposing Rossmann domains that are 
connected by a flexible linker (47). The active site is localized within the pronounced 
interdomain cleft. The activated nucleotide sugar donor is oriented within a binding pocket 
formed by the C-terminal domain (28). While this domain is structurally well conserved, the 
acceptor binding N-terminal domain is prone to structural alterations. This diversity reflects 
the potential of GT-B glycosyltransferases to adapt to a multitude of different acceptor 
molecules (26). Although certain recurring peptide motifs have been observed (48), there is 
no evidence for strictly conserved residues that convey general function of GT-B enzymes 
(39). While some members of this structural family do bind divalent cations, these metal ions 
are most likely involved in product release (37, 49). The stabilization of the negative charge 
on the phosphate is instead taken over by positively charged amino acid side chains (42).  
Non-nucleotide sugar utilizing glycosyltransferases (non-Leloir GTs) use lipid-linked donor 
substrates and belong to the less common GT-C and lysozyme-like structural families (50-
52). Enzymes of the GT-C family exhibit both a α-helical transmembrane domain and an 
alternating α/β periplasmic domain. Among the tertiary sequences that have so far been 
determined for this group is the bacterial oligosaccharyltransferase (OST) PglB of 
Campylobacter lari (52) (Figure 3C). Bacterial penicillin binding proteins such as Pbp2 were 
the first to be crystallized and serve as examples for GTs with a lysozyme-like fold (50, 51). 
These membrane associated glycosyltransferases are involved in cell wall biosynthesis and 
often connected to a transpeptidase domain (50, 53) (Figure 3D).  
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Figure 3. Structural overview of described glycosyltransferase folds. Ribbon diagrams of representative 
A) GT-A (green), B) GT-B (cyan), C) GT-C (brown) and D) lysozyme-type (purple) fold glycosyltransferases. The 
bound nucleotide sugars in the GT-A structure of mouse alpha-1,4-N-acetylhexosaminyltransferase (EXTL2) 
(PDB: 1OMZ) and in the GT-B structure of E. coli MurG (PDB: 1NLM) are depicted as sticks (carbon: yellow, 
phosphate: orange, oxygen: red, nitrogen: blue). The GT-C structure of C. lari PglB (3RCE) and the 
lysozyme-type structure of Staphylococcus aureus Pbp2 (PDB: 2OLV) are depicted according to their 
approximate orientation within the cytoplasmic membrane (black lines). 
 
During the glycosyl transfer reaction, the configuration at the anomeric carbon atom of the 
sugar is either retained or inverted (Figure 4A). The specific stereochemical outcome of the 
reaction is a consequence of the structural characteristics of a given GT and can therefore 
be used to classify glycosyltransferases into inverting and retaining enzymes (27). As both 
GT-A and GT-B comprise members employing either of the two reaction mechanisms, these 
structural prerequisites are not limited to either of the folds and the stereochemical outcome 
is not dictated by overall GT fold (27, 42). 
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Figure 4. Overview of mechanisms for retaining and inverting glycosyl transfer reactions. A) Conceptual 
difference between retaining (left) and inverting (right) glycosylation. B) Double displacement mechanism for 
retaining GTs. C) SNi-like mechanism for retaining GTs. D) SN2 mechanism for inverting GTs. E) Twisted amide 
mechanism for catalytic activation of asparagine by inverting GTs. The amino acid backbones of involved 
glycosyltransferases and acceptors are indicated by blue and green dashed lines respectively. In B), C) and D), 
the acceptor substrates are indicated by a red ‘R’. This figure was adapted and extended from Breton et al. (29), 
Lizak et al. (54), and Ardevol et al. (55). 
 
The molecular mechanism of retaining glycosyltransferases has long been and still is a 
matter of debate (56). Early suggestions include a double displacement mechanism 
(Figure 4B) in which a nucleophilic GT side chain (glutamate or aspartate) attacks the 
anomeric carbon, thereby forming a glycosyl-enzyme intermediate. In a second step, the 
nucleophile of the acceptor substrate attacks the now vacant position of the leaving group, 
resulting in retention of the anomeric configuration (57, 58). This mode of transfer requires 
the presence of a properly localized nucleophilic side chain within the active site of the GT. 
Glycosyltransferases lacking a corresponding nucleophile are suggested to employ an 
uncommon SNi (substitution nucleophilic internal)-like mechanism (Figure 4C). Here, the 
nucleophile that is used to activate the acceptor substrate develops upon leaving group 
departure and formation of the phosphate ion (59, 60). As both the double displacement and 
the SNi-like carbohydrate transfer involve the formation of an oxocarbenium ion-like transition 
state, they can be considered as variants of a mechanistically similar reaction. The molecular 
differences most likely reflect the necessity to account for specific properties of the donor and 
acceptor substrates of a given retaining glycosyltransferase (55).  
Inversion of the anomeric configuration during the transfer reaction is accomplished by a 
SN2 (substitution nucleophilic bimolecular)-like reaction mechanism in which an acceptor 
nucleophile attacks the anomeric carbon of the donor substrate (Figure 4D) (29, 42). In 
general, the negatively charged side chain of a GT aspartate or glutamate is suggested to 
act as base catalyst that partially deprotonates the acceptor to increase its nucleophilicity 
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(42). By simultaneously promoting leaving group departure, either mediated by coordinated 
metal ions or positively charged amino acid side chains, inverting glycosyltransferases 
catalyse the nucleophilic attack of the acceptor onto the donor substrate and thus the direct 
displacement reaction (26, 42). Beside this general mechanism for inverting glycosyl transfer, 
alternative pathways have been described. The fucosyltransferase POFUT1 does not 
possess a suitable negatively charged amino acid for activation of the nucleophile in the 
reaction centre and was thus proposed to utilize an unusual SN1 (substitution nuclear 
monomolecular)-like reaction mechanism instead (61).  
Due to the poor nucleophilicity and the partial double bond character of the asparagine 
amido group, it was long unclear how this amino acid might be activated for a nucleophilic 
attack (4, 62). The landmark structure of the OST PglB from C. lari was the first to provide 
insight into the catalysis of inverting N-glycosylation of asparagine (52) (Figure 4E). 
A negatively charged dyad - namely glutamate 319 and aspartate 56 - of PglB forms 
hydrogen bond interactions with the amido group of the acceptor. These interactions induce 
rotation of the N-C bond and abolish conjugation of the π-electrons which thereby facilitating 
the nucleophilic attack onto the anomeric carbon (52, 54). In 2018, the structure of the 
catalytic STT3 subunit of the Saccharomyces cerevisiae OST complex was determined by 
cryo-electron microscopy analysis. This data suggests that PglB and STT3 employ a 
common molecular mechanism for activation of their acceptor substrates (63). 
1.3 Post-translational protein glycosylation 
Glycosylation of proteins represents one of the most diverse forms of post-translational 
modification (64). The most common target sites of protein glycosyltransferases are the 
hydroxyl groups of serine and threonine (O-glycosylation) as well as the amido group of 
asparagine (N-glycosylation) (65). In eukaryotes, the modification state of a newly 
N-glycosylated protein is essential to determine how it will be processed in the endoplasmic 
reticulum (ER) (66). During transfer of peptides into the ER lumen, a generic polysaccharide 
(Man5GlcNAc2) is transferred en bloc from a dolichol-linker to the accepting asparagine 
amido group by an oligosaccharyltransferase (67). The glycan-binding (lectin-)chaperones 
calnexin and calreticulin are part of the ER quality control system and retain these N-linked 
glycoproteins in the folding environment until they have attained their native conformation or 
misfolded proteins have been marked for degradation (67, 68). Due to its highly hydrophilic 
nature, the generic glycan intrinsically assists in folding of some glycoproteins (67, 69, 70). 
Correctly folded proteins are further processed in the ER and more importantly in the Golgi 
apparatus (71). The immense diversity of N-glycan structures that are obtained after these 
processing steps make them ideal components to play a role in multiple molecular interaction 
and recognition pathways (72).  
 
8 
 
Along the same line, O-glycosylation in the ER and Golgi apparatus produces a plethora 
of differently decorated peptides including cell-surface proteins. The resulting glycans are 
involved in various different recognition events and targeting to specific subcellular locations 
(73, 74). The modifications are sequentially assembled by soluble glycosyltransferases 
utilizing activated nucleotide sugar donor substrates (61, 75). Considering the multitude of 
biological processes in which glycans are involved, it is no surprise that aberrant modification 
patterns lead to formation of diseased states (76-78). 
While protein glycosylation has been recognized as an important molecular principle in 
eukaryotes for 80 years, it has long been thought to be restricted to this domain of life (79, 
80). The first O-linked bacterial glycoprotein was described in 1975 almost 40 years after the 
process of protein glycosylation had first been reported (79, 81, 82). Today, two pathways for 
bacterial O-glycosylation are known (80). The first way of biosynthesis has been identified 
both in Gram-positive and Gram-negative bacteria and follows the same principles that were 
described for eukaryotic O-glycosylation. Accordingly, soluble cytoplasmic 
glycosyltransferases utilize nucleotide sugar donor substrates to sequentially mono- or 
polyglycosylate their corresponding protein targets. This pathway is, for instance, important 
during assembly and stabilization of bacterial flagella (83, 84).  
A functionally unrelated pathway for O-glycosylation was identified in Gram-negative 
bacteria, where a periplasmic OST modifies its target proteins using a preassembled 
undecaprenyl sugar donor (85). The abundant protein pilin was the first identified target of 
this modification system that has since been shown to exhibit relaxed acceptor substrate 
specificity (86-89).  
Another 20 years after it had been established that O-glycosylation is a common theme in 
prokaryotic cells, the first pathway for bacterial N-glycosylation was discovered in the 
Gram-negative ε-proteobacterium Campylobacter jejuni (90-92) (Figure 5A). Analogously to 
eukaryotic nitrogen-linked carbohydrate transfer, a preassembled lipid-linked oligosaccharide 
(LLO) is used as donor substrate for this reaction. An undecaprenyl phosphate lipid carrier is 
initially glycosylated by PglC and the heptasaccharide (GalNAc2[Glc]GalNAc3-diNAcBac) is 
subsequently elongated by the concerted action of PglA, PglJ and PglH (93-96). The 
maturated LLO is translocated across the cytoplasmic membrane by the ATP-dependent 
flippase PglK (97, 98). PglB is structurally similar to the STT3 subunit of the eukaryotic OST 
complex and mediates the en bloc transfer of the heptasaccharide onto more than 60 
different protein targets (99, 100). The targeting sequence of PglB has been identified to be 
D/E-X1-N-X2-S/T (where X represents any amino acid except proline (101)) and thus 
constitutes an extended version of the eukaryotic OST sequon N-X-S/T (102, 103). 
Alternatively, the Haemophilus influenzae high-molecular-weight adhesin (HMW1) has 
been shown to be sequentially N-glycosylated in the cytoplasm by the corresponding 
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glycosyltransferase HMW1C (104) (Figure 5B). This mode of action resembles the pathway 
of O-glycosylation in the Golgi apparatus and represents an atypical mechanism of N-linked 
glycosylation. HMW1C is capable of mono- and diglycosylating HMW1 at 31 distinct sites, 
with the latter requiring initial modification with glucose (105). The modified adhesin is 
subsequently shuttled into the periplasm via the general secretory (Sec) pathway (106, 107). 
Only upon modification is the glycoprotein HMW1 capable of resisting degradation and 
maintaining interaction with the outer membrane translocator HMW1B that anchors the 
glycoprotein on the cell surface (105).  
 
 
Figure 5. Overview of bacterial pathways for N-glycosylation of asparagine and arginine. A) Block transfer 
of the heptasaccharide (GalNAc2[Glc]GalNAc3-diNAcBac) from undecaprenyl pyrophosphate to the target sequon 
(D/E)X1NX2(S/T) in C. lari. Undecaprenyl phosphate [1] (depicted as black zigzag line and orange sphere) is 
initially glycosylated with diNAcBac by PglC. The resulting glycolipid [2] is successively elongated by PglA, PglJ 
and PglH. The lipid-linked oligosaccharide [3] is translocated across the cytoplasmic membrane by PglK and 
subsequently used as donor substrate by the membrane bound OST PglB (yellow) that mediates the transfer to 
the acceptor asparagine. B) Sequential transfer of monosaccharide moieties in H. influenzae. The high molecular 
weight adhesin glycosyltransferase (HMW1C, yellow) utilizes the nucleotide sugar donors UDP-glucose and 
UDP-galactose to modify its target protein at 31 distinct positions. 30 of these modification sites exhibit the 
eukaryote-like NX(S/T) sequon. The modified glycoprotein is subsequently translocated into the periplasm by the 
Sec (red) secretory pathway. From there it is excreted and concomitantly tethered to the outer membrane by 
HMW1B. C) Activation of elongation factor P in Pseudomonas aeruginosa. The EF-P arginine specific 
rhamnosyltransferase EarP (yellow) uses the nucleotide sugar TDP-β-L-rhamnose to modify EF-P at a highly 
conserved arginine (R) in an unstructured acceptor loop region. This covalent carbohydrate linkage activates the 
elongation factor, which in turn facilitates translation of polyproline containing peptides at the ribosome. This is so 
far the only known bacterial pathway that involves glycosylation of arginine in the cytosol and is not associated 
with glycoprotein translocation. This figure was adapted and extended from Nothaft and Szymanski (80). 
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As many bacterial glycoconjugates are secreted or presented on the cell surface, it might 
appear that the major role of prokaryotic glycosylation is in mediating pathogenicity (108, 
109). Indeed, several virulence associated glycans have been identified so far. For instance, 
glycosylated bacterial adhesins are known to facilitate pathogenicity by targeting the surface 
of host epithelial cells (110) and the glycosylation of flagella has been shown to be important 
for motility and host colonization in Helicobacter pylori and other pathogenic bacteria (80). 
Interestingly though, both commensal and non-virulent bacteria have been found to encode 
for the same systems as their pathogenic relatives (71). As protein glycosylation modulates a 
multitude of peptide properties including solubility, subcellular localization, antigenicity and 
activity it seems likely that the purpose of bacterial protein glycosylation goes beyond the 
mediation of virulence and is yet to be fully understood (71, 100).  
1.4 Arginine glycosylation 
An additional level of proteome complexity emerged with the discovery that arginine might 
be an additional target for protein N-glycosylation. The amylogenin of sweet corn was the 
first enzyme suggested to perform autoglucosylation on arginine. While this modification 
appears to stabilize the protein, the exact function of the glucose addition remains elusive 
(111). A similar mechanism of self-glucosylation and concomitant protein activation was 
described for the UDP-arabinopyranose mutase of rice (112). While both of these studies 
managed to determine arginine as the accepting amino acid of the glycosyl transfer reaction, 
the underlying catalytic mechanism remains unclear.  
In 2013 two groups independently reported the first enzyme directly involved in 
N-glycosylation of arginine (113, 114). The effector glycosyltransferase NleB1 is a 
pathogenicity factor of enteropathogenic E. coli and injected into the host via type III 
secretion. After translocation, this enzyme blocks death receptor signaling by inactivating 
several downstream targets of the tumor necrosis factor receptor (TNFR). Specifically, the 
addition of GlcNAc to a conserved arginine inactivates the TNFR1-associated death domain 
protein (TRADD) (113, 114). Structural analysis of the NleB1 orthologue SseK3 from 
Salmonella enterica, revealed that the glycosyltransferase exhibits a GT-A fold and contains 
a conserved DXD motif for binding of divalent cations (115). SseK3 hydrolyzes the nucleotide 
sugar donor in absence of the acceptor substrate (115). While analysis of the resulting sugar 
product suggests a retaining mode of glycosyl transfer, this finding is still a matter of debate 
as structural data on the modified acceptor is missing. 
In 2015, another case of arginine glycosylation was initially reported in the facultative 
γ-proteobacterium Shewanella oneidensis (116) and subsequently confirmed in 
Pseudomonas aeruginosa (117). The specialized translation elongation factor P (EF-P) is a 
universal bacterial orthologue of the eukaryotic and archaeal initiation factor 5 (e/aIF5A) and 
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involved in the rescue of polyproline stalled ribosomes (118-120). In about 25 % of 
sequenced bacteria, including E. coli, EF-P (lysine-type) is modified by β-lysylation of a 
conserved lysine via the EF-P-lysine lysyltransferase EpmA (119, 121-123). Conversely, 
γ-proteobacteria and 10 % of sequenced bacteria in total encode for an EF-P isoform 
(arginine-type) that harbors an invariant arginine at the position corresponding to the 
modification site (116). Mass-spectrometry and mutational analysis revealed that a 
deoxyhexose moiety is covalently linked to this amino acid side chain. The presence of this 
modification is dependent on a domain of unknown function that is genetically coupled with 
efp and has hence been renamed to EF-P arginine 32 rhamnosyltransferase essential for 
post-translational activation (EarP). Additional mutational analyses identified 
TDP-β-L-rhamnose (TDP-Rha) as the activated donor substrate for this reaction. In vitro 
experiments with purified protein variants and biochemically synthesized TDP-Rha 
unambiguously demonstrated that EarP is a glycosyltransferase that mono-rhamnosylates its 
protein acceptor EF-P (116).  
This modification shows marked differences to previously described mechanisms of 
N-glycosylation (52, 116, 124) (Figure 5). Considering the cellular localization and the 
molecular players involved (direct transfer of single sugar moieties onto the acceptor from an 
activated nucleotide sugar donor), the mode of action is in principle reminiscent of the 
HMW1C pathway (80, 105, 124) (Figure 5B). However, the product of the rhamnosylation 
reaction, EF-P, is not exported from the cytoplasm after modification but instead activated for 
function within the bacterial cell (116) (Figure 5C). Thus the elongation factor is to-date the 
only known example of a bacterial cytoplasmic glycoprotein. Additionally, the modification of 
arginine by a dedicated glycosyltransferase represents a new principle for N-linked 
glycosylation that is so far poorly understood both from a functional and a structural point of 
view. As the arginine guanidinium group is chemically distinct from the asparagine amido 
group, a so far unknown mode of acceptor activation might be involved in this reaction (116, 
125). Additionally, deletion of earP abolishes pathogenicity in P. aeruginosa, indicating that 
the glycosyltransferase could also be an effective target for antibiotics (116). Taken together, 
EarP is of both mechanistic novelty and clinical significance. The aim of the present thesis is 
therefore the structural and functional characterization of this rhamnosyltransferase. 
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Resolving the a-glycosidic linkage of arginine-
rhamnosylated translation elongation factor P
triggers generation of the first ArgRha specific
antibody†
Xiang Li,‡a Ralph Krafczyk,‡bc Jakub Macošek,d Yu-Lei Li,ae Yan Zou,a Bernd Simon,d
Xing Pan,f Qiu-Ye Wu,a Fang Yan,e Shan Li,f Janosch Hennig,d Kirsten Jung,bc
Jürgen Lassak*bc and Hong-Gang Hu*a
A previously discovered posttranslational modification strategy – arginine rhamnosylation – is essential for
elongation factor P (EF-P) dependent rescue of polyproline stalled ribosomes in clinically relevant species
such as Pseudomonas aeruginosa and Neisseria meningitidis. However, almost nothing is known about this
new type of N-linked glycosylation. In the present study we used NMR spectroscopy to show for the first
time that the a anomer of rhamnose is attached to Arg32 of EF-P, demonstrating that the corresponding
glycosyltransferase EarP inverts the sugar of its cognate substrate dTDP-b-L-rhamnose. Based on this
finding we describe the synthesis of an a-rhamnosylated arginine containing peptide antigen in order to
raise the first anti-rhamnosyl arginine specific antibody (anti-ArgRha). Using ELISA and Western Blot
analyses we demonstrated both its high affinity and specificity without any cross-reactivity to other
N-glycosylated proteins. Having the anti-ArgRha at hand we were able to visualize endogenously
produced rhamnosylated EF-P. Thus, we expect the antibody to be not only important to monitor EF-P
rhamnosylation in diverse bacteria but also to identify further rhamnosyl arginine containing proteins. As
EF-P rhamnosylation is essential for pathogenicity, our antibody might also be a powerful tool in drug
discovery.
Introduction
Glycosylation is one of the most important posttranslational
modications (PTMs) of proteins in biological systems1,2 and is
associated with numerous biological processes including viral
and bacterial infection, cancer metastasis, inammatory
response, innate and adaptive immunity, as well as many
signaling pathways.3,4 For a long time, protein glycosylation was
considered to be restricted to eukaryotes. Today it is well
accepted that also bacteria including important human patho-
gens contain a large number of O- and N-linked glycoproteins.5,6
However until 2013 only one case of a sugar being added to
arginine was reported.7 At that time, two research groups
discovered independently that the type III secretion system
effector NleB, of enteropathogenic Escherichia coli (EPEC) acts
as arginine-N-acetylglucosamine (ArgGlcNAc) transferase on
human death receptor domains, thereby interfering with the
host defense.8,9 We elucidated that another type of arginine
glycosylation plays an important role in the activation of the
specialized translation elongation factor EF-P, which alleviates
ribosome stalling at polyproline sequences (Fig. 1).10–13
For effective ribosome rescue certain bacteria, including not
only the versatile g-proteobacterium Shewanella oneidensis MR-
1 but also the important human pathogens Pseudomonas aeru-
ginosa and Neisseria meningitidis, post-translationally rhamno-
sylate a conserved Arg32.14–16 When EF-P is bound to the
ribosome the rhamnosylated arginine protrudes towards the
peptidyltransferase center thereby contributing to the favorable
positioning of the peptidyl-Pro-tRNA and stabilization of the
CCA-end of the prolyl-tRNA.14,17,18 Loss of the rhamnose modi-
cation abolishes the pathogenicity of P. aeruginosa14 and
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increases its susceptibility to certain antibiotics.15 Thus inhi-
bition of EF-P rhamnosylation might be a novel strategy to
selectively suppress virulence. However, little is known about
the corresponding glycosyltransferase EarP or arginine rham-
nosylation itself. Here we used NMR spectroscopy and found
the rhamnosyl moiety on the protein acceptor EF-P in the
a-conguration, unambiguously demonstrating that EarP is an
inverting glycosyltransferase. Based on this result, we report the
generation of the rst high-affinity anti-ArgRha-specic antibody
that allowed us to detect rhamnosylated EF-P even from crude
cell lysates. With this molecular tool in hand, we will not only be
able to improve our understanding of EarP mediated EF-P
rhamnosylation, but the antibody might also help to develop
new potent targeted antibiotics and to unveil other arginine
rhamnosylated proteins.
Results and discussion
EarP mediates an inverting glycosyl transfer reaction
Previously we and others demonstrated that mono-rhamnosy-
lated EF-P-Arg32 in the EarP-arginine phylogenetic subfamily is
essential to efficiently alleviate ribosome stalling at polyproline
stretches.14–16 However, nothing is known about the anomeric
conguration of the attached sugar. Knowledge about steric
conguration is important to understand how the modication
contributes to the stabilization of the CCA-end of the P-site
prolyl-tRNA and to classify EarP either as a retaining or invert-
ing glycosyltransferase.19,20 Notably, the activated sugar
substrate is dTDP-b-L-rhamnose. In order to determine the
conguration aer glycosylation, we employed 13C-edited
NOESY-HSQC to assign the sugar resonances (Fig. 2a and b).
1JCH couplings can inform about the conguration of the
anomeric carbon. An equatorial position of H10 (a-anomer)
would result in a coupling of around 170 Hz, whereas #160 Hz
would indicate an axial position (b-anomer).21,22 An unde-
coupled 13C-HSQC gave rise to a coupling of 167 Hz, clearly
indicating an a-conguration on the protein acceptor EF-P
(Fig. 2c and d). This was conrmed by the absence of an
observable NOE between H10 and H50 (Fig. 2b). If H10 was in the
axial position a strong NOE should be visible. The change of
conguration at the anomeric center from dTDP-b-L-rhamnose
to Arg-a-L-rhamnose during the glycosylation reaction identies
EarP to be an inverting glycosyltransferase.
Synthesis of the a-rhamnosylated arginine containing hapten
Having solved the conguration of the rhamnose moiety
attached to EF-P-Arg32 we were encouraged to raise specic
antibodies against the modication employing an a-rhamno-
sylated arginine containing peptide, for immunization (Fig. 3a).
Such a modication-specic antibody would be a useful tool to
investigate EarP mediated rhamnosylation in vivo and in vitro
but might also help in the identication of further arginine
rhamnosylated proteins from diverse organisms.
Based on previous work,23,24 we chose a strategy for glyco-
peptide synthesis that involves direct silver-promoted glycosyl-
ation between an S-alkyl-isothiourea and the amine of the
amino acid side chain on the solid phase. First, we synthesized
the key building block, N-glycosyl-S-alkyl-isothiourea 6, starting
from L-rhamnose 2 (Fig. 3b): glycosyl chloride 3 in the desired
conguration was obtained using well established procedures
(85% yield).25,26 Subsequently, 3 was treated with potassium
thiocyanate (KSCN) and tetrabutylammonium hydrogen iodide
(TBAI) in anhydrous acetonitrile to get glycosyl isothiocyanate 4
(70% yield).27 Next, glycosyl thiourea 5 was prepared via
ammoniation of 4 in tetrahydrofuran (99% yield).28 Finally,
a two-step, one-pot procedure converted 5 into 6 in the presence
of ethyl iodide and tert-butoxycarbonyl anhydride (75% yield).29
Taken together from 2 to 6 we ended up with an efficiency of
about 44%. The conguration of the attached rhamnose in the
hapten depends on the stereochemistry of the key intermediate
compounds 5 or 6. NMR-HSQC showed that the 1JCH coupling
underwent a change from 174 Hz to 154 Hz (Fig. 3c) when
compound 4 was converted into 5. Thus we determined the
anomeric carbon conguration of compound 5. A single crystal
was obtained via slow evaporation of a dichloromethane/n-
hexane solution at room temperature (Fig. 3d). With this (N-
(2,3,4-tri-O-acetyl-6-deoxy-a-L-manno-pyranos-1-yl)thiourea) in
hand, we could show unambiguously that the rhamnose moiety
is attached in an a conguration, being consistent with rham-
nosylated EF-P. All of the intermediates were fully characterized
using 1H-NMR, 13C-NMR, and HR-Q-TOF-MS (Fig. 3c and ESI†).
To synthesize the hapten glycopeptide 1 with the rhamnose
moiety in the a-conguration from building block 6, we chose
an on-resin glycosylation strategy (Fig. 3e): to obtain the linear
peptide we used 9-uorenylmethyloxycarbonyl (Fmoc) SPPS
standard procedures with Fmoc-Orn(Alloc)-OH as the precursor
for the ArgRha residue. A 2-chlorotrityl resin acted as the solid
support. Subsequent to the peptide assembly, the Alloc group
was removed in the presence of tetrakis(triphenylphosphine)
palladium (0) to get compound 7 on-resin.30–34 Then the on-resin
glycopeptide 8 was synthesized with a silver-promoted solid-
phase glycosylation between the free amino group of 7 and the
key building block 6. Next, the rhamnose moiety was
Fig. 1 EF-P arginine rhamnosylation and mode of action. Certain
bacteria including P. aeruginosa, S. oneidensis, and N. meningitidis
encode an EF-P variant with an invariant arginine at position 32. The
glycosyltransferase EarP activates EF-P by rhamnosylation of Arg32
using dTDP-b-L-rhamnose as substrate. EF-P and its rhamnose
modification stimulate proline–proline peptide bond formation
thereby alleviating ribosome stalling at polyproline stretches. EF-P ¼
translation elongation factor P; EarP ¼ EF-P specific arginine rham-
nosyl transferase for posttranslational activation.
6996 | Chem. Sci., 2016, 7, 6995–7001 This journal is © The Royal Society of Chemistry 2016
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deacetylated with 5% NH2NH2 in dimethylformamide (DMF).
35
Subsequently the resin was treated with 5% triisopropylsilane
(TIPS) in triuoroacetic acid (TFA) to release the glycopeptide 1
which was further puried via preparative reverse-phase HPLC.
We calculated from resin loading that the total yield of isolated 1
was 28%, manifesting a good efficiency for the on-resin glyco-
sylation process.36–38 All of the key intermediates were monitored
using analytical HPLC and characterized using HR-Q-TOF-MS
(Fig. S1†). The nal peptide – Cys–Gly–Arg(Rha)–Gly–Leu – was
characterized using 1D-NMR, 2D-NMR, and HR-Q-TOF-MS.
Generation and purication of a rhamnosyl arginine specic
primary antibody
To raise the high affinity ArgRha specic antibody (anti-ArgRha),
the hapten was conjugated to BSA as carrier protein via the free
N-terminal sulydryl group distal from the arginine rhamnosyl
side chain (Fig. 3a). The resulting BSA-glycoconjugate was
injected into rabbits to raise polyclonal antibodies targeting the
ArgRha moiety.39,40 Aer the third immunization, the crude anti-
sera were collected and their specicity was monitored by
employing an enzyme-linked immunosorbent assay (ELISA)
analysis with horseradish peroxidase linked anti-rabbit IgG. The
antibodies from two batches of crude anti-sera from two immu-
nized rabbits were found to bind robustly and specically to the
BSA-glycoconjugate with high titers, showing strong immune
reactivity even aer 128 000 fold dilution (Fig. 3f and S3†).
To purify anti-ArgRha from the crude rabbit anti sera, in a rst
step we used a Protein A Sepharose 4 column (Amersham
Biosciences). In a second purication step two agarose columns
coupled with BSA or BSA carrying the non-glycosylated “naked”
pentapeptide (H-CGRGL-OH) were used to exclude cross-reac-
tivity. Taken together, these two steps resulted in a 95% pure
anti-ArgRha antibody (Fig. S4 and S5†) showing a signicantly
improved specicity against the glycoconjugated BSA compared
to the crude anti-sera (Fig. 3g and S6†).
anti-ArgRha allows sensitive and specic detection of
endogenous EF-PRha
Having the anti-ArgRha at hand, we tested whether we can detect
the EF-P rhamnose modication. Therefore we used 0.5 mg of
Fig. 2 Determination of the EarP rhamnosylation mechanism via NMR. (a) Zoomed in view of the sugar resonance region of the 13C-HSQC of
rhamnosylated EF-P. The assignment is based on a 13C-edited NOESY-HSQC (exemplary strips are shown in panel b). Unassigned peaks at
around 70 ppm and 18 ppm are the resonances of EF-P's threonine Hb/Cb and methyl groups, respectively. (b) Strips of the
13C-edited NOESY-
HSQC to illustrate the lack of an observable NOE between H10 and H50 (green rectangle), which confirms that the rhamnose adopts an a-
configuration, when bound to EF-P. (c) H10–C10 resonance of EF-P rhamnose from an undecoupled 13C-HSQC to derive the 1JCH coupling. The
resulting coupling of 167 Hz indicates an a-configuration of the sugar.21,22 (d) Stick representations of a-L-, and b-L-rhamnose.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 6995–7001 | 6997
Edge Article Chemical Science
O
p
en
 A
cc
es
s 
A
rt
ic
le
. 
P
u
b
li
sh
ed
 o
n
 2
1
 J
u
ly
 2
0
1
6
. 
D
o
w
n
lo
ad
ed
 o
n
 1
0
/2
8
/2
0
1
8
 6
:5
6
:5
9
 P
M
. 
 T
h
is
 a
rt
ic
le
 i
s 
li
ce
n
se
d
 u
n
d
er
 a
 C
re
at
iv
e 
C
o
m
m
o
n
s 
A
tt
ri
b
u
ti
o
n
 3
.0
 U
n
p
o
rt
ed
 L
ic
en
ce
.
View Article Online
puried EF-P which was modied in vivo (EF-PRha) employing
the enzymatic activity of EarP. Unmodied EF-P served as
a negative control. As expected, an EF-P specic antibody (anti-
EF-P) detected both protein variants with no difference in signal
intensity. By contrast anti-ArgRha specically targeted only the
EF-P ArgRha modication and no signal occurred in the lane
with unmodied EF-P (Fig. 4a). The amino acid context of the
arginine rhamnosylation site in EF-P is Ser30–Gly31–Arg32(Rha)–
Asn33–Ala34 and thus signicantly differs from the peptide Cys–
Gly–Arg(Rha)–Gly–Leu, previously used to raise anti-ArgRha.
Thus, we conclude that our antibody recognizes ArgRha irre-
spective of the adjacent amino acid residues.
Next we assessed the detection limits of anti-ArgRha by using
varying concentrations of either EF-PRha or anti-ArgRha (Fig. 4b
and c). When keeping the EF-PRha concentration constant at
25 mg ml1 (1.25 mM), the signal intensity progressively
decreased starting from 2 mg ml1 anti-ArgRha until no further
detection was possible at an antibody concentration of 0.04 mg
ml1. When keeping the anti-ArgRha concentration constant at
2 mg ml1, 15 ng of EF-PRha were efficiently detected.
To further prove the specicity against ArgRha we performed
a Western Blot based competition assay in which our antibody
was preincubated with various concentrations of L-rhamnose,
L-fucose, or L-arginine. Pre-added EF-PRha served as specic
Fig. 3 Synthesis of mono-ArgRha peptide and antibody generation. (A) Work-flow of antibody generation: in the first step an ArgRha containing
glycopeptide was synthesized via guanidyl formation, cleavage and subsequent coupling to bovine serum albumin (BSA). The resulting glyco-
conjugate was used to immunize rabbits and accordingly to collect crude sera containing polyclonal antibodies against ArgRha. Using a two-step
affinity chromatography technique we finally purified a highly sensitive and specific polyclonal anti-ArgRha antibody. Trt ¼ trityl; Boc ¼ tert-
butoxycarbonyl. (B) Synthesis of building block 6. Reagents and conditions: (a) acetyl chloride, r.t., 2 days, 85%; (b) KSCN, TBAI, and CH3CN, reflux,
3 h, 70%; (c) NH3, and THF, 1 h, 99%; (d) EtI, andMeOH, reflux, 3 h; then Boc2O, Et3N, and CH2Cl2, 75%. (C) NMR spectroscopic characterization of
compounds 4, 5, 6 and 1. (D) Single crystal structure of compound 5. (E) Solid-phase synthesis of mono-ArgRha peptide 1. Reagents and
conditions: (a) TEA, DMF, AgNO3, and 6 (3 eq.), r.t.; (b) 5% NH2NH2 in DMF; (c) 5% TIPS in TFA. (F) ELISA analysis of two batches of crude anti-sera.
The crude anti-sera immunized by the BSA-glycoconjugate can recognize ArgRha with high affinity. anti-Serum 1# and anti-serum 2# were
successively diluted up to 128 000 fold and subjected to indirect ELISA experiments against the BSA-glycoconjugate. (G) ELISA analysis of
purified anti-ArgRha. Purified anti-ArgRha can recognize ArgRha with high specificity. The purified antibody was successively diluted up to 32 000
fold and subjected to indirect ELISA experiments against the BSA-glycoconjugate (BSA-ArgRha) and BSA carrying the non-glycosylated peptide
(BSA-Arg).
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competitor and completely prevented detection of EF-P already
at concentrations of 1.5 mM (Fig. 4d). On the contrary even 15
mM of L-arginine or L-fucose could not decrease the signal
intensity. At this concentration only L-rhamnose abolished the
EF-PRha signal and therefore constitutes a competitor that is
around 10 000 times less effective than EF-PRha (Fig. 4d and
S7†). To examine whether the anti-ArgRha antibody shows cross
reactivity towards other types of arginine N-glycosylation, we
prepared lysates from 293T cells ectopically expressing NleB. As
expected arginine GlcNAcylation could be detected using anti-
ArgGlcNAc9,24 but no signal occurred when using anti-ArgRha
(Fig. 4e). Taken together, our antibody can be regarded as highly
sensitive and specic against arginine rhamnosylation.
We ultimately asked whether we can visualize endogenous
arginine rhamnosylated proteins from crude cell lysates. From
our sensitivity analysis we calculated that it was possible to
detect single ArgRha with about 100 copies per cell when sub-
jecting 108 cells and 2 mg ml1 anti-ArgRha to Western Blot
analysis. Rich media exponentially growing E. coli EF-P carry
about 10 000 copies of EF-P per cell41 and therefore it should be
possible to detect the modied protein. As Enterobacteriales
modify EF-P with (R)-b-lysine42–44 we used S. oneidensis which
naturally employs EarP mediated rhamnosylation. Whereas we
could readily identify EF-P in wildtype cells, mutants lacking
either efp or earP gave no signal (Fig. 4f). Similarly, we could not
detect EF-P rhamnosylation in a strain DrmlC that cannot
produce the EarP substrate for glycosylation – dTDP-b-L-rham-
nose. We used P. aeruginosa PAO1 crude cell lysates to test the
activity of the anti-ArgRha antibody in another species and
detected a single band (Fig. 4f). The band was veried to be EF-P
in a parallel Western Blot, yielding a signal at the same height,
by use of a S. oneidensis anti-EF-P antibody. Thus our anti-ArgRha
represents a potent tool to detect EF-P rhamnosylation in
diverse species.
Conclusion
We recently demonstrated the use of a high affinity anti-N-acetyl
glucosaminyl arginine antibody (anti-ArgGlcNAc) to monitor the
glycosylation of human death receptor domains mediated by
Fig. 4 Sensitivity and specificity analysis of anti-ArgRha against EF-PRha. (a) The anti-ArgRha antibody specifically recognizes EF-PRha. Immuno-
detection of purified EF-P both unmodified (EF-P) and rhamnosylated (EF-PRha) using anti-EF-P and anti-ArgRha. 0.5 mg of purified EF-P was
subjected to SDS-PAGE and subsequentWestern Blot analysis with 0.2 mgml1 anti-EF-P or anti-ArgRha respectively. (b) Immunodetection of EF-
PRhawhen anti-ArgRhawas successively diluted. (c) Immunodetection of EF-PRhawhen EF-PRhawas successively diluted and anti-ArgRhawas used
in concentrations of 2 mg ml1 or 0.2 mg ml1. (d) Cross-reactivity analysis of anti-ArgRha against L-rhamnose, L-fucose and L-arginine. 0.5 mg of
purified EF-PRha were subjected to SDS-PAGE and subsequent Western Blot analysis using 0.2 mg ml1 anti-ArgRha. anti-ArgRha was preincubated
with varying concentrations of EF-PRha, L-rhamnose, L-fucose and L-arginine. Buffer only served as a control. (e) anti-ArgRha cannot detect
ArgGlcNAc. 293T cells were transfected with mock vector or pCS2–EGFP–NleB plasmids. Western Blot analysis of total cell lysates using either
anti-ArgGlcNAc or anti-ArgRha. anti-EGFP and anti-tubulin served as a control. (f) Detection of EF-PRha from S. oneidensisMR-1 lysates of wildtype
(WT) and different mutant strains lacking efp (Defp) the glycosyltransferase EarP (DearP) or interfering with dTDP-b-L-rhamnose biosynthesis
(DrmlC). P. aeruginosa PAO1 WT crude lysates served as an additional in vivo control. Approximately, 108 cells were used per lane.
This journal is © The Royal Society of Chemistry 2016 Chem. Sci., 2016, 7, 6995–7001 | 6999
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NleB during EPEC infection.9,24 Similarly, anti-ArgRha represents
a novel tool to diagnose infections caused by pathogens such as
P. aeruginosa14,15 or N. meningitidis.16 Ultimately, our anti-ArgRha
might allow us to identify further arginine-rhamnosylated
proteins from diverse species. This in turn might help to unveil
novel antimicrobial targets and contribute to the task of over-
coming the increasing problem of multi resistance. In this
regard, it is indispensable to understand the mode of action of
arginine dependent glycosyltransferases as they appear to be
involved in pathogenicity development. However, our knowl-
edge of N-linked glycosylation is so far mainly restricted to
asparagine. The stereospecic outcome of the glycosylation
reaction is a major characteristic of its molecular mechanism.
By determining the a-anomeric nature of the rhamnosyl moiety
on EF-P and with this the inverting mode of glycosyl transfer
mediated by EarP, we made the rst step to elucidating the
catalysis of this novel type of glycosyltransferase. Our nding
might also help to further understand how the sugar partici-
pates in stabilizing the CCA-end of the P-site prolyl-tRNA and
thus contributes to the rescue of polyproline dependent ribo-
some arrest situations.
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ABSTRACT Glycosylation is a universal strategy to posttranslationally modify pro-
teins. The recently discovered arginine rhamnosylation activates the polyproline-
specific bacterial translation elongation factor EF-P. EF-P is rhamnosylated on argi-
nine 32 by the glycosyltransferase EarP. However, the enzymatic mechanism remains
elusive. In the present study, we solved the crystal structure of EarP from Pseudomo-
nas putida. The enzyme is composed of two opposing domains with Rossmann folds,
thus constituting a B pattern-type glycosyltransferase (GT-B). While dTDP--L-rhamnose is
located within a highly conserved pocket of the C-domain, EarP recognizes the KOW-like
N-domain of EF-P. Based on our data, we propose a structural model for arginine glyco-
sylation by EarP. As EarP is essential for pathogenicity in P. aeruginosa, our study pro-
vides the basis for targeted inhibitor design.
IMPORTANCE The structural and biochemical characterization of the EF-P-specific
rhamnosyltransferase EarP not only provides the first molecular insights into arginine
glycosylation but also lays the basis for targeted-inhibitor design against Pseudomo-
nas aeruginosa infection.
KEYWORDS Pseudomonas aeruginosa, Pseudomonas putida, TDP-rhamnose,
glycosylation, glycosyltransferase, nucleotide sugar, posttranslational modification,
ribosomes, translation
Translation elongation is a nonuniform process and directly depends on the aminoacids (aa) to be incorporated into the growing polypeptide chain (1). Due to its
chemical and physical properties, proline delays the peptidyl transfer reaction (2), and
ribosomes can even stall upon translation of distinct diprolyl-containing sequence
motifs (Fig. 1) (3, 4). Such ribosome stalling is alleviated by the eukaryotic and archaeal
elongation factor 5A (e/aEF-5A) (5–7) and its prokaryotic orthologue the bacterial
translation elongation factor P (EF-P) (8–14). The L-shaped EF-P is composed of three
-barrel domains and structurally resembles tRNA in both size and shape (15). EF-P
binds to the polyproline-stalled ribosomes between the binding sites of peptidyl-tRNA
(P-site) and the exiting tRNA (E-site) (16) and stimulates peptide bond formation by
stabilization of the CCA end of the P-site prolyl-tRNA (Fig. 1) (17, 18). A conserved
positively charged residue—located at the tip of the EF-P KOW-like N-domain—is
essential for function (11, 17). However, for full EF-P activity, this residue is posttrans-
lationally elongated (19). Certain bacteria—including Escherichia coli and Salmonella
enterica—ß-lysinylate a conserved lysine, K34EF-P, by EpmA. This EF-P-specific ligase
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uses -(R)-lysine as the substrate, which is generated by isomerization of -(S)-lysine by
employing the activity of the amino mutase EpmB (20–23). In contrast, activation of a
phylogenetically distinct group of EF-Ps encoded in species such as Pseudomo-
nas aeruginosa and Neisseria meningitidis depends on rhamnosylation of an arginine,
R32EF-P, in the equivalent position (17, 24, 25). Rhamnosylation is mediated by the
recently discovered inverting glycosyltransferase EarP, which utilizes dTDP-beta-L-
rhamnose (TDP-Rha) as donor substrate, resulting in -rhamnosyl-arginine on the
acceptor EF-P (26, 27). Unlike with the common and relatively well understood glyco-
sylation of asparagine, sugar modifications on the guanidino group of arginine appear
to be rare, and almost nothing is known about the molecular mechanism (28, 29). To
date, there are only two reported cases of arginine glycosylation other than EF-P
rhamnosylation. The first one described self--glycosylation of sweet corn amylogenin
(30). In the second case, an effector glycosyltransferase termed NleB of enteropatho-
genic E. coli (EPEC) was shown to inactivate human cell death domain-containing
proteins by N-acetylglucosaminylation of arginine, with this being a major pathoge-
nicity determinant during infection (31). Similarly, a lack of earP abolishes the patho-
genicity of P. aeruginosa (17). Accordingly, solving the molecular mechanism of arginine
rhamnosylation might pave the way to ultimately design and develop targeted inhib-
itors against EarP.
Here we present the X-ray crystal structure of EarP from Pseudomonas putida KT2440
(EarPPpu) bound to its cognate nucleotide-sugar donor substrate TDP-Rha at a 2.3-Å
resolution (PDB accession number 5NV8). Together with reporting the results of nuclear
magnetic resonance (NMR) spectroscopy analyses and an in vitro/in vivo biochemical
enzyme characterization, we lay the foundation for understanding arginine glycosyla-
tion.
RESULTS
Despite low sequence conservation most nucleotide sugar dependent (Leloir-type)
glycosyltransferases adopt one of two major folding patterns, GT-A or GT-B (28).
However, so far, there is no available information on the structure and folding prop-
erties of EarP. We used SWISS-MODEL (32), Phyre2 (33), and the I-TASSER server for
protein structure and function predictions (34–36) to generate fold recognition models
of EarP from Pseudomonas putida (see Fig. S3A in the supplemental material). These
predictions suggested the UDP-N-acetylglucosamine (UDP-GlcNAc)-dependent glyco-
syltransferases MurG from E. coli (MurGEco) (37) and O-GlcNAc transferase (OGT) from
Xanthomonas campestris (OGTXca) (38) as structural orthologues. Accordingly, EarPPpu
adopts a clamp-like structure with two opposing Rossmann-like domains that are
separated by an interdomain cleft (Fig. S3A). With this, the protein is presumably a
GT-B-type glycosyltransferase (28).
FIG 1 Activation and molecular function of EarP-arginine-type translation elongation factor EF-P. (Left)
The bacterial translation elongation factor EF-P is composed of two OB-Fold domains (light blue) and one
KOW-like N-domain (light green). In about 10% of all bacteria, EF-P is posttranslationally activated by
-glycosylation of a strictly conserved arginine (R32) (17, 26). The glycosylation reaction is catalyzed by
the EF-P–arginine rhamnosyltransferase EarP (purple) using dTDP--L-rhamnose (TDP-Rha [red]) as a
substrate. (Right) Activated EF-P is recruited to polyproline-stalled ribosomes and binds between the E
and P sites. Thereby, R32EF-P and the attached rhamnose moiety presumably stabilize the CCA end of the
P-site prolyl-tRNA, which in turn stimulates Pro–Pro peptide bond formation and thus alleviates the
translational arrest.
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Structure of Pseudomonas putida EarP.We were able to subsequently confirm the
GT-B fold by having solved the crystal structure of EarPPpu at 2.3-Å resolution (Fig. 2A;
Data Set S2). Indeed, the EarPPpu C-domain includes residues 184 to 361 and follows the
Rossmann fold topology, with six -strands (8 to 13) and seven -helices (8 to 14)
(Fig. 2 and see Fig. 4A). On the other hand, the N-domain (aa 1 to 153 and 362 to 377)
could only be built in part. Although weak electron density for likely other regions of
the N-domain was noticed, it was not sufficient to be unambiguously and reliably
interpreted as particular missing parts of the protein chain. It is important to note that
there is no indication that the diffraction data are twinned or anisotropic. The poor
density of the N-domain is not caused by misinterpretation of noncrystallographic
symmetry as crystallographic symmetry, because choosing a space group with lower
symmetry does not improve the electron density. Yet, the structure has a higher-than-
usual R-free (35.1%) value at this resolution, which cannot be explained by a simple
absence of disordered regions. This is likely due to the N-domain adopting different
conformations in different unit cells, causing crystal disorder. The potential mobility of
the N-domain is further supported by higher average B-factors for this domain than for
the C-domain (61 Å2 versus 46 Å2) (see Fig. S3B for B-factors mapped onto the protein
structure). In addition, our rigorous attempts to obtain crystals in different space groups
by screening various crystallization conditions were not successful. In the predicted
structure (Fig. S3A, model 2), the N-domain features a central -sheet of seven
-strands (1 to 7), surrounded by the -helices (1 to 5 and 15) (see Fig. 4A and
Fig. S3A). In the crystal structure, only -strands 1, 2, and 3, as well as -helixes 1,
5, and 15, are modeled (Fig. 2A). However, the missing structural elements in the
protein N-domain are not in close vicinity to the active site according to the fold
recognition model (Fig. S3A, model 2), and we did not observe any unassigned electron
density in the vicinity of the ligand. Thus, despite this disorder, our crystal structure still
provides crucial information important for understanding ligand binding and the
catalytic mechanism. For structure validity assessment, the EarP crystal structure with
electron density is shown in Fig. S4 in the supplemental material.
Furthermore, the presence of the predicted strands and helices and thus the validity
of the model and crystal structure could be confirmed by NMR secondary chemical
shifts (Fig. 2B). A prerequisite for this analysis is the backbone chemical shift assignment
by triple-resonance NMR experiments. The relatively large size of EarPPpu at 43 kDa
exceeds the sensitivity limitations of NMR, demanding deuteration in order to decrease
FIG 2 EarP folding pattern and topology. (A) Ribbon representation of the 2.3-Å crystal structure of EarPPpu. The
illustration was generated with UCSF Chimera (82). Secondary-structure elements are shown, with -helices in red
and green for the N- and C-domains, respectively, and -strands correspondingly in blue and cyan. The bipartite
helix of the linker domain is grey. -Strand 3, -helix 5, and short loops with weak electron density are also
displayed here but are missing in the PDB coordinate file to improve statistics, as discontinuity in the electron
density did not allow proper modeling. (B) Secondary structure of EarP determined by NMR secondary shifts. The
secondary structure of individual amino acids is indicated as propensity to form either an -helix (grey) or a
-strand (brown). The amino acids with a propensity to adopt a random coil or lacking information about
secondary structure were assigned zero values in the plot. The propensity values were obtained from C, C, NH,
and H chemical shifts using TALOS (103). The N- and C-terminal EarP domains are boxed in peach and green,
respectively. The interconnecting linker is boxed in grey.
EarP Structure and Biochemistry ®
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cross-relaxation effects and to decrease the signal line width. Nonetheless, using
transverse relaxation-optimized spectroscopy (TROSY)-based experiments, we were
able to assign 62% of the EarPPpu backbone.
The two domains are interconnected by a bipartite helix (6, 7) comprising aa 156
to 176. This linker region together with an unstructured segment that positions 15 in
the vicinity of the N terminus defines the floor of the cleft that separates the domains
(Fig. 2A and see Fig. 4).
Based on these and previous data (17, 24–27), EarP was built in the carbohydrate-
active enzymes (CAZy) database (39) and now represents the new glycosyltransferase
family GT104.
Analysis of the TDP--L-rhamnose binding site in the EarP C-domain. In Leloir-
type GT-B glycosyltransferases, the nucleotide-sugar binding site is canonically located
in the protein C-domain (40). Similarly, TDP-Rha in the EarPPpu crystal structure is
located in a binding pocket that is composed of residues located in the C-domain
(Fig. 3A). F191EarP, F252EarP, and F258EarP side chains form an aromatic cage that stacks
against the base of the nucleotide moiety of TDP-Rha. The sugar ring of the nucleotide
is then specifically recognized by a hydrogen bond between the hydroxyl group on C3=
of the sugar and the side chain of Q255EarP. The diphosphate is recognized by hydrogen
bonds formed with the side chain guanidine of R271EarP, the Y193EarP side chain
hydroxyl, and backbone amides of E273EarP and D274EarP. The binding pocket is closed
by the bulky side chain of Y193EarP, which may sterically ensure proper positioning of
the rhamnose sugar (Fig. 3A). The rhamnose sugar itself does not seem to make any
contact with the protein and is solvent exposed. We further confirmed this by satura-
tion transfer difference (STD) NMR experiments (41), where we did not observe any
difference signal from the rhamnose moiety but did observe one from the TDP moiety
of TDP-Rha (Fig. S5A).
In parallel, small-angle X-ray scattering (SAXS) of free EarPPpu and EarPPpu bound to
TDP-Rha has been performed (Fig. S3D). The overall shape of the molecule could be
validated to be the same in solution. Protein backbone conformational changes upon
TDP-Rha binding are confirmed by chemical shift perturbations (see Fig. 7B); however,
SAXS indicates that there are no large (10-Å) conformational changes or movements
of the two Rossmann fold domains with respect to each other upon binding of
TDP-Rha, as the scattering density does not change from that in the free state. To show
that TDP-Rha is bound to EarP under SAXS experimental conditions, STD NMR exper-
iments were performed. They confirm again that TDP-Rha binding occurs with the
ligand at a 7-fold excess compared to the amount of protein (Fig. S5B).
Database mining identified 432 EarP homologues representing about 10% of se-
quenced bacteria (Data Set S3) (17). Phylogenetically, EarP originated presumably in the
betaproteobacterial subdivision and was horizontally transferred into the gammapro-
teobacterial orders of Pseudomonadales, Aeromonadales, and Alteromonadales (17). It
can also be found in certain Fusobacteria, Planctomycetes, and Spirochetes (17).
In order to identify conserved amino acids, we used Clustal Omega (42) and generated
a multiple-sequence alignment (Fig. 4A). We found 49 residues with a sequence conser-
vation of 95%. Mapping of these residues onto the crystal structure revealed an accu-
mulation at or near the interdomain cleft (Fig. 4B), including the binding pocket for the
nucleotide sugar donor substrate (Fig. 3A), which is highly supportive of the correctness of
the solved structure.
To substantiate our structural findings with biochemical data, we prepared EarPPpu
constructs with single-amino-acid substitutions of the individual residues forming the
binding pocket and tested the activities of the EarPPpu variants both in vivo and in vitro
(Fig. 5). This included F191EarP, F252EarP, and F258EarP, which form the aromatic pocket,
as well as Y193EarP, Q255EarP, R271EarP, and D274EarP, which are involved in hydrogen
bond networking (Fig. 5B).
Previously, we could show that the heterologous expression of efp and earP from
Shewanella oneidensis in E. coli can fully complement a lack of EF-P (17) with respect to
Krafczyk et al. ®
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the activation of the lysine-dependent acid stress response by the transcriptional
activator CadC (11). Similarly, coproduction of wild-type EF-PPpu and wild-type EarPPpu
(WTEarP) can restore -galactosidase activity in an E. coli PcadBA::lacZ Δefp strain (Fig. 5A
and S1B). From the nine tested EarPPpu substitution variants, we measured reduced
-galactosidase activities for the variants F191AEarP, Y193AEarP, R271AEarP, S275AEarP,
and Y291AEarP. The variants R271AEarP and Y291AEarP failed to induce -galactosidase
expression at all (Fig. 5B and S1B).
In parallel, the enzymatic activity of EarPPpu was investigated in vitro by employing
an anti-ArgRha antibody. The antibody was raised against a chemically synthesized
glycopeptide antigen (SGRRhaNAAIVK) and specifically detects arginine rhamnosylation
FIG 3 EarP TDP--L-rhamnose binding site. (A, left) Three-dimensional structure of EarPPpu in a ribbon representation. The TDP-Rha
binding pocket in the C-domain is circled in black. (Right) Zoom into the nucleotide-sugar binding pocket with bound TDP-Rha (blue
sticks). Important residues for TDP-Rha positioning are depicted as green sticks and labeled with single-letter code identifiers. (B, left)
Ribbon representation of the nucleotide-sugar binding pocket with stick representation of bound TDP-Rha (blue sticks) as well as the
three invariant residues D13, D17, and E273 (green sticks), which are presumably involved in catalysis. (Right) Surface representation
of the nucleotide-sugar binding pocket with stick representation of bound TDP-Rha (blue). Surfaces of D13, D17, and E273 are in green.
Ribbons are color coded according to their degree of conservation, as follows: yellow, 100%; black, 95%; dark grey, 90%; light grey,
50%; and white, 50% identical residues in all analyzed EarP orthologues. The electron density for TDP-Rha bound to EarP is shown
in Fig. S3C. All illustrations were generated with UCSF Chimera (82).
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(see Materials and Methods) (Fig. S1A). This in turn enabled the quantification of
rhamnosylation rates of EF-PPpu by Western blot analysis (Fig. 5C and D). In a first step,
the Km and kcat of WTEarP were determined to be 53 M and 35 min1, respectively
(Fig. 5B, C, and D).
We wondered whether this Km makes sense physiologically and therefore analyzed
the cellular TDP-Rha levels in P. putida, P. aeruginosa, and E. coli, which were 3.5 mM,
FIG 4 Evolutionary conservation of amino acids in EarP homologues. (A) Multiple-sequence alignment of EarP proteins from Shewanella oneidensis,
P. aeruginosa, P. putida, and Neisseria meningitidis as a selection from the alignment of 432 protein sequences that were collected from the NCBI database (Data
Set S3). The multiple-sequence alignment was generated using Clustal Omega (104). Secondary-structure elements of EarP are shown and based on the EarPPpu
crystal structure, NMR analysis, and predictions by MINNOU (105). -Helices are in red and green for the N- and C-domains, respectively, and -strands are in
blue and cyan. The bipartite helix of the linker domain is grey. Helices and -strands not resolved in the crystal structure are yellow. Amino acids selected for
mutational analysis are indicated by asterisks. (B) The EarPPpu crystal structure was colored according to the degree of conservation of the respective amino
acids. Ribbon (left) and surface (right) representations of the EarPPpu crystal structure are shown. Colors indicate the following: yellow, 100%; black, 95%; dark
grey, 90%; light grey, 50%; and white, 50% identical residues in all analyzed EarP orthologues. Illustrations were generated with UCSF Chimera (82).
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2.0 mM, and 4.0 mM, respectively (see Materials and Methods and Fig. S6). In good
accordance with our measurements, the physiological TDP-Rha concentration in Lac-
tococcus lactis was previously determined to be as high as 1 mM (43). Thus, within a
bacterial cell, the donor substrate reaches saturating concentrations, according to the
WTEarP Km measurements.
Next, the Km and kcat of EarPPpu substitution variants were determined and com-
pared to those of the wild-type protein. Strikingly, all earPmutations affected enzymatic
activity (Fig. 5B and S2B). Depending on the substituted residue, the Km increased up
to 60-fold for the F252AEarP variant (Km  3.4 mM). Conversely, the kcat decreased up
to 3,500 times when we measured the kinetics of the F191AEarP and Y193AEarP variants.
To exclude the possibility that decreased enzyme activity was due to fold disruption,
selected EarPPpu variants (F191AEarP, Y193AEarP, F252AEarP, R271AEarP, D274AEarP, and
Y291AEarP) were analyzed by NMR 1H-15N heteronuclear single quantum coherence
(HSQC) experiments (Fig. S7). All tested substitution variants showed no structural
alterations from the wild-type protein, except for the D274AEarP variant. The structural
instability of this EarP variant might be a result of disrupting a salt bridge that is formed
between the side chains of D274EarP in the protein C-domain and an equally conserved
arginine at position 23 (R23EarP) in the protein N-domain (Fig. 4). This salt bridge
might be of importance in clamping both EarP domains together, and a lack of it
might therefore destabilize the protein. Indeed, further purification of the D274AEarP
variant by size exclusion chromatography (SEC) revealed an elution pattern with three
distinct EarP peaks, indicating a certain degree of protein aggregation. However, the
lowest molecular peak in the D274AEarP SEC profile is congruent with the one that we
found when subjecting WTEarP to SEC. Accordingly, Km (TDP-Rha) and kcat values were
determined from this protein fraction to be 206 M and 0.74 min1, respectively
(Fig. 5B).
In parallel, a bacterial two-hybrid analysis (44) was set up to investigate interactions
between EF-PPpu and WTEarP as well as the above-mentioned nine substitution variants
FIG 5 Analysis of kinetic parameters and in vivo activities of EarPPpu variants. (A) Molecular principle of the in vivo EF-PPpu
functionality assay. This assay is based on the lysine decarboxylase acid stress response of E. coli, the CadABC module (68).
At low pH and with the concomitant presence of lysine, the transcriptional activator CadC activates the promoter of its two
downstream genes (PcadBA) and with this induces expression of lacZ in an E. coli MG1655 PcadBA::lacZ strain (11). Proper
translation of CadC is dependent on the presence of EF-P and its corresponding modification system, and thus
-galactosidase activity can be taken as a direct readout for EF-P and EarP functionality. (B) Degree of conservation
(identity/similarity) in percent, in vivo activities, and kinetic parameters of tested single-amino-acid exchange variants of
EarPPpu. In vivo EarPPpu activities were determined by measuring the -galactosidase activities of an E. coli MG1655
PcadBA::lacZ Δefp strain heterologously expressing efpPpu together with wild-type or mutant earPPpu genes from o/n cultures
in LB (pH 5.8). Background corrected mean values from three independent measurements are shown. Standard deviations
were determined from three independent experiments to be 10%; the Km and kcat of wild-type EarPPpu (WTEarP) and
variants with single-amino-acid substitutions are given in micromolar concentrations and per minute, respectively.
Standard errors were determined by SigmaPlot to be 20%. (C, top) 2,2,2-Trichlorethanol (TCE) protein stain (75) of a
representative SDS gel used for determination of kinetic parameters. Fixed amounts of EF-PPpu (2.5 M) and WTEarP (0.1 M)
were incubated with various concentrations of TDP-Rha for 20 s and subjected to SDS-PAGE. (Bottom) Detection of
rhamnosylated EF-PPpu. EF-PPpu was visualized after Western blotting using 0.25 g/ml anti-ArgRha. (D) TDP-Rha saturation
curve of WTEarP. Band intensities from panel C were quantified using ImageJ (76). Reaction rates were calculated as means
of four independent measurements. Standard deviations are shown as error bars for each concentration.
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(Fig. 5B). Therefore, fusions were generated with two complementary fragments, T25
and T18, encoding segments of the catalytic domain of the Bordetella pertussis adenyl-
ate cyclase CyaA. If EF-PPpu and WTEarP do interact, then CyaA is reconstituted, which in
turn allows induction of the lac promoter and results in lacZ expression. Accordingly,
-galactosidase activity is a measure of the interaction strength. When coproducing
EF-PPpu with WTEarP, we determined ca. 250 MU, whereas combinations with solely T25
and T18 resulted in 60 MU, thus defining the threshold of the assay (Fig. S1C). Except
for the R271AEarP and Y291AEarP proteins, all other variants were below this threshold,
indicating that alterations in the donor binding site might also affect acceptor binding
(Fig. S1C).
The KOW-like EF-P N-domain is sufficient for EarP-mediated rhamnosylation.
To test which part of EF-P is involved in the interaction with EarP, NMR chemical shift
perturbation experiments were performed by comparing 1H-15N HSQC results between
unbound EF-PPpu and EarPPpu-bound EF-PPpu (Fig. 6A). Triple-resonance experiments of
EF-PPpu enabled backbone assignment, with a sequence coverage of 97%. Missing
assignments are for residues S123, R133, N140, V164, D175, and G185. The assignment
also enabled secondary-structure determination from secondary chemical shifts and
confirmed the validity of the EF-P model for P. putida, based on the crystal structure of
P. aeruginosa EF-P (Fig. S3E) (45). The titration experiment showed clear chemical shift
perturbations in the N-terminal acceptor domain of EF-PPpu (Fig. 6B and C). However,
R32EF-P and residues surrounding the rhamnosylation site (e.g., S30EF-P, G31EF-P, R32EF-P,
FIG 6 Interaction of EF-PPpu with EarPPpu. (A) NMR titration of unmodified EF-PPpu titrated by EarPPpu. Overlay of 1H-15N HSQC spectra of EF-P recorded at
different titration steps. EF-P was titrated in a 1:2 EF-PPpu/EarPPpu molar ratio. Color coding for respective titration steps is indicated in the upper left corner.
Examples of peaks with high chemical-shift perturbations (CSPs) or severe line broadening are shown by labels indicating the assignment of given peaks. (B,
top) Domain structure of EF-P. EF-P consists of three -barrel domains. The KOW-like EF-P N-domain harbors the rhamnosylation target R32EF-P. (Bottom) CSPs
of EF-PPpu titrated by EarPPpu derived from panel A. Unmodified and rhamnosylated EF-PPpu proteins were titrated by EarPPpu to a 1:2 EF-PPpu/EarPPpu molar ratio.
To analyze the interaction, CSPs were calculated as described in Materials and Methods and plotted against residue numbers. Color coding is indicated in the
upper right corner. Full lines indicate median CSPs, dashed lines indicate median CSPs plus standard deviations, and residues with CSPs higher than the median
plus standard deviation are shown in brighter shades of the colors. The N-terminal loop containing rhamnosylation target R32EF-P is indicated. (C) CSPs of
unmodified EF-PPpu titrated by EarPPpu plotted on the model of EF-P from P. aeruginosa (45) (PDB accession number 3OYY) using a white-to-orange gradient,
where white represents the weakest CSP and orange depicts the strongest CSP. The position of R32EF-P is indicated. (D) Rhamnosylation experiments
using full-length EF-PPpu and C-terminally truncated variants (EF-PPpu with aa 1 to 128, EF-PPpu with aa 1 to 65). EF-P was detected using 0.2 g/ml
anti-EF-P. Rhamnosylation of purified protein was detected using 0.25 g/ml anti-ArgRha. The domain structure of the respective protein variants is
indicated as in panel B.
Krafczyk et al. ®
September/October 2017 Volume 8 Issue 5 e01412-17 mbio.asm.org 8
 o
n
 O
c
to
b
e
r 2
8
, 2
0
1
8
 b
y
 g
u
e
s
t
h
ttp
://m
b
io
.a
s
m
.o
rg
/
D
o
w
n
lo
a
d
e
d
 fro
m
 
N33EF-P) are severely line broadened beyond detection. Therefore, chemical shift per-
turbation values cannot be determined for these and vicinal residues. This line broad-
ening is an indication that they are bound by EarPPpu and thus have rotational
correlation times expected for a complex of that size. Several residues located in the
S1-like OB-domain are also slightly affected. However, this is not necessarily due to
direct contacts with EarPPpu but might also be propagating effects. Therefore, we also
investigated in vitro rhamnosylation of truncated EF-PPpu variants comprising either
amino acids 1 to 128 or amino acids 1 to 65 (Fig. 6D). Both truncations were readily
rhamnosylated by EarPPpu, further corroborating that EF-P contact sites are predomi-
nantly located in the KOW-like N-domain.
In addition, we compared NMR interactions between EarPPpu and unmodified
EF-PPpu or rhamnosylated EF-PPpu. This experiment clearly showed that chemical shift
perturbations for unmodified EF-P are stronger than for rhamnosylated EF-P (Fig. 6B).
Thus, EarP releases EF-P after rhamnosylation due to decreased affinity, while unmod-
ified EF-P binds with higher affinity to enable efficient posttranslational modification.
Mutational analysis of the three invariant EarP residues D13, D17, and E273.
We and others previously showed that EarP inverts the anomeric configuration on the
sugar moiety from TDP--L-rhamnose to -rhamnosyl arginine (26, 27). Reportedly,
inverting glycosyltransferases employ a direct-displacement SN2-like reaction (46). The
molecular basis for inverted N-linked glycosylation was elucidated for the oligosaccha-
ryl transferase PglB (47). Here the catalytic site features three acidic side chains (29). As
with PglB, three negatively charged residues—aspartates D13EarP and D17EarP and
glutamate E273EarP—were identified as potential candidates to catalyze the glycosyl-
ation reaction (Fig. 3B). All three residues are invariant in all EarP orthologues (Fig. 4A;
Data Set S3). Moreover, the D13EarP and D17EarP variants as well as the E273EarP variant
are in the vicinity of the rhamnose moiety and might therefore be proximal to the
putative active center and R32 of EF-P (Fig. 3B). The distances of these three residues
to rhamnose atoms range from 2.5 to 4.5 Å (the carboxyl group of D13 is the closest,
with a distance of 2.5 Å to the methyl group of the rhamnose, followed by the side
chains of D17 and E273, with distances of 3.9 and 4.5 Å to the hydroxyl group of C4 and
C2, respectively). Consequently, we constructed the corresponding alanine substitution
variants D13AEarP, D17AEarP, and E273AEarP and investigated their enzymatic activities in
vitro. In line with the idea that these residues might be involved in catalysis, EF-P
rhamnosylation could not be detected even after 8 h of incubation, and accordingly
these EarP variants are inactive (Fig. 7A).
To exclude misfolding being causative for the nonfunctional EarPPpu protein vari-
ants, 15N HSQCs were measured for D13AEarP, D17AEarP, and E273AEarP. The spectra
show no structural alterations from WTEarP (Fig. 7B, C, and D and see Fig. S7). Addi-
tionally, the variants D13AEarP and D17AEarP were titrated with TDP-Rha being indistin-
guishable from WTEarP perturbations. Interestingly, although D13EarP and D17EarP res-
onances could not be assigned, other residues in close proximity (G16EarP and G19EarP)
exhibited strong perturbations not only in WTEarP but also in the D13AEarP and D17AEarP
variants upon TDP-Rha binding, despite not forming direct ligand contacts (Fig. 7E).
Similarly, we could measure TDP-Rha binding for E273A/D/NEarP variants using STD
NMR (Fig. S5C). This confirms that these mutations do not affect donor substrate
binding.
To investigate interactions between EF-PPpu and the D13AEarP, D17AEarP, and
E273AEarP variants, we again performed a bacterial two-hybrid analysis and were able
to show that all substitution variants are capable of acceptor binding, demonstrated by
a blue colony on X-Gal (5-bromo-4-chloro-3-indolyl--D-galactopyranoside)-containing
LB plates (Fig. 7F, S1C).
To further corroborate our findings on the in vitro-inactive D13AEarP, D17AEarP, and
E273AEarP variants, they were subjected to an in vivo experiment in which we investi-
gated their ability to activate EF-PPpu (Fig. 5A). Additional substitutions—D13N/EEarP,
D17N/EEarP, and E273Q/DEarP—were also included in the study. Expectedly, coproduc-
tion of the D13AEarP, D17AEarP, and E273AEarP variants with EF-PPpu phenocopies Δefp
EarP Structure and Biochemistry ®
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with respect to PcadBA activation and in vivo rhamnosylation (Fig. 7G; Fig. S1B). Similar
results were obtained with the D17N/EEarP and E273QEarP variants, whereas the
D13EEarP and E273DEarP variants were drastically impaired in function, although they
retained some residual activity. Their impairment is indicated by a certain degree of
FIG 7 Mutational analysis of the three invariant EarP residues D13, D17, and E273. (A) In vitro rhamnosylation of EF-PPpu by single-amino-acid exchange variants,
specifically, D13AEarP, D17AEarP, and E273AEarP variants. EF-P (2.5 M) and TDP-Rha (1 mM) were incubated together with the EarPPpu variants (0.5 M) and
sampled at different time points. Rhamnosylated EF-PPpu (EF-PRha) was detected after Western blotting using 0.25 g/ml anti-ArgRha. (B) Overlay of 1H-15N HSQC
spectra of wild-type EarPPpu that was free and bound to TDP-Rha. (C) Overlay of 1H-15N HSQC spectra of the free and TDP-Rha-bound D13AEarP variant. (D)
Overlay of 1H-15N HSQC spectra of the free and TDP-Rha-bound D17AEarP variant. The color coding is indicated in the upper left corner of each spectrum. The
titrations are described in detail in Materials and Methods. (E) Zoom into the overlaid spectra shown in panels B, C, and D. The position of the zoom is indicated
by a black frame in the corresponding original overlay. Peak assignments are shown. The movement of G16 and G19 upon TDP-Rha titration is indicated by
dashed arrows. (F) Bacterial two-hybrid analysis of protein-protein interactions between EarPPpu, the D13AEarP, D17AEarP, and E273AEarP variants, and the protein
acceptor EF-PPpu in E. coli BTH101. The blue color of colonies results from cleavage of X-Gal by -galactosidase and indicates protein-protein interaction between
coexpressed hybrids. (G, top) Analysis of in vivo activities of EarPPpu, D13AEarP, D17AEarP, and E273AEarP. In vivo EarPPpu activities were determined by measuring
the -galactosidase activities of an E. coli MG1655 PcadBA::lacZ Δefp strain heterologously expressing efpPpu together with the wild-type or mutant earPPpu genes
from o/n cultures in LB (pH 5.8). Means of three independent measurements are shown. Standard deviations from three independent experiments were
determined. (Bottom) Western blot analysis of o/n cultures of E. coli MG1655 PcadBA::lacZ Δefp heterologously expressing efpPpu together with the wild-type or
earPPpu mutants. Rhamnosylated EF-PPpu (EF-PRha) was detected using 0.25 g/ml anti-ArgRha.
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PcadBA activation as well as a band in the in vivo rhamnosylation blot (Fig. 7G; Fig. S1B).
In contrast, a variant with a change of D13 to asparagine was indistinguishable from
WTEarP, implying an importance of the chain length over charge.
Our thorough analysis of these EarP variants suggests that they are promising
candidates to be involved in catalysis.
DISCUSSION
Activation of the proline-specific translation elongation factors EF-P and IF-5A is
usually achieved by posttranslational elongation of the -amino group of a conserved
lysine (20–23, 48, 49). The resultant noncanonical amino acids—-lysinyl-hydroxylysine,
hypusine, and 5-amino-pentanolyl-lysine—appear to be chemically and structurally
analogous. We recently showed that in a subset of bacteria, a so-far-unappreciated
form of posttranslational modification plays an important role in the activation of EF-P.
Here, instead of lysine, the guanidine group of a conserved arginine is modified with a
rhamnose moiety by a glycosyltransferase termed EarP (17). This type of modification
not only contrasts with the other known EF-P/IF-5A activation strategies but is also one
of only two reported cases of enzyme-mediated arginine glycosylation. In canonical
N-linked glycosylation, the sugar is attached to the amide nitrogen of an asparagine in
an N-X-S/T consensus sequence (X is any amino acid except for a proline) (46, 50). In
contrast, the effector glycosyltransferase NleB of enteropathogenic E. coli N-acetyl-
glucosaminylates (GlcNAc) specifically the arginines at positions 117 and 235 in the
death domain-containing proteins FADD and TRADD, respectively (31, 51). This in turn
antagonizes the apoptosis of infected cells, thereby blocking a major antimicrobial host
response. Notably, EarP shows neither sequential nor structural homologies to the
GT-A-type glycosyltransferase NleB, and thus the arginine glycosylation of death do-
mains and EF-P are examples of convergent evolution. Instead EarP seems to be
structurally related to MurG. Moreover, and despite the lack of a significant overall
sequence similarity, certain residues important for function remain the same. According
to these facts, one might speculate that EarP is not simply analogous to MurG but a
distinct homologue. Note that MurG is essential for cell wall biosynthesis in both
Gram-negative and Gram-positive bacteria, and due to its degree of conservation, it is
most likely more ancient then EarP. Although there is no real evidence for this, one
might hypothesize about the possibility of a duplication of MurG in a betaproteobac-
terial progenitor, which is the presumed origin of EarP (17). Subsequently, the se-
quences of both proteins more and more diverged in consequence of distinct donor
and acceptor substrates. This assumption is at least also in line with the theory that
NleB (GT-A type) and EarP (GT-B type) are phylogenetically nonrelated enzymes.
Accordingly, one can also assume that the molecular mechanisms of the glycosyl
transfer reactions in both arginine glycosyltransferases differ. In 2016, Wong Fok Lung
and coworkers mutated nleB and identified certain residues in NleB either interfering
with FADD binding or preventing GlcNAcylation (52). They confirmed the importance
of two invariant aspartate residues, D221 and D223, from among the nonfunctional
NleB protein variants (31). A catalytic Asp-X-Asp motif is featured by various GT-A
glycosyltransferases. Here, the two negatively charged aspartate side chains coordinate
a divalent cation that facilitates departure of the nucleoside phosphate. Negatively
charged amino acids also play important catalytic roles in inverting GT-B glycosyltrans-
ferases (46). In the case of the metal-independent fucosyltransferase FucT (53), for
example, the side chain carboxyl groups of D13 and E95 may work as base catalysts
(46). Also, the activation of the acceptor amide nitrogen by the lipid donor utilizing
bacterial oligosaccharyltransferase PglB depends on the two negatively charged amino
acids D56 and E319. These residues abolish the conjugation of the nitrogen electrons
and allow the positioning of a free electron pair for the nucleophilic attack onto the
anomeric center of the donor substrate (29, 47). Analogously, the invariant negatively
charged residues D13EarP, D17EarP, and E273EarP in the EarP glycosyltransferase family
might play a role in activating the R32 guanidino group of EF-P. Especially D17EarP and
E273EarP—both in close proximity to each other—may form a catalytic dyad (Fig. 3B).
EarP Structure and Biochemistry ®
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While activation of the acceptor substrate might be driven by the essential amino
acids D13EarP, D17EarP, and E273EarP, the nucleotide sugar donor TDP-Rha is bound in a
highly conserved cavity of the protein C domain. A cocrystal structure of the putative
structural EarP analogue MurGEco with its cognate substrate reveals that aromatic
amino acid side chains play important roles in UDP binding (PDB accession number
1NLM) (54). Similar interactions were reported for the protein O-fucosyltransferase
POFUT1 (PDB accession number 3ZY6), where F357 is involved in -stacking with the
respective nucleobase (55). Stacking interactions also play a role in EarP, in which the
aromatic side chains of F252EarP and F258EarP bind the thymine and ribose moiety of
TDP-Rha, respectively. In contrast, contacts with the ribose or the phosphate moieties
frequently occur via interactions with side chain amines, hydroxyl groups, and back-
bone amides (37, 54, 55). Accordingly, this is also the case for EarP.
In GT-B glycosyltransferases, positively charged amino acids are often involved in
facilitating leaving group departure. This is achieved by neutralization of evolving
negative charges on the phosphate moiety during the glycosyl transfer reaction, as
described, e.g., for R261 of MurGEco (PDB accession number 1F0K) (37). Notably, earPPpu
encodes an invariant R271EarP in the equivalent position and a substitution to alanine
(R271AEarP) strongly impairs protein function, all of which suggests that they have
similar roles in product stabilization.
In GT-B glycosyltransferases, the two Rossmann folds can generally be divided into
one donor and one acceptor substrate binding domain (40). As with other glycosyl-
transferases, the nucleotide sugar is bound by the protein C-domain of EarP. Accord-
ingly, it is worth assuming important binding sites for EF-P in the protein N-domain.
Conversely, EF-P presumably contacts EarP by amino acids that are in close proximity
to the glycosylation site R32EF-P. In agreement with this hypothesis, the EF-P -lysine
ligase EpmA, for example, recognizes EF-P via identity elements in a region located
around the E. coli EF-P modification site K34 (21, 22, 56). Along the same line, the
deoxyhypusine synthase (DHS) can efficiently modify a human eIF-5A fragment com-
prising only the first 90 amino acids of the protein (57). Similarly, we could show that
the KOW-like N-terminal domain of EF-P (Fig. 6B) is sufficient to be glycosylated by EarP
(Fig. 6D), being congruent with the NMR titrations of EF-P with EarP (Fig. 6A to C). Upon
titration with EarP, the chemical shift perturbations observed were (with a few excep-
tions) restricted to the first 65 residues.
Taking all of this together, we propose a three-step model for the rhamnosylation
of EF-P by its cognate modifier EarP. In the ground state, both the nucleotide sugar
binding site in the C-domain and the putative acceptor binding site in the N-domain
are unoccupied.
In the donor-bound state, TDP-Rha is coordinated within a highly conserved cavity
in the protein C-domain, including an aromatic pocket that surrounds the thymine ring
(Fig. 3). Previous studies showed that binding of the donor substrate induces structural
alterations in both the N and C-domains of glycosyltransferases (40, 58, 59). In MurG,
these rearrangements include rotation of F244, which stacks over the nucleobase to
cap the donor binding pocket (37). Notably, in the crystal structure of EarP, a phenyl-
alanine, F252, is in the equivalent position, indicating that this capping interaction is
conserved (Fig. 3A) (54).
In the catalytic state, the R32 guanidino group of EF-P might be activated by a
mechanism analogous to the one that was reported for the oligosaccharyltransferase
PglB (47). Hence, in the EF-P rhamnosylation reaction, R271EarP might stabilize the
nucleotide product, thereby facilitating leaving group departure. Upon successful
inverting glycosyl transfer from TDP-Rha to R32EF-P, presumably by a single SN2
displacement reaction, the products are released from the active site of EarP, in turn
reverting to the unbound ground state.
We point out that there is most likely no strict sequence of binding events, as NMR
measurements demonstrate that EarP can interact with either substrate independently.
Altogether, our structural and biochemical investigation of EarP provides first
insights into arginine glycosylation and improves our general understanding of
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N-linked glycosyl transfer reactions. Additionally, our research might open up new
avenues for the development of antimicrobial drugs in order to fight, e.g., P. aerugi-
nosa infections.
MATERIALS AND METHODS
Bacterial strains and growth conditions. Strains and plasmids used in this study are listed in Data
Set S1 in the supplemental material. P. putida and E. coli were routinely grown in lysogeny broth (LB) (60,
61) according to the Miller modification (62) at 30°C (for P. putida) and 37°C (for E. coli), unless indicated
otherwise. When required, media were solidified by using 1.5% (wt/vol) agar. If necessary, media were
supplemented with 50 g/ml chloramphenicol, 100 g/ml kanamycin sulfate, and/or 100 g/ml ampi-
cillin sodium salt. For promoter induction from PBAD-containing plasmids (63), L-arabinose was added to
a final concentration of 0.2% (wt/vol) in liquid medium. For promoter induction from plasmids compris-
ing the lac operator sequences, isopropyl -D-1-thiogalactopyranoside (IPTG) (Sigma-Aldrich) was added
to a final concentration of 1 mM.
Molecular biology methods. Enzymes and kits were used according to the manufacturers’ direc-
tions. Genomic DNA was obtained according to the protocol of Pospiech and Neumann (64), and plasmid
DNA was isolated using a Hi Yield plasmid minikit (Süd-Laborbedarf GmbH). DNA fragments were
purified from agarose gels by employing a Hi Yield PCR cleanup and gel extraction kit (Süd-Laborbedarf).
Restriction endonucleases were purchased from New England Biolabs (NEB). Sequence amplifications by
PCR were performed utilizing the Q5 high-fidelity DNA polymerase (NEB) or the OneTaq DNA polymerase
(NEB). Mutations were introduced into the earP gene by overlap extension PCR (65, 66). Oligonucleotides
used in this study are listed in Data Set S1. All constructs were analyzed by Sanger sequencing (LMU
Sequencing Service). Standard methods were performed according to the instructions of Sambrook and
Russel (67).
-Galactosidase activity assay. Cells expressing lacZ under the control of the cadBA promoter were
grown in buffered LB (pH 5.8) overnight (o/n) and harvested by centrifugation. -Galactosidase activities
were determined as described in reference 68 in biological triplicates and are given in Miller units (MU)
(69). The significance of the results was determined by applying a two-sided Student t test and stating
a result as significantly different if P was 0.05.
Bacterial two-hybrid analysis. Protein-protein interactions were detected using the bacterial
adenylate cyclase two-hybrid system kit (Euromedex) according to the product manuals. Chemically
competent (70) E. coli BTH101 cells were cotransformed with pUT18C-efpPpu and/or the respective pKT25
variants (pKT25-earP, pKT25-D13A, pKT25-D17A, pKT25-F191A, pKT25-Y193A, pKT25-F252A, pKT25-
Q255A, pKT25-F258A, pKT25-R271A, pKT25-D274A, pKT25-S275A, pKT25-R278A, pKT25-Y291A, pKT25-
E273A) and plated on LB screening medium containing 40 g/ml 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-Gal) and 0.5 mM IPTG as well as 50 g/ml kanamycin sulfate and 100 g/ml
ampicillin sodium salt. Transformants containing pUT18-zip and pKT25-zip were used as positive controls.
Transformants carrying pUT18C and pKT25 vector backbones were used as negative controls. Bacteria
expressing interacting protein hybrids exhibit a blue phenotype on screening plates due to functional
complementation of the CyaA fragments (T18 and T25). After 48 h of incubation at 30°C, plates
containing around 100 colonies were evaluated. Representative colonies were transferred to liquid LB
cultures containing kanamycin sulfate and ampicillin sodium salt and incubated o/n at 30°C. Subse-
quently, 2 l of the o/n culture were spotted on LB X-Gal–IPTG screening plates. Pictures were taken after
48 h of cultivation at 30°C.
For quantification of interaction strength, which corresponds to the -galactosidase activity, cells
were inoculated in 1.5 ml LB medium containing 0.5 mM IPTG as well as 50 g/ml kanamycin sulfate
and 100 g/ml ampicillin sodium salt. After incubation in 2-ml reaction tubes under microaerobic
conditions at 30°C for 42 h, cells were harvested and -galactosidase activities were determined as
described above.
Protein purification. C-terminally His6-tagged EarPPpu variants (pBAD33-earPPpu) were overproduced
in E. coli LMG194 by addition of 0.2% arabinose to exponentially growing cells and subsequent
cultivation at 18°C o/n. N-terminally His6-tagged EarP (pACYC-DUET-earPPpu) and His6-SUMO-tagged
EF-PPpu (pET-SUMO-efpPpu) were overproduced in E. coli BL21(DE3) by addition of 1 mM IPTG to
exponentially growing cells. Subsequently, cells were incubated at 18°C overnight. Rhamnosylated
EF-PPpu (EF-PRha) was produced by cooverproduction with His6-tagged EarPPpu. Cells were lysed by
sonication, and His6-tagged proteins were purified using Ni-nitrilotriacetic acid (Ni-NTA; Qiagen) accord-
ing to the manufacturer’s instructions. The His6-SUMO tag was removed by incubation with 1 /mg
His6-Ulp1 (71) overnight. Subsequently, tag-free EF-PPpu was collected from the flowthrough after metal
chelate affinity chromatography. For biochemical analyses, cells were cultivated in LB. For use in NMR
spectroscopy, cells were grown in M9 minimal medium (62). If necessary, 15N-labeled nitrogen (15NH4Cl)
and 13C-labeled glucose were used. For NMR backbone assignment of EarPPpu, additionally 99.8%-pure
heavy water D2O (Sigma-Aldrich) was used instead of H2O in growth medium to allow partial deuteration
of the protein in order to reduce cross-relaxation effects and increase the signal-to-noise ratio. Size
exclusion chromatography of EarPPpu and the D274AEarP variant was performed in 100 mM NaPi (pH 7.6)
50 mM NaCl using a Superdex 200 Increase 10/300-Gl column with a flow rate of 0.3 ml/min on an Äkta
purifier (GE Healthcare). Four milligrams of protein was loaded in a volume of 0.5 ml (8 mg/ml). Eluting
protein was detected at 280 nm. Fractions of 0.5 ml were collected.
For the production of selenomethylated EarPPpu, E. coli BL21(DE3) cells expressing N-terminally
His6-tagged EarPPpu were cultivated in 1 liter M9 minimal medium at 37°C to an optical density at 600
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nm (OD600) of 0.6. One hundred micrograms of threonine, 100 g lysine, and 50 g isoleucine were
added to feedback inhibit methionine biosynthesis (72). Additionally, 50 g L-()-selenomethionine was
added 15 min prior to induction. Protein production was induced by addition of 1 mM IPTG, and cells
were incubated at 18°C overnight. Protein concentrations were determined as described by Bradford
(73). For biochemical analyses, EarPPpu and EF-PPpu were dialyzed against 100 mM NaPi, pH 7.6, 5 mM
dithiothreitol (DTT), whereas a buffer composed of 100 mM NaPi, pH 7.6, 50 mM NaCl, and 5 mM DTT was
used when the proteins were subjected to NMR analysis.
Synthesis of a single rhamnosyl-arginine containing glycopeptide. Moisture- and air-sensitive
reactions were conducted in flame-dried glassware under an argon atmosphere. Commercially available
reagents and solvents were used without further purification. CH2Cl2 was distilled from calcium hydride,
and tetrahydrofuran (THF) was distilled from sodium benzophenone immediately prior to use. Dimeth-
ylformamide (DMF) was stored under argon in a flask containing 4 Å molecular sieves. Reactions were
monitored by thin layer chromatography (TLC) with precoated Silica Gel 60 F254 aluminum plates (Merck,
Darmstadt, Germany) using UV light and methoxyphenol reagent (100 ml 0.2% ethanolic methoxyphenol
solution and 100 ml 2 M ethanolic sulfuric acid) as the visualizing agent. Flash chromatography was
performed using silica gel (35 to 70 m) from Acros Organics. Peptide purification by reverse-phase
high-performance liquid chromatography (RP-HPLC) was performed on a JASCO purification system with
a UV–visible-light detector (model UV-2075Plus) using a Phenomenex Aeris Peptide 5-m XB-C18 column
(250 by 21.2 mm). Analytical RP-HPLC was measured on a JASCO system with a Phenomenex Aeris
Peptide 5-m XB-C18 column (250 by 4.6 mm). In all cases, mixtures of water (eluent A) and acetonitrile
(eluent B) were used as eluents; if required, 0.1% formic acid (FA) or 0.1% trifluoroacetic acid (TFA) was
added. High-resolution electrospray ionization (HR-ESI) mass spectra were recorded on a Thermo
Finnegan LTQ FT mass spectrometer or on a Bruker maxis apparatus equipped with a Waters ACQUITY
ultrahigh-performance liquid chromatograph (UPLC) using a Kinetex C18 column (2.6 m, 100 Å) at 40°C
(Fig. 8).
Glycopeptide SGRRhaNAAIVK was synthesized using a Liberty Blue automated microwave peptide
synthesizer, followed by on-resin glycosylation and deprotection (Fig. 8). For construction of peptide 1,
0.1 mmol of preloaded H-Lys(Boc)-2-chlorotrityl resin (loading concentration, 0.78 mmol/g) was applied.
Cleavage of the Fmoc-protecting group was achieved with 20% piperidine in DMF (75°C, 35 W, 3 min).
Fmoc-protected amino acids (5 eq) were activated for peptide coupling using 5 eq of ethyl (hydroxy-
imino)cyanoacetate (Oxyma Pure), 0.5 eq of N,N-diisopropylethylamine (DIPEA), and 5 eq of N,N=-
diisopropylcarbodiimide. All coupling reactions were conducted at 75°C and 28 W for 5 min. Removal of
the allyloxycarbonyl-protecting group and subsequent coupling of the sugar moiety, as well as depro-
tection of the acetyl groups, were performed according to established procedures (26). Final deprotec-
tion gave the desired glycopeptide, SGRRhaNAAIVK, yielding 39% after HPLC purification. The amino acid
sequence of the glycopeptide corresponds to the primary structure of the S. oneidensis acceptor loop,
which is highly similar to the consensus sequence of EarP-arginine-type EF-Ps (17).
High-resolution mass spectrometry (HRMS) (ESI), calculated for C44H82N14O16 [M2H]2, m/z 
531.3011; found, 531.3016.
HPLC (0.1% TFA, 0 min, 8% B ¡ 45 min, 50% B; flow, 1 ml/min), tR (retention time)  9.61 min, 	 
204 nm (Fig. 9).
Antibody generation. Polyclonal antibodies were raised commercially by Eurogentec according to
the Rabbit Speedy 28-day (AS superantigen) program. The mono-rhamnosyl-arginine-containing peptide
was coupled to bovine serum albumin (BSA) according to an internal protocol (AS-PECO 05). Antibodies
capable of binding to rhamnosyl-arginine were purified from rabbit sera by affinity chromatography
(AS-PURIMED) against the glycopeptide SGRRhaNAAIVK. To test the specificity of the purified polyclonal
antibodies toward EF-PRha, 1.5 g of unmodified and 0.5 g of modified EF-P were transferred to a
nitrocellulose membrane by Western blotting. While polyclonal antibodies that were raised against EF-P
from S. oneidensis detect both unmodified and modified EF-PPpu, anti-ArgRha specifically detects the
modified protein variant (Fig. S1A).
SDS-PAGE and Western blotting. Electrophoretic separation of proteins was carried out using
SDS-PAGE as described by Lämmli (74). Separated proteins were visualized in gel using 0.5% (vol/vol)
2-2-2-trichloroethanol (75) and transferred onto a nitrocellulose membrane by vertical Western blotting.
Antigens were detected using 0.1 g/ml anti-His6 tag (Abcam, Inc.), 0.2 g/ml anti-EF-P, or 0.25 g/ml
of anti-ArgRha. Primary antibodies (rabbit) were targeted by 0.2 g/ml alkaline phosphatase-conjugated
anti-rabbit IgG (H&L) (goat) antibody (Rockland). Target proteins were visualized by addition of substrate
FIG 8 Synthesis of glycopeptide SGRRhaNAAIVK. a, SiPhH3 (phenylsilane), Pd(PPh3)4, CH2Cl2; b, 1-(tert-butoxycarbonyl)-3-(2,3,4-tri-O-acetyl-6-deoxy-L-mannopyranos-
1-yl)-2-ethyl-isothiourea (26) AgNO3 (silver nitrate), NEt3 (triethylamine), DMF; c, N2H4·H2O (5% solution in DMF); d, TFA-H2O-phenol-TIPS (88/5/5/2).
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solution (50 mM sodium carbonate buffer, pH 9.5, 0.01% [wt/vol] nitroblue tetrazolium, 0.045% [wt/vol]
5-bromo-4-chloro-3-indolylphosphate).
Determination of kinetic parameters. Kinetic parameters were determined by varying TDP-Rha
concentrations while keeping concentrations of EarPPpu (0.1 M) and unmodified EF-PPpu (2.5 M)
constant. A mixture of EarPPpu and unmodified EF-PPpu was equilibrated to 30°C in 100 mM NaPi (pH 7.6).
The reaction was started by the addition of TDP-Rha and was stopped after 20 s of incubation at 30°C
by the addition of 1 vol of 2 Lämmli buffer (74) and incubation at 95°C for 5 min. Samples were
subjected to SDS-PAGE, and rhamnosylated EF-PPpu was detected as described above. Band intensities
were quantified using ImageJ (76). Product formation (in nanomoles per milligram) was calculated
relative to fully (in vivo) rhamnosylated EF-PPpu. Km and kcat values were determined by fitting reaction
rates (in nanomoles per milligram per second) to the Michaelis-Menten equation using SigmaPlot. Time
course experiments conducted at a TDP-Rha concentration of 500 M show that the rhamnosylation
reaction is not saturated after 20 s of incubation (Fig. S2A).
Fold recognition. Fold recognition models were generated using the online user interface of Phyre2
(33, 77), SWISS-MODEL (78–81), and the I-TASSER server (34–36) as instructed on the websites. Model
structures were selected from the array of results according to best confidence, Q mean, and z scores,
respectively. All images of tertiary protein structures in this work were generated using the UCSF Chimera
package developed by the Resource for Biocomputing, Visualization, and Informatics at the University of
California, San Francisco (82). Protein structures were obtained as .pdb files from http://www.rcsb.org (83)
or the respective modeling platforms mentioned above.
Determination of intracellular TDP-Rha concentrations. Cells were grown in 1 liter LB to an OD600
of 0.5 (5  108 cells/ml), harvested by centrifugation, and resuspended in 25 ml 100 mM NaPi (pH 7.6)
(2  1010 cells/ml). After disruption of cells with a Constant Systems Ltd. continuous-flow cabinet at 1.35
kb, cell debris were removed by centrifugation and lysates were sterilized by filtration (Steriflip). A
mixture of EarPPpu (0.1 M) and unmodified EF-PPpu (2.5 M) was equilibrated to 30°C in 10 l 100 mM
NaPi (pH 7.6). The reaction was started by addition of 10 l lysate from ~2  107 or ~2  108 cells and
stopped after 20 s of incubation at 30°C by addition of 1 vol 2 Lämmli buffer (74) and incubation at
95°C for 5 min. In parallel, a TDP-Rha calibration series was generated by addition of TDP-Rha at final
concentrations ranging from 5 M to 160 M, including the linear range of the rhamnosylation reaction
rate (Fig. 5D). Samples were subjected to SDS-PAGE, and rhamnosylated EF-PPpu was detected as
described above. Band intensities were quantified using ImageJ (76). TDP-Rha concentrations in samples
containing lysate were calculated by dividing the respective relative band intensities by the slope of the
corresponding calibration curve (5 M to 80 M TDP-Rha). Intracellular TDP-Rha concentrations were
calculated from the amount of substance (in moles) per cell, with an assumption of equal distribution of
TDP-Rha across all cells as well as an average cell volume of 3.9 m3 for E. coli (84) and 2.1 m3 for
P. putida and P. aeruginosa (85).
NMR spectroscopy and backbone assignment of EF-P and EarP. All NMR experiments were
performed at 298 K on Bruker Avance III spectrometers with a magnetic field strength corresponding to
a proton Larmor frequency of 600 MHz (equipped with a Bruker TXI cryogenic probe head), 700 MHz
(equipped with a Bruker room temperature probe head), or 800 MHz (equipped with a Bruker TXI
cryogenic probe head). All data sets were processed using NMRPipe (91).
Before NMR measurements of 15N- and 13C-labeled EF-P (700 M) in 100 mM NaPi, 50 mM NaCl, and
5 mM DTT (pH 7.6), 0.02% NaN3 was added to the sample. Sequential resonance assignment was
obtained from two-dimensional (2D) 1H-15N HSQC and three-dimensional (3D) HNCA, CBCACONH, and
HNCACB backbone experiments, using a constant time during 13C evolution (86). The assignment process
was assisted by CARA (http://cara.nmr.ch) and CcpNmr Analysis (63), and 98% of the backbone reso-
nances could be assigned. Missing assignments for residues other than prolines are S123, R133, N140,
V164, D175, and G185. Secondary chemical shift analysis was performed based on the difference
between measured 13C and 13C chemical shifts and random coil chemical shifts of the same nuclei to
assign a secondary structure to the EF-P sequence (Fig. S3E) and confirm the validity of the model shown
in Fig. 6 (87, 88).
FIG 9 HPLC data.
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Due to the size of EarP (43 kDa), backbone resonance assignment was possible only for 2H-, 15N-, and
13C-labeled samples to reduce the number of protons and thus cross-relaxation effects, which also
enables efficient acquisition of backbone assignment experiments in TROSY mode (89). TROSY-HNCA,
-HNCACB, and -CBCACONH experiments (90), processed by NMRPipe (91) and analyzed using CARA
(http://cara.nmr.ch), enabled backbone resonance assignment of 62% of all assignable residues (exclud-
ing prolines).
The NMR titrations were always performed by adding an unlabeled interaction partner to the
15N-labeled protein sample and monitoring the progress of the titration by recording 1H-15N HSQC.
First, 15N-labeled 150 M unmodified EF-P was titrated with unlabeled EarP to a 1:2 EF-P/EarP molar
ratio with intermediate steps at 1:0, 1:0.5, 1:1, and 1:1.5 EF-P/EarP molar ratios. 15N-labeled 41 M
rhamnosylated EF-P was titrated with unlabeled EarP to a 1:2 EF-P/EarP molar ratio without any
intermediate steps. 15N-labeled 540 M wild-type EarP was titrated with unlabeled TDP-Rha to a 1:5
EarP/TDP-Rha molar ratio with intermediate steps at 1:0, 1:0.2, 1:1, and 1:3 molar ratios. 15N-labeled
186 M D13A variant or 209 M D17A EarP variant was titrated by the addition of TDP-Rha to an
approximately 1:10 molar ratio with no intermediate steps. To analyze the EF-P/EarP and wild-type
EarP/TDP-Rha ratio titration, the chemical-shift perturbations (CSPs) were calculated according to
the formula CSPs 
 
H
2 N0.15
2, where 0.15 is the weighting factor to account for nitrogen
resonances generally spanning a broad frequency range.
To check proper folding of EarP variants, 1H-15N HSQC spectra of 15N-labeled EarP variants with the
following single-amino-acid substitutions at the indicated concentrations were recorded: 209 M D13A,
209 M D17A, 162 M F191A, 197 M Y193A, 139 M D274A, 186 M R271A, and 162 M Y291A.
STD NMR experiments were performed with 10 M WTEarP or mutants and either 70 M (1:7 ratio of
protein to ligand to mimic SAXS conditions) or 1 mM TDP-Rha in 100 mM potassium phosphate buffer,
pH 7.5, 150 mM NaCl, 1 mM DTT, and 10% D2O. The experiments were performed on a Bruker Avance
III 700-MHz spectrometer equipped with a triple resonance (TXI) room temperature probe head at 277 K.
Protein was saturated with 49-ms Gaussian pulses at the resonance frequency of methyl resonances at
0.592 ppm. The experimental results were collected after a total saturation time of 20 s, with 1,596 scans
performed for the WTEarP sample with a 100-fold excess of ligand, and after a total saturation time of 5 s,
with 4,096 scans performed for the WTEarP sample with a 7-fold excess of ligand. For EarP mutants, the
experimental results were collected after a total saturation time of 4 s and with 128 scans.
Small-angle X-ray scattering. Thirty microliters of EarP, EarP plus TDP-rhamnose, and buffer (with
and without TDP-rhamnose) were measured at 20°C at BioSAXS beamline BM29 at the European
Synchrotron Radiation Facility using a 2D Pilatus detector. For each measurement, 10 frames with a 1-s
exposure time per frame were recorded for each EarP and buffer sample, using an X-ray wavelength (	)
of 0.9919 Å. Measurements were performed in flow mode, where samples are pushed through a capillary
at a constant flow rate to minimize radiation damage. The protein concentrations measured were 1.0, 2.0,
4.0, and 8.0 mg/ml. TDP-Rha was used in a 7:1 excess (ligand to protein). The buffer measurements were
subtracted from each protein sample, and the low Q range of 1.0 mg/ml was merged with the high Q
range of the 8.0-mg/ml sample, using PRIMUS (92). The merging was done due to the rising scattering
density at low Q ranges for the more highly concentrated samples, indicative of aggregation. CRYSOL
(93) was used to fit the back-calculated scattering densities from the crystal structure to the experimental
data.
X-ray crystallography. For crystallization, N-terminally His6-tagged EarPPpu expressed as a seleno-
methionine derivative was used. The protein was dialyzed to 50 mM Tris, 100 mM NaCl, 1 mM DTT,
pH 7.6, and concentrated to 183 M. TDP-Rha was added to a final concentration of 10 mM. The
crystallization condition was 0.2 M ammonium acetate, 0.1 M bis-Tris (pH 6.0), and 27% (wt/vol)
polyethylene glycol 3350. A full data set was collected at the ID29 beamline, ESRF, Grenoble, France, at
a wavelength of 0.97 Å (the absorption peak for selenium) and with a 15.05% beam transmission with
a 0.15° oscillation range, 0.037-s exposure time, and 2,400 frames. The space group was determined to
be I4. The data set was phased using single-wavelength anomalous diffraction (SAD) by the Crank2 (94)
automatic pipeline in CCP4 (95), using Afro provided by N. S. Pannu (unpublished) for substructure factor
amplitude (FA) estimation, Crunch2 (96) for substructure detection, and Solomon (97) for density
modification. The anomalous signal extended to a 3.4-Å resolution (in a data set with a 3-Å resolution).
We could successfully find 3 Se-Met signals with an occupancy of 1 located in the C-terminal domain and
2 Se-Met signals with an occupancy of ~0.5 located in the N-terminal domain. The initial structure was
built in Phenix Autobuild (98), completed with several rounds of manual model building in Coot (99), and
used as the model for molecular replacement (MR) of a native data set extending to 2.3 Å. Despite our
rigorous efforts in manual model building, which included extreme density modification, use of homol-
ogy models to model the N-terminal domain, Rosetta modeling, and refinement strategies with different
refinement software (Phenix [98], refmac [100], and CNS [101, 102] [and CNS-DEN-assisted refinement]),
the structure displays an R-free of 35% at 2.3 Å, with large parts of the electron density in the N-domain
not interpretable. No crystallographic pathology (twinning, anisotropy) could be identified in any of the
multiple data sets that we obtained, and trying to interpret crystallographic symmetry as noncrystallo-
graphic symmetry by deliberately choosing space groups with lower symmetry (C2, P1) did not improve
the density. This indicates intrinsic crystal disorder caused by the N-terminal domain adopting several
conformations in different unit cells.
Accession number(s). Atomic coordinates and structure factors for the reported crystal structures
have been deposited with the Protein Data Bank under accession number 5NV8.
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Summary 
Tripeptides with two consecutive prolines are the shortest and most frequent 
sequences causing ribosome stalling. The bacterial translation elongation factor P 
(EF-P) relieves the arrest, allowing protein biosynthesis to continue. A seven amino 
acids long loop between beta-strands β3/β4 is crucial for EF-P function and is 
modified at its tip by lysylation of lysine or rhamnosylation of arginine. Phylogenetic 
analyses unveiled an invariant proline in the -2 position of the modification site in 
EF-Ps that utilize lysine modifications such as Escherichia coli. Bacteria with arginine 
modifications such as Pseudomonas putida have selected against it. Focusing on the 
EF-Ps from these two model organisms we demonstrate the importance of the β3/β4 
loop composition for functionalization with chemically distinct modifications. 
Ultimately we show that amino acid changes in E. coli EF-P are needed for switching 
the activation strategy from lysylation to rhamnosylation. 
 
Introduction 
Protein biosynthesis is a universally conserved three-step process that occurs on ribosomes 
and provides a platform for tRNA mediated amino acid delivery. During translation elongation 
aminoacyl-tRNAs bind to the ribosomal A-site and peptide bond formation is mediated with a 
peptidyl-tRNA located in the P-site. Relocation of the P-site tRNA to the E-site enables 
ribosome exiting. The speed of incorporating amino acids into the growing polypeptide chain 
varies and strongly depends on their chemical nature (1). Due to its rigid structure, 
particularly proline delays the peptidyl transfer reaction, being both a poor A-site donor and 
P-site acceptor substrate (1-6). When translating stretches of two or more prolines, 
ribosomes become arrested (5, 7-15). Thus consecutive prolines are disfavored in evolution 
(16). However, the structural benefits of polyproline sequences in proteins (17, 18) seems to 
outweigh the translational drawback and favored the evolution of a specialized universal 
elongation factor termed e/aIF5A in eukaryotes/archaea and EF-P in bacteria (5, 8, 11). 
Upon polyproline mediated stalling e/aIF5A and EF-P are recruited to the ribosome and bind 
between the P- and E-tRNA binding sites (19-24). 
With its three domains, EF-P (Figure 1A) spans both ribosomal subunits and forms an L-
shaped, tRNA mimicking structure (25, 26). Whereas the two OB-fold domains 
(Oligonucleotide Binding) II and III are likely to be involved in P-site tRNAPro (27) and E-site 
codon (24) recognition, the EF-P KOW-like N-domain I is crucial for the catalytic activity. 
Specifically, a seven amino acid long apical loop region between beta strands three and four 
(β3Ωβ4) protrudes towards the peptidyl transferase center (19, 24). A conserved positively 
charged residue at the loop tip mediates stabilization and positioning of the CCA-end of the 
P-site tRNAPro in a way favorable for peptide bond formation (5, 6, 28). EF-P activity is further 
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enhanced by post-translational extensions of this specific tip residue (5, 28). Interestingly the 
underlying bacterial modifications appear to be chemically diverse (29) (Figure 1B). In a 
subset of bacteria including the Gram-negative model organism Escherichia coli, a lysine 
residue K34 is β-lysylated (30-32) with (R)-β-lysine (33) at the ε-amino group, employing the 
catalytic activity of the EF-P specific ligase EpmA (YjeA, PoxA, GenX) (34). Subsequent 
hydroxylation by EpmC (YfcM) (35, 36) presumably at the (R)-β-lysyl-lysine C5 atom (24) 
completes the modification, but is negligible for function (37). A chemically related amino acid 
- 5-amino-pentanolyl-lysine - was found in Bacillus subtilis EF-P (38). By contrast, activity of 
a distinct EF-P subset encoded in the β-proteobacterial subdivision and certain γ-
proteobacteria such as Pseudomonas putida and Shewanella oneidensis depends on α-
rhamnosylation of arginine at the equivalent position (28, 39, 40). This glycosylation is 
mediated by the GT-B fold glycosyltransferase EarP (41, 42) belonging to the enzyme family 
GT104 according to the CAZy database (43). 
Despite their distinct chemical nature both lysine as well as arginine modifications of EF-P 
promote proline-proline peptide bond formation. This raises the question which protruding 
residue and modification puts which selective pressure onto the EF-P β3Ωβ4 sequence to 
ultimately fulfill the same function. Using bioinformatics and site directed mutagenesis, we 
were able to show that only very few sequential changes in β3Ωβ4 of EF-P are needed to 
switch modification specificity and even allow functionalization. Beside the crucial 
lysine/arginine our analyses pointed towards amino acids located at the 2nd position N-
terminal of the modification site. While bacteria that encode EF-P with protruding lysine 
contain an invariant proline, those with protruding arginine instead strictly select against it. 
We argue that the presence or absence of this specific proline orients β3Ωβ4 in a way that 
allows EF-P activation with modifications similar to either (R)-β-lysylation or 
α-rhamnosylation. 
 
Results and discussion 
Phylogenetic analysis of EF-P β3Ωβ4  
Our study began with a bioinformatics analysis of EF-P β3Ωβ4. In a first step we constructed 
a phylogenetic tree based on 4421 sequences including both EF-P and IF5A sequences, 
with the latter used as an outgroup. To define modification specific protein subsets, EpmABC 
and EarP orthologs were collected as described previously (28) (Figure S1A, Table S1). The 
EF-P modification system present in B. subtilis was excluded in this study, as the full 
pathway is still poorly understood (38, 44). A first weblogo of β3Ωβ4 numbered according to 
the E. coli protein (amino acids 31 to 37) was generated based on the complete EF-P 
dataset (Figure 1A, Table S1). In line with earlier reports (30) the vast majority (78.91%) of 
EF-Ps have a lysine at the β3Ωβ4 tip (K34), whereas arginine is the second most frequent 
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amino acid occurring in 15.33% of the proteins (Table S1). The remaining 5.76% contain A 
(0.05%), G (0.07%), H (0.02), M (0.68%), N (1.97%), Q (2.78%) and S (0.18%) in this 
position. We next extracted two subsets of proteins with either a protruding lysine (lysine 
type) or arginine (arginine type) (Figure 1C). This analysis revealed a highly conserved 
proline in the 2nd position N-terminal of the modification site (P32) in the lysine type subset 
being almost absent in the arginine type EF-Ps. Consistently, bacteria with EpmA pathway 
have the conserved proline whereas bacteria with EarP do not (Figure 1D). The two 
modification systems thus appear to be mutually exclusive (28) (Figure S1B). Based on 
these observations, EF-P sequences were grouped according to the presence or absence of 
P32 (Figure 1E). Beside lysine (97.25%) we also found that asparagine in the protruding 
position strongly co-occurs with proline (97.7%), whereas other types of amino acids co-
occur with P32 extremely rarely: arginine (2.95%), alanine (0%), glycine (0%), histidine (0%), 
methionine (0%), glutamine (0%) and serine (0%) (Figure 1D, Table S1). 
These findings led us to speculate that P32 might play a role in orienting the protruding 
residue for proper functionality and thus be a determinant of the chemical nature of the post-
translational modification. Phylogenetic analysis of β3Ωβ4 in EF-P and the variability in this 
crucial structural element also prompted us to investigate the evolutionary order of events 
resulting in the observed co-occurrence patterns between the residues occupying positions 
34 and 32 as well as in the emergence of the EpmA or EarP modifying enzymes. To this end 
we performed a phylogenetic tree reconstruction using the maximum likelihood method from 
the phytools R package (45). As the lysine at the β3Ωβ4 tip was found in more than three 
quarters of all EF-P sequences, and is also conserved in the eukaryotic and archaeal 
orthologs e/aIF5A, we hypothesized that this amino acid is evolutionary ancient. Indeed, we 
found EF-P with a protruding lysine to be most likely (62%) at the root of our tree with 
subsequent emergence of the first arginine, followed by asparagine, glutamine and 
methionine (Figure S1D). 
When reconstructing evolutionary scenarios at position 32 (Figure 2A), threonine is the most 
likely amino acid in an EF-P progenitor despite the fact that proline is found in about 80% of 
extant sequences. Interestingly, threonine in the equivalent position is highly conserved in 
the archaeal/eukaryotic EF-P homolog a/eIF5A as well (46). As a common ancestor of EF-
P/IF5A most likely emerged before diversification into the three domains of life one can 
speculate that threonine was disfavored in most bacterial lineages and outcompeted by 
proline to match the specific requirements of prokaryotic ribosomes. Based on the 
reconstructed phylogenetic order of events the emergence of proline might also has favored 
the evolution of the EpmABC modification system (Figures S1C and S1D). By contrast, an 
evolutionary distinct EF-P branch, which lacks proline at position 32 and with a protruding 
arginine, allowed for the recruitment of EarP and rhamnosylation as an activation strategy. 
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Although our data suggest that EpmABC is phylogenetically older than EarP, the latter 
seems to have evolved independently, but interestingly from a P32-containing progenitor 
(Figures S1D and S1C). It is also noteworthy that our data imply an advantage of arginine 
over lysine at the β3Ωβ4 tip during early evolution of EF-P, which was lost once proline P32 
had emerged (Figures S1E and S1D). 
 
Mutagenesis of β3Ωβ4 of E. coli and P. putida EF-P 
To investigate the importance of the amino acid composition of β3Ωβ4 we initially chose the 
EF-P from E. coli (EF-PEco) being dependent on EpmABC (R)-β-lysylation of lysine K34. 
Accordingly, when analyzing β3Ωβ4 we first focused on K34 and its impact on EF-PEco 
activity. EF-P activity was measured in vivo using a previously established β-galactosidase 
dependent reporter system (11) (Figure 3A). The assay is based on the effective translation 
of the polyproline motif containing acid stress responsive transcriptional regulator CadC (47, 
48) and activation of its cognate promoter PcadBA fused to lacZ (11). Consequently, β-
galactosidase activity is low in E. coli cells lacking efp but becomes elevated when 
complementing with a wild-type EF-PEco copy in trans (Figure 3B). Interestingly the absence 
of the modification system allows for residual PcadBA activation which could be further 
enhanced upon efpEco overexpression (Figure S2A). Presumably the increased copy number 
of unmodified EF-PEco can partially compensate for a lack of modification as the lysine K34 
side chain forms important stabilizing contacts with the CCA-end of the P-site tRNAPro (24). 
We next substituted K34 by any other amino acid to be found in the protruding position of 
β3Ωβ4 of other bacteria (Figure 1A, Table S1). β-galactosidase activity was completely lost 
when exchanging lysine by alanine (K34AEco), asparagine (K34NEco), glutamine (K34QEco) or 
methionine (K34MEco) (Figure 3B). Presumably species with EF-Ps containing these tip 
residues underwent further evolutionary adjustments or might have developed yet unknown 
post-translational modifications that promote polyproline biosynthesis. By contrast we 
observed residual EF-P activity when complementing with K34REco. On the one hand side 
chain similarities of arginine with lysine presumably preserve certain of the above-mentioned 
interactions that might be otherwise absent. On the other hand, the significant decrease in 
activity with K34REco compared to unmodified EF-PEco points towards a non-stimulating or 
even negative effect, possibly caused by the guanidino group. Having demonstrated that 
substitution of K34 is hardly tolerated, we went on to analyze the impact of its sequence 
context residues. Consistent with our phylogenetic analysis (Figures 1C and 1E) an 
exchange of P32 (P32SEco, P32GEco) abolishes EF-P activity, as can be concluded from low 
β-galactosidase activities (Figure 3B). Similarly, substitution of G33 (G33AEco, G33SEco) is not 
tolerated and leads to a loss of function. In comparison, when mutating G35 (G35NEco) and 
Q36 (Q36SEco) a residual rescue activity is retained. Altogether our analysis of EF-PEco 
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β3Ωβ4 unveils important determinants for protein function and thus explains their high 
degree of conservation. 
As second EF-P, we investigated the one from P. putida KT2440 (EF-PPpu) being activated 
by EarP mediated arginine R32 α-rhamnosylation. We generated the substitution variants 
K29RPpu, S30PPpu, R32KPpu, N33GPpu and S34QPpu according to amino acids predominantly 
found in the lysine type weblogo (Figure 1C). We also constructed K29APpu, S30APpu, 
S30GPpu, G31APpu, G31SPpu, N33DPpu, S34APpu and A35SPpu to further study the impact of the 
corresponding positions on EF-P activity and rhamnosylation efficiency. An in vitro time 
course analysis was performed (Figure 3C) with wild-type EF-PPpu as well as its variants 
S30PPpu, G31APpu, R32KPpu, N33GPpu and S34QPpu using 50 µM TDP-β-L-rhamnose (=10fold 
KM; Figure S3A; see also supplemental materials and methods). This revealed relative 
rhamnosylation rates with S30PPpu (1% of wild-type activity) and G31APpu (1% of wild-type 
activity) being slowest, while N33GPpu and S34QPpu reach 62% and 12% compared to wild-
type EF-PPpu, respectively (Figure 3C). We next assessed in vivo EF-PPpu activity employing 
the E. coli PcadBA::lacZ reporter strain. This is possible as cross-complementation with a 
combination of EF-PPpu and EarPPpu (Figure 3D) restores wild-type levels of β-galactosidase 
activity in Δefp cells. We note that all EF-PPpu variants – except changes of R32 – were fully 
modified by EarPPpu when co-expressing them in E. coli in vivo (Figure 3D). Accordingly, one 
can assume that when analyzing EF-PPpu variants a corresponding PcadBA::lacZ mutant 
phenotype rather reflects impaired protein function than reduced rhamnosylation rate. In this 
regard we found S30PPpu to be almost inactive (4% of wild-type β-galactosidase activity) and 
with this matching the result of the corresponding E. coli EF-P substitution P32S. On the 
contrary, the alanine and glycine substitutions S30APpu and S30GPpu reached 39% and 96% 
of wild-type β-galactosidase activity, respectively. These data support our observation of a 
strong selection against proline in the arginine type EF-Ps, but at the same time allowing for 
a certain degree of freedom in the -2 position of the modification site. Substitutions in 
positions N33, S34 and A35 as well as K29 are also tolerated without significant EF-P activity 
loss in vivo (Figure 3D). Similar to G33 in EF-PEco (32) (Figure 3B) the position equivalent 
G31 in EF-PPpu is crucial for both modification efficiency (Figure 3C) and protein function 
(Figure 3D), which might be explained by sterically hindering interactions with either the 
ribosome or EarP caused by longer side chains. Interestingly and in contrast to K34REco 
R32KPpu is not only inactive but the β-galactosidase activity measured with this variant is 
even below the level of Δefp harboring the empty vector control. This drastic phenotype 
indicates an inhibitory effect on polyproline translation. Notably, we saw the same when 
testing unmodified EF-P of both P. putida or S. oneidensis (28) (Figure 3D). A similar 
phenomenon was also observed by others when analyzing the growth of the P. aeruginosa 
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EF-P R32K variant (39). The most plausible explanation is a distinct orientation of the 
protruding residue in dependence of β3Ωβ4 composition. 
 
Activation of E. coli EF-P hybrids by rhamnosylation  
Having established the impact of single substitution variants on function for both E. coli and 
P. putida EF-P, we were curious whether we can adjust the β3Ωβ4 loop composition in a way 
that allows for cross-interaction, cross-rhamnosylation and ultimately cross-activation of 
E. coli EF-P by EarP. Based on the knowledge we gained from our experiments here and 
earlier studies (41, 42) we chose EF-PEco hybrids with a swapped β3Ωβ4 as well as also 
included the K34REco and the double substitution P32S/K34REco to be initially analyzed. 
Despite their sequential diversity EF-PEco and EF-PPpu are structurally similar (32, 49), which 
led us to hypothesize about a possible cross-interaction of EarPPpu even with wild-type EF-
PEco. To test this, we constructed an E. coli ΔcyaA deletion, in which we integrated the lux 
operon (luxCDABE) at the lac locus (Figure 4A). The resultant strain KV1 was used in 
combination with the Euromedex bacterial two-hybrid system (50). This system is based on 
functional reconstitution of split Bordetella pertussis adenylate cyclase CyaA, which in turn 
activates the lac promoter Plac being dependent on cAMP receptor protein CAP (Figure 4A). 
As proof of principle, self-interaction of the GCN4 leucine zipper (50) was assessed in E. coli 
KV1 and the commercially available bacterial two-hybrid strains E. coli BTH101 (Euromedex) 
and E. coli DHM1 (Euromedex) on X-Gal containing screening plates. For this purpose, the 
reporter strains were co-transformed with the plasmids pKT25-zip (Euromedex) and 
pUT18C-zip (Euromedex) that encode for protein hybrids of the leucine zipper and the 
corresponding CyaA fragment. While all reporter strains responded with comparable β-
galactosidase mediated color formation on culture plates, KV1 exhibits an additional light 
output. In liquid culture, we could quantify the light output over a course of approximately 40 
hours. In this regard, E. coli KV1 transformed with pKT25-zip and pUT18C-zip, emitted a 
maximum of 12x106 relative light units (RLU) after ~10 hours. These results demonstrate that 
E. coli KV1 enables continuous monitoring of protein-protein interaction by detection of light 
emission while maintaining the possibility for blue/white screening assays on X-Gal 
containing culture plates (Figure 4B). 
Having demonstrated the functionality of our reporter KV1 we asked whether we can detect 
even the transient interaction that occurs between the enzyme EarPPpu and its (non)cognate 
partner EF-P(Eco)/Ppu. To this end C-terminal fusions of T25 and T18 (T25-EarPPpu, T18-EF-
PPpu, T18-EF-PEco, T18-EF-P K34REco, T18-EF-P P32S K34REco, T18-EF-PEco loopPpu) were 
generated using commercially available expression vectors (Euromedex). Interactions were 
assessed by continuous monitoring of luminescence emission from E. coli KV1 (Figure S2D). 
Co-expression of the cognate interaction partners EarPPpu and EF-PPpu resulted in a 
maximum of 7,000 RLU (Figure 4C). When we co-produced EarPPpu and the non-cognate 
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EF-PEco, a maximal light emission of 255 RLU was observed. This value was significantly 
higher than the luminescence generated in any combination that employs solely T18 or T25 
(maximal RLU of <100) and thus clearly demonstrates cross-interaction of EarPPpu and EF-
PEco. We also observed interaction between EarP and EF-PEco loopPpu, K34REco and 
P32S/K34REco however their strengths were indistinguishable from the one with wild-type EF-
PEco. We additionally performed NMR titration experiments employing EF-PEco and its 
variants with EarPPpu to determine their interaction at a molecular level in vitro (Figure 4D, 
S4A, S4B). EF-PEco interacts with EarPPpu as shown by the decrease in total amount of peak 
intensities in the EF-PEco 
15N-HSQC spectrum upon EarPPpu titration. Physical interaction 
leads to an increased molecular tumbling time, which in turn decreases transverse relaxation 
times and peak intensities. The interaction was substantially enhanced in the K34REco 
variant, resulting in even lower peak intensities. This was expected, as R34 makes important 
contacts with EarP and its cognate EF-P in Neisseria meningitidis (42). In contrast to K34REco 
we observed reduced interaction strength in the P32S variant as peak intensities were 
stronger than for EF-PEco wild type. This result might be counterintuitive, however, only if one 
ignores that EF-P must not only be efficiently rhamnosylated by EarP, but at the same time 
has to interact optimally with the P-site tRNA on the ribosome. In this light, the substitution of 
proline can be regarded as an evolutionary consequence to maintain functionality at the 
expense of rhamnosylation efficiency. In line with the findings for K34REco and P32SEco the 
K34R/P32SEco double substitution variant showed intermediate interaction with EarPPpu 
compared to K34REco and increased further with the EF-PEco loopPpu variant. In addition to 
K34REco and P32SEco the EF-PEco loopPpu construct bears two additional substitutions at 
positions 35 and 36, which seem to be important for EF-P/EarP interaction. Thus, we can 
interpret our finding as an adjustment to compensate for the negative interaction effect, that 
we saw with P32SEco. It is possible that substitution of proline P32 cause substantial changes 
in the loop dynamics due to its rigid nature. To test this, we performed 15N R1, R2, and 
steady-state heteronuclear {1H}–15N-NOE relaxation experiments on EF-PEco and its variants 
and compared it with EF-PPpu. Our analysis suggests that substitution of single EF-PEco 
β3Ωβ4-loop residues with residues from EF-PPpu or even with the complete β3Ωβ4 does not 
significantly alter the NMR relaxation properties of β3Ωβ4 and hence its dynamics (Figure 
S4C-F). Thus, differences observed in the interaction of EF-PEco and its variants with EF-PPpu 
can be attributed to the molecular nature of resulting interactions rather than changes in the 
loop dynamics. 
Knowing that EF-PEco and EarPPpu do cross-interact, we next assessed cross-rhamnosylation 
and activation. First, we tested the EF-PEco variant in which solely the modification site K34 
was substituted to arginine. Strikingly, this single substitution was sufficient to allow in vivo 
modification in an EarP dependent manner, however did not result in EF-P activation (Figure 
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4E). Moreover, we did not observe significant rhamnosylation in vitro presumably as a result 
of suboptimal contacts between EF-PEco and EarPPpu (42) (Figure 4F, Figure S3B). As 
important interaction sites between EF-P and its corresponding modification system are 
predominantly located within the first 65 amino acids (31, 32, 41, 42) we next swapped the 
N-domain of EF-PEco with the one from EF-PPpu (EF-PEco domainIPpu). In line with our 
expectations EF-PEco domainIPpu was readily modified both in vivo and in vitro (Figures 4E-4F 
and S3B) and allowed activation comparable to wild-type EF-PPpu. It also shows that binding 
to the ribosome occurs presumably at the same position, despite an identity below 30% 
between the OB-domains of the two EF-Ps. In a subsequent step we tested the variant with 
swapped β3Ωβ4 - EF-PEco loopPpu with in total four amino acid substitutions P32S, K34R, 
G35N and Q36S. Subsequent β-galactosidase assays showed that these alterations are 
sufficient to allow for partial EF-P activation by rhamnosylation. The remaining discrepancy in 
β-galactosidase activities compared with wild-type EF-PPpu is presumably a result of a less 
effective interaction with EarP as can be concluded from the in vitro interaction studies 
(Figure 4D) as well as the time course experiments with EF-PEco loopPpu (Figure 4F and S3B). 
We also note that the activity of EF-PEco loopPpu is not restricted to three consecutive prolines, 
but also alleviates ribosome stalling at other diprolyl arrest motifs as demonstrated for APP, 
DPP, PPD, PPG and PPN (Figure S2B). 
Our data shows that the presence of P32 is crucial for activation of EF-PEco on the one hand 
and prevents activation of EF-PPpu on the other hand. Although our in vivo analysis with 
P32S/K34REco did not result in a significant upshift of β-galactosidase activity in combination 
with EarPPpu, we measured slightly increased Miller units when using EarP of S. oneidensis 
MR-1 instead (Figure S2C). Sengoku and co-workers previously showed that amino acids 
immediately downstream of the modification site interact with EarP. Consequently, we 
additionally substituted G35 and Q36 for asparagine and serine. Congruent with this 
assumption both resultant EF-PEco variants P32S/K34R/G35NEco and P32S/K34R/Q36SEco 
alleviated CadC translation when coproducing EarPPpu, exhibited by a 2fold and 3fold 
increase in β-galactosidase activities, respectively. However, neither the double substitution 
K34R/G35NEco, K34R/Q36SEco nor the triple exchange K34R/G35N/Q36Eco had an alleviating 
effect on translational arrest. Thus, our analysis clearly shows that cross-activation of EF-PEco 
by EarPPpu is strictly prohibited in the presence of proline P32. On the contrary cross-
modification solely depends on the protruding residue to be arginine. Combined with our in 
vitro interaction analysis and the fact that a substitution of P32 even weakens the contact of 
EF-PEco with EarPPpu, we conclude that specifically the selection against proline is an 
adaptation to rescue polyproline stalled ribosomes with α-rhamnosylarginine rather than for 
efficient modification. On the other hand, our data also implies that additional adjustments in 
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the β3Ωβ4 sequence composition have been made to compensate for the negative effect on 
rhamnosylation by EarP in EF-Ps lacking P32. 
 
Concluding remarks 
In this study we provide a comprehensive analysis of EF-P β3Ωβ4 and how its sequence 
composition allows functionalization with chemically and structurally distinct modifications. It 
might also help to predict the type of novel, yet undiscovered EF-P post-translational 
activation strategies in the >50% of bacteria which do not encode any known modification 
enzyme. Our assumption is supported by the recent identification of lysine 5-amino-
pentanolylation which takes place in B. subtilis and presumably a few other firmicutes (51). 
This EF-P activation strategy chemically resembles β-lysylation and also occurs on a β3/β4 
loop with an invariant proline in position 32. Further, in certain prokaryotes that have a 
β3Ωβ4 similar to EF-PEco with lysine at the loop tip or alternatively an asparagine (Figure 1E), 
one can identify a deoxyhypusine synthase (DHS) like protein (52). In eukaryotes and 
archaea DHS elongates a lysine in the EF-P ortholog IF5A by an amino-butyryl moiety (53, 
54). Accordingly, it is plausible that the bacterial ortholog might attach an analogous 
modification onto the respective EF-Ps although the experimental connection remains 
elusive. 
The evolutionary flexibility in modification systems and β3Ωβ4 sequence composition is not 
fully understood yet. However, one could speculate that beside the universally conserved 
role in alleviating ribosome stalling at polyproline stretches (8, 11) diverse EF-Ps might have 
extended functionality. In this regard the Green and the Alepuz lab (55, 56) reported that 
IF5A also acts on non-polyproline arrest motifs and even facilitates termination. Although EF-
P activity seems to be restricted to the alleviation of translational arrest situations at 
consecutive prolines (11, 15) it should be noted that all global analyses thus far were 
performed solely in E. coli (10, 15) and Salmonella enterica (9) both of which depend on (R)-
β-lysylation of lysine. One might therefore speculate whether other EF-Ps with distinct 
modifications and β3Ωβ4 sequence composition might have expanded functions similar to 
eIF5A. EarP dependent EF-Ps might therefore be of particular interest. First evolved in β-
proteobacteria, this EF-P type seems to have spread into certain γ-proteobacterial orders 
and other phyla (28). Conversely however, horizontal gene transfer events of EpmABC 
dependent EF-Ps into the β-proteobacterial subdivision hardly occur. This in turn could 
indicate a selection in favor of EF-P arginine rhamnosylation caused either by an expanded 
target spectrum or improved functionality. 
The results of this study also demonstrate the possibility of switching the EarP acceptor 
substrate specificity. The interaction of EarP with its cognate EF-P has been shown to be 
both sequence- and structure dependent (42). Our data show that a substitution of lysine to 
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arginine in the EF-P of E. coli K34Eco is already sufficient to allow for rhamnosylation in an 
EarP dependent manner. As the EF-Ps of E. coli and P. putida share only 30% identity in the 
EarP-interacting EF-P_N domain, sequence specific contacts between EF-P and EarP (42) 
might only enhance interaction strength between the two proteins. This is further supported 
by our corresponding bacterial two hybrid and in vitro NMR analyses. The recognition motif 
for the AIDA-associated heptosyltransferase Aah has been described as a “short b-strand–
short acceptor loop–short b-strand” (57). Analogously the two beta-strands bracketing β3Ωβ4 
might constitute a structural recognition motif for EarP dependent rhamnosylation. 
Determining the minimal recognition motif is of particular interest as this information allows 
for targeted rhamnosylation even for proteins other than EF-P. Thus, our study also lays the 
foundation to evolve EarP into a glycosynthase that can ultimately be used in heterologous 
production of eukaryotic glycoproteins.  
 
Material and methods 
Bioinformatics analysis 
Amino acid sequence of EF-P/IF5A, EpmA, EpmB, EpmC and EarP were collected by 
extracting sequences that have EF-P_N, tRNA-synthetase II, Radical_SAM, EpmC, and 
DUF2331 domains, respectively, from the Pfam and InterPro databases with subsequent 
filtration, as described in the Supplementary Section. The final dataset contains 4421, 858, 
4894, 317 and 306 sequences of EF-P/IF5A, EpmA, EpmB, EpmC and EarP, respectively 
(Table S1). Multiple sequence alignments (MSA) and phylogenetic trees were built using 
MAFFT and FastTree (58, 59). Taxonomic assignments for the EF-P/IF5A and modification 
system proteins were determined based on the NCBI Taxonomy IDs. Using a rooted 
phylogenetic tree of the EF-P KOW-like N-domain I, maximum likelihood ancestral state 
reconstruction was performed with the phytools R package (45). 
Bacterial stains, oligonucleotides and plasmids 
A description of all strains, plasmids and oligonucleotides used in this study can be found in 
the Supplemental Information (Table S2, Table S3 and Table S4). E. coli strain KV1 for 
bacterial two-hybrid analysis was constructed as follows: The luxCDABE operon from 
Photorhabdus luminescens was amplified from pBAD/HisA-Lux (60) and integrated into E. 
coli LF1 as essentially described previously by (61). To keep the ability of blue/white 
screening, a synthetic ribosomal binding site (62, 63) which precedes the lacZ ORF was 
introduced. Afterwards cyaA was deleted using Red®/ET® recombination technology and the 
kanamycine cassette was removed using the 709-FLPe/amp expression vector in 
accordance to the Quick & Easy E. coli Gene Deletion Kit (Gene Bridges, Germany). In the 
same way, epmA was deleted in the E. coli ∆efp reporter strain MG-CR-efp-KanS, resulting 
in the ∆efp/∆epmA reporter strain MG-CR-efp-epmA-KanR. The ∆efp reporter strain MG-CR-
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efp-KanS itself was generated by removing the kanamycin resistance cassette from MG-CR-
efp (28) using also the Quick & Easy E. coli Gene Deletion Kit of Gene Bridges according to 
the manufacturer’s instructions. 
β-galactosidase activity assay 
E. coli ∆efp (MG-CR-efp-KanS) or ∆efp/∆epmA (MG-CR-efp-epmA-KanR) reporter strain 
cells, in which lacZ expression is controlled by the cadBA promoter, were grown over night in 
100 mM sodium-phosphate buffered Miller modified LB (pH 5.8) under microaerobic 
conditions, with minimal agitation at 37 °C. On the next day, cells were harvested by 
centrifugation, and the β-galactosidase activities were determined as described (64) and are 
given in relative Miller units (MU) (65). 
NMR experiments 
NMR 1H, 15N HSQC titration and relaxation experiments were performed at 298 K on an 800 
MHz Bruker Avance III spectrometer equipped with a TXI cryogenic probehead on 15N-
labeled EF-PEco and its variants and unlabeled EarPPpu. Backbone assignment of EF-PEco and 
EF-PEcoloopPpu was performed on 
15N, 13C isotope labeled protein using HNCACB, 
CBCA(CO)NH and HNCA experiments. Assignments of all other EF-P variants were done by 
tracing the peaks from the EF-PEco and EF-PEco loopPpu spectra. For NMR titrations, 2fold 
excess of unlabeled EarP was titrated to 15N labelled EF-PEco variants and NMR relaxation 
experiments were performed at concentrations ranging between 0.15-0.18 mM EF-PEco 
variants except for P32SEco variant for which 0.09 mM protein was used for due to lower 
expression yield. Detailed experimental parameters are descried in the supplementary text. 
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Figures and legends 
 
 
Figure 1. Composition of β3Ωβ4 of the EFP_N superfamily (A) Domain architecture of EF-P: The first 
magnification illustrates β3Ωβ4 of the KOW-like EF-P_N-domain I including the post-translational modification 
(PTM) site. The second magnification depicts the general amino acid composition of the seven amino acid long 
loop between the strands β3 and β4 based on 4421 sequences. (B) PTMs present either in E. coli EF-P 
(left, (R)-β-lysylation) or P. putida EF-P (right, α-rhamnosylation). The modifying enzymes EpmA and EarP are 
indicated. (C) Weblogo of β3Ωβ4 for the EF-Ps with lysine (lysine type EF-P) or an arginine (arginine type EF-P) 
at position 34 according to the numbering of the E. coli ortholog. (D) Weblogo of β3Ωβ4 for the EF-Ps of bacteria 
co-occurring with EpmA (upper logo) or EarP (lower logo). (E) Weblogo of β3Ωβ4 for the EF-Ps containing 
(upper logo) or not containing (lower logo) a proline at position 32 according to the numbering of the E. coli 
ortholog. 
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Figure 2. EF-P phylogeny and β3Ωβ4 sequence evolution (A) Phylogenetic tree reconstruction of the 32nd 
position (-2 relative to the β3Ωβ4 tip) of the EF-P KOW-like N-domain I: The colored circle areas correspond to 
the likelihood of a certain amino acid (see color code legend) to occupy the position at the phylogenetic knot. (B) 
Colors in the left bar indicate the amino acid located at the 34
th
 position (β3Ωβ4 tip). Colors in the right bar 
indicate the corresponding type of modification system. Each colored line corresponds to one bacterial species in 
the EF-P data set. 
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Figure 3. Characterization of single amino acid substitutions in EF-P β3Ωβ4 of E. coli and P. putida (A) 
LacZ based E. coli reporter for the detection of EF-P functionality: Post-translationally modified EF-P ((R)-β-
lysylated or α-rhamnosylated) promotes production of the polyproline containing pH-sensor CadC. At mild acidic 
pH and the concomitant presence of lysine CadC induces lacZ expression by activation of the cadBA promoter 
(B) In vivo activity measurements of E. coli EF-P β3Ωβ4 variants using the E. coli reporter strain described in (A). 
Here, either efp (E. coli MG-CR-efp-KanS, epmA+Eco, dark grey bars) or both, efp as well as epmA were deleted 
(E. coli MG-CR-efp-epmA-KanR, epmA-Eco, light grey bars) and complemented with a plasmid encoded E. coli 
His6-tagged EF-P variant. β-galactosidase activities are given in relative Miller units with the wild-type EF-PEco in 
the epmA+ background set to 100%. EF-P production was confirmed by Western blot analysis using Anti-His6. 
(C) In vivo activity analysis of P. putida EF-P β3Ωβ4 using the E. coli reporter strain described in (A) in which efp 
is deleted (E. coli MG-CR-efp-KanS). E. coli Δefp cells were complemented either with plasmid encoded P. putida 
His6-tagged EF-P variant solely (earP-Ppu, dark grey bars) or in combination with EarPPpu (earP+Ppu, light grey 
bars). β-galactosidase activities are given in relative Miller units with the wild-type EF-PPpu in earP+ cells set to 
100%. Rhamnosylation of EF-P was confirmed by Western blot analysis using Anti-rhamnosylarginine antibody 
(Anti-Arg
Rha
). (D) Relative in vitro rhamnosylation rates of EF-PPpu wild type (set to 100%) and amino acid 
substitution variants. 
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Figure 4. Cross-modification and activation of E. coli EF-P by EarP of P. putida (A) Molecular principle of the 
Euromedex bacterial two-hybrid system with E. coli KV1 (adjusted from the Euromedex KIT Manual): The 
Bordetella pertussis adenylate cyclase CyaA apoprotein catalyzes the formation of cyclic AMP from ATP. Splitting 
the enzyme into two parts – T18 and T25 – renders CyaA inactive even upon co-expression. Fusing T18 and T25 
to interacting proteins brings the fragments into close proximity and thus allows reconstitution of the Apo-CyaA. In 
E. coli KV1, the cyclic AMP dependent lac promoter precedes a translational fusion of the lux-operon and lacZ, 
allowing the indirect measurement of protein-protein interactions by light emission and colorimetric detection. (B) 
Proof of principle of E. coli KV1 as an in vivo reporter for protein-protein interaction using the self-interacting 
leucine zipper of GCN4. The colorimetric detection in E. coli KV1 cells was assessed semi quantitatively based on 
the formation of blue colonies on LB (Miller)-plates containing 40 µg/mL X-Gal. E. coli KV1 light emission was 
measured in a time course experiment recording relative luminescence (RLU) and optical density at 600 nm 
(OD600) in time intervals of 10 minutes. (C) In vivo interaction analysis of a T25-EarPPpu fusion or T25 solely with 
T18 fusions to cognate (EF-PPpu), and non-cognate EF-Ps (EF-PEco) as well as its corresponding substitution 
variants. The maximal light emission from a 40 h time course experiment is given in RLU. 95 % confidence 
intervals of at least 6 replicates are shown. (D) NMR-single titration experiment: Average change in the intensity 
ratio of EF-PEco and its variants upon titration with 2fold EarPPpu. Error bars represent standard deviation of the 
intensity ratios within each titration. (E) Relative in vitro rhamnosylation rates of EF-PPpu (set to 100%) and EF-
PEco variants. (F) In vivo rhamnosylation and functionality analysis of EF-P hybrids co-expressed with EarP from 
P. putida. Measurements were performed in the E. coli reporter strain (MG-CR-efp-KanS). E. coli Δefp cells were 
complemented either with plasmid encoded His6-tagged EF-PEco/Ppu variants solely (earP-Ppu, dark grey bars) or 
in combination with EarPPpu (earP+Ppu, light grey bars). β-galactosidase activities are given in relative Miller units 
with the wild-type EF-PPpu in earP+ cells set to 100%. Rhamnosylation of EF-P was confirmed by Western blot 
analysis using Anti-Arg
Rha
. In the hybrid, EF-PEco domainIPpu, the EF-P KOW-like N-domain I of E. coli was 
swapped with the one from P. putida. The hybrid, EF-PEco loopPpu, was generated by replacing β3Ωβ4 from E. coli 
by the corresponding β3Ωβ4 from P. putida.  
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ABSTRACT: The analysis of the function of essential genes in
vivo depends on the ability to experimentally modulate levels of
their protein products. Current methods to address this are
based on transcriptional or post-transcriptional regulation of
mRNAs, but approaches based on the exploitation of translation
regulation have so far been neglected. Here we describe a
toolbox, based on amber suppression in the presence of Nε-
acetyl-L-lysine (AcK), for translational tuning of protein output.
We chose the highly sensitive luminescence system LuxCDABE
as a reporter and incorporated a UAG stop codon into the gene
for the reductase subunit LuxC. The system was used to
measure and compare the effects of AcK- and Nε-(tert-
butoxycarbonyl)-L-lysine (BocK) dependent amber suppression in Escherichia coli. We also demonstrate here that, in
combination with transcriptional regulation, the system allows protein production to be either totally repressed or gradually
adjusted. To identify sequence motifs that provide improved translational regulation, we varied the sequence context of the
amber codon and found that insertion of two preceding prolines drastically decreases luminescence. In addition, using LacZ as a
reporter, we demonstrated that a strain encoding a variant with a Pro-Pro amber motif can only grow on lactose when AcK is
supplied, thus confirming the tight translational regulation of protein output. In parallel, we constructed an E. coli strain that
carries an isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible version of the AcK-tRNA synthetase (AcKRS) gene on the
chromosome, thus preventing mischarging of noncognate substrates. Subsequently, a diaminopimelic acid auxotrophic mutant
(ΔdapA) was generated demonstrating the potential of this strain in regulating essential gene products. Furthermore, we
assembled a set of vectors based on the broad-host-range pBBR ori that enable the AcK-dependent amber suppression system to
control protein output not only in E. coli, but also in Salmonella enterica and Vibrio cholerae.
KEYWORDS: translational regulation, gene silencing, PylRS, Salmonella enterica, Vibrio cholerae, genetic screen
M ost gene silencing strategies target gene expression at thelevel of transcription by exploiting the activity of
transcriptional regulators, e.g., TetR,1 LacI2 or the CRISPRi
system.3 Alternatively, gene expression can be tightly regulated
post-transcriptionally by the use of, e.g., microRNAs or small
interfering RNAs.4 Here, we show that translational regulation
can also be employed to sensitively adjust protein levels.
Canonically, 20 different amino acids can be utilized for
polypeptide synthesis by the translational apparatus. However,
the genetic code can be translationally expanded to direct the
incorporation of two natural but noncanonical amino acids
(ncAAs), namely selenocysteine (Sec)8 and pyrrolysine (Pyl).9
Both Sec-tRNA and Pyl-tRNA recognize codonsUGA and
UAG, respectivelythat are usually reserved for translation
termination. Whereas Sec is found in a variety of proteins in all
domains of life,10,11 Pyl is restricted to a small number of
proteins in a few archaeal and bacterial species.12 In
methanogenic archaea such as Methanosarcina barkeri, the
pyrrolysyl tRNA-synthetase (PylRS) charges its cognate
tRNACUA (encoded by pylT) (Figure 1A) to suppress the
amber stop codon UAG.13 Due to its substrate promiscuity and
its narrow distribution, PylRS has become a powerful means of
expanding the genetic code to include synthetic ncAAs.14
Today, over 150 substrates can be incorporated into proteins
by means of amber suppression.15,16 This in turn has enabled
researchers not only to investigate post-translational modifica-
tions,17 but also to introduce fluorescent labels,18 and ultimately
allows one to engineer proteins with modified functions. In
2015 Rovner et al. introduced the orthogonal translation system
consisting of an aminoacyl-tRNA synthetase and its cognate
UAG-reading tRNA from Methanococcus janaschii, which is
optimized for the incorporation of p-acetyl-L-phenylalanine,
into an E. coliMG1655 derivative.19 With this strain, they found
that three amber mutations, one in each of the open reading
frames of the essential genes murG, dnaA and serS, can be
rescued by an external supply of 4-acetyl-L-phenylalanine.
Along the same line Yusuke Kato and co-workers demonstrated
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the tunable translational control using site-specific 3-iodo-L-
tyrosine incorporation in Escherichia coli.20,21 Thus, the amber
suppression system can be used to efficiently deplete essential
gene products at the translational level.
In the present study we describe the assembly of a versatile
toolbox for control of protein levels in diverse bacterial species
using Nε-acetyl-L-lysine (AcK)-dependent amber suppression.
■ RESULTS AND DISCUSSION
Selection of Nε-Acetyl-L-lysine for Amber Suppres-
sion. Our study began with the selection of a suitable substrate
to be incorporated by PylRS-mediated amber suppression. We
chose Nε-acetyl-L-lysine (AcK) for this purpose because an
evolved variant of PylRS has been reported to charge tRNACUA
with AcK,7,22 and AcK occurs frequently in bacterial proteins as
a product of the post-translational modification of the ε-amino
group of lysine residues.23−26 Lysine acetylation can be
catalyzed by protein acetylases such as YfiQ (PatZ) in
E. coli,27 but can also result from a nonenzymatic reaction
with acetyl phosphate.24,26 Note that protein acetylation is not a
permanent modification, but can be reversed by deacetylases,
e.g., CobB, in bacteria.27 This would allow the production of an
unaltered protein when a native lysine codon is replaced by
UAG and read by AcK-dependent amber suppression.22,28
Apart from the fact that AcK is found naturally in proteins, it
has no effect on bacterial growth (Supplementary Figure S1), is
commercially available and is relatively cheap. For example,
supplementing 1 L of culture medium with 1 mM AcK costs
around 5€, and is thus about as expensive as IPTG. Taken
together, these considerations make AcK an ideal substrate. We
used the previously described PylRST expression system from
Methanosarcina mazei29 and introduced the mutations reported
by Umehara et al.7 to render the enzyme specific for AcK,
resulting in the Nε-acetyl lysyl-tRNA synthetase/tRNACUA pair
(AcKRST) (Figure 1B).
Development of a Luminescence-Based Amber
Suppression Reporter. Amber suppression is conventionally
quantified using either green fluorescent protein (GFP)30 or β-
galactosidase (LacZ)7 as the reporter. We decided to use
luminescence as the readout, and chose the system based on
expression of the luxCDABE operon from Photorhabdus
luminescens (Lux) (Figure 2A, B). In this system luxA and
luxB encode the α- and β-subunits of the luciferase heterodimer
(Figure 2A), while the reductase, transferase and synthase
specified by LuxC, D and E, respectively, together form the
complex that synthesizes and regenerates the myristyl aldehyde
substrate required for the bioluminescent reaction (Figure
2A).31,32 The Lux system is highly sensitive and allows one to
quantify amber suppression in living cells in real time.33
To make luminescence development not only dependent on
amber suppression but also tunable at the transcriptional level
we cloned the luxCDABE cassette into pBAD/HisA, placing it
under the control of the L-arabinose (Ara)-inducible promoter
PBAD. The stop sequence TAG was inserted at position 3 in the
luxC gene (Figure 2B)
We note that alterations at the 5′ end of coding sequences
might affect translation efficiency due to changes in mRNA
folding34−36 and accordingly one should be careful when
inserting TAG here. On the other hand, the region close to the
protein start site often lacks structural features important for
protein function and therefore tolerates manipulation without
perturbation of functionality. In the case of LuxC, secondary
structure prediction did not identify any α-helix or β-sheet in
the first six amino acids and thus giving first hint for a tolerance
toward insertions. Furthermore, there is relative low sequence
conservation in this region and some LuxC homologues even
have N-terminal extensions, e.g., LuxC of Photobacterium
phosphoreum altogether indicating this region to be suitable
for TAG insertion.
We analyzed Lux-amber reporter (LuxAm) activity in E. coli
BW25113 which, in addition to pBAD/HisA-Lux(Am), harbors
the vector pACYCDuet-AcKRST that codes for AcKRS and its
cognate tRNACUA (Figure 1B, 2C, Table 1). We grew the cells
in LB and supplemented the medium with either 0.2% Ara, 1
Figure 1. PylRS and AcKRS based amber suppression. (A) The pyrrolysyl-tRNA synthetase (PylRS) of Methanosarcina mazei loads its natural
substrate pyrrolysine onto its cognate suppressor tRNACUA (encoded by pylT). The six amino acids that form the pyrrole ring binding pocket are
indicated.5,6 (B) Acetyl lysyl-tRNA synthetase (AcKRS), a PylRS variant bearing the highlighted amino acids at positions 301, 306, 309 and 348,
which enable it to interact specifically with Nε-acetyl-L-lysine (AcK).7
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mM AcK or both compounds together (Figure 2C). The Lux
reporter plasmid pBAD/HisA-Lux, in which the wildtype luxC
ORF was unchanged, served as a positive control (Lux+). The
maximal luminescence was determined and is given in relative
light units (RLU). As expected, cells harboring pBAD/HisA-
Lux produced light after induction with 0.2% Ara, irrespective
of the presence or absence of AcK (Figure 2C). In contrast, in
LuxAm-expressing E. coli cells, luminescence was best stimulated
by a combination of the two substances. However, under Ara-
inducing conditions, we detected significant light emission (1 ×
106 RLU) even in the absence of AcK. This result can be
explained by translational read-through mediated by binding of
near-cognate tRNAs37 or by misaminoacylation of tRNACUA.
38
Strikingly, while Lux+-harboring cells showed a certain degree
of light production in the absence of Ara, the LuxAm-containing
cells remained completely dark (Figure 2C). Thus, the
combination of transcriptional and translational control
completely abolishes protein output, in line with an earlier
report.19
In the next step we systematically varied both the
concentration of Ara and AcK and compared the luminescence
of LuxAm with Lux+ cells (Figure 2D, Supplementary Figure
S2). As before, light production by the Lux+ strain was
essentially unaffected by increasing concentrations of AcK
(Supplementary Figure S2), and reached a maximum when the
growth medium contained ≥0.02% Ara (Figure 2C, Supple-
mentary Figure S2). In contrast, luminescence in the LuxAm
strain responds to the increasing presence of AcK, which allows
for adjustment of the light output over a range that extends
from “below detection” (blue) to more than 3.8 × 106 RLUs
(green), corresponding to 41% of the maximal light intensity
that we could measure with Lux+ (Figure 2C, D, Supplementary
Figure S2).
Additionally, we used the LuxAm luminescence reporter to
investigate the potential of Nε-(tert-butoxycarbonyl)-L-lysine
(BocK) as alternative substrate for translational protein level
control. BocK can be incorporated into the genetic code
employing the wildtype PylRST.39 Like AcK, BocK is
commercially available and comparably cheap. In contrast to
AcKRS, PylRS is not promiscuous to charge tRNACUA with
natural amino acids,7,40 and thus we were curious to compare
the two aminoacyl-tRNA-synthetases in our test system with
respect to misacylation and amber suppression efficiency. To
this end we transformed E. coli BW25113 cells harboring
pBAD/HisA-Lux(Am) in combination with pACYCDuet-
PylRST,29 pACYCDuet-AcKRST or the empty vector
pACYCDuet-1, respectively, in order to discriminate between
misacylation and translational read through. Subsequently, light
production was analyzed in the resulting strains in the presence
of 0.2% Ara with and without the supplement of 10 mM BocK
and AcK, respectively (Supplementary Figure S3). Independent
of PylRS and AcKRS we measured a base level luminescence of
about 2.0 × 105 RLU. This value further increased in cells
harboring pACYCDuet-AcKRST to about 5.0 × 105 RLU
without the addition of AcK, indicating mischarging of
tRNACUA by endogenously available noncognate substrates.
By contrast, in cells bearing pACYCDuet-PylRST we did not
observe such an increase in luminescence clearly showing, that
natural amino acids are not recognized by PylRS. Therefore,
BocK might be a good alternative to AcKRS in order to control
protein output translationally. Note that the BocK supplement
resulted in an approximately 5-fold increase in luminescence in
cells expressing pylRS/pylT. This was slightly (1.0 × 106 RLU)
lower compared to the maximal value measured with AcKRST.
Thus, and similar to AcK dependent amber suppression, the
translational regulation with BocK/PylRST allows a tight
Figure 2. A luminescence-based amber suppression bioreporter (A) Basic principle of the luminescence system (Lux) from Photorhabdus luminescens.
The lux genes are organized in the luxCDABE operon, which encodes the multienzyme complex LuxCDE and the luciferase heterodimer LuxAB.
These two orchestrate substrate synthesis/regeneration of myristyl aldehyde and generate luminescence, respectively. (B) The LuxAm luminescence
reporter: The luxCDABE operon of P. luminescens was placed under the control of the Ara-inducible promoter PBAD, and the third codon of the open
reading frame of luxC was replaced by an amber stop codon, resulting in the Lux-amber reporter (LuxAm). (C) Luminescence production of LuxAm in
E. coli BW25113. A construct in which the wildtype luxC ORF was left unaltered was used as a positive control (Lux+): Cells harboring the
corresponding Lux reporter plasmid in combination with pACYCDuet-AcKRST, which codes for the AcKRS and its cognate tRNACUA, were grown
in LB overnight and luminescence production was monitored in response to Ara and/or AcK, and is given in relative light units (RLU). Error bars
represent the standard deviation of data from three different experiments. (D) Parameter optimization for Lux+- and LuxAm-encoding E. coli strains.
Ara and AcK concentrations were varied and maximal luminescence was determined. The resulting luminescence values ranged from “below
detection” (0) RLU (blue) to 9.0 × 106 RLU (yellow).
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protein output control when combined with inducible gene
expression.
Adjustment of the Amber Codon Context Permits
Modulation of Protein Output. In the preceding section we
showed that the LuxAm strain produces significant levels of
luminescence even in the absence of the cognate AcKRS
substrate AcK (Figure 2C), which prompted us to ask whether
an additional amber codon in the reporter gene might eliminate
this background signal. Indeed, the introduction of a second
TAG into luxC completely abolished light production, despite
supplementation with AcK (Table 1). This implies that the
second amber codon brings translation of luxC to a halt. We
therefore undertook further engineering to enable suppression
to compete with termination.41,42
It is known that the context of an internal stop codon can
have a huge impact on translational readthrough.43,44 This led
us to analyze the influence of sequence motifs known to have
significant effects on amber suppression. AcK incorporation
into the nascent chain competes with translational termination
mediated by the release factor RF1. This competition is
reflected by the fact that even at saturating AcK concentrations
the luminescence of LuxAm cells does not reach the level
observed in the Lux+ E. coli strain (Figure 2C). However, the
efficiency of recognition of the amber stop codon by RF1 is
modulated by the base that follows it. While in E. coli a 3′ uracil
best ensures termination, amber suppression is favored by a
neighboring adenine.45,46 The threonine sense codon ACU that
follows the UAG in the LuxAm reporter should therefore
promote suppression and was left intact. Accordingly, we
focused on the sequence context 5′ to the amber codon.
Although the codon directly upstream of the stop site is of
importance,47 in 1994 Mottagui-Tabar and co-workers found
that the penultimate codon has a major influence on
termination in E. coli.43 In that study, the authors described a
hierarchy of suppression, with arginine codons in this position
showing the lowest and aspartate codons stimulating the
highest suppression efficiency when UGA was the stop codon.
On the basis of these findings, we decided to investigate the
influence of R−2 A−1 and D−2 A−1 on amber suppression. We
also included H−2 H−1, a context motif that was identified in a
screen for efficient incorporation of ncAAs.44 Moreover, we
chose K−3 D−2 P−1 and P−2 P−1, as well as a combination of the
two (K−4 D−3 P−2 P1), to precede the stop site. These sequence
contexts are known to cause ribosome stalling and should thus
interfere with translation termination.48−50
All LuxAm variants were constructed essentially as depicted in
Figure 2B, by insertion of the motif after Gly2 in the luxC gene.
Luminescence was measured under PBAD-inducing conditions as
described above, and in the presence and absence of 1 mM
AcK, respectively (Table 1).
As before (Figure 2C), the strain containing the LuxAm
reporter construct produced a maximal level of luminescence
of about 2.4 × 106 RLU upon supplementation with AcK. This
is a 3.5-fold increase relative to cells that were grown without
AcK. In comparison, the maximal light intensities emitted by
Lux-RA(Am) and Lux-DA(Am) cells grown in the presence of
AcK were 3.4 × 106 and 5.0 × 105 RLU, respectively, and
differed significantly from each other. This might be explained
by altered luxC expression, as regulatory elements are located
within the first 50 codons.51 Regardless of these differences, the
relative increases in luminescence in the presence of AcK were
comparable, at 3.7-fold for LuxRA(Am) and 2.6-fold for
LuxDA(Am). Mottagui-Tabar et al. showed that, in principle,
arginine and aspartate in the second last position to UAG
follow the same rules as when UGA is the stop codon, but that
the effect with UAG was less pronounced.43 This latter factor
may account for the small differences in light production seen
between amber-suppressed LuxRA(Am) and LuxDA(Am).
In agreement with the findings of Pott et al., we observed
increased luminescence for LuxHH(Am) compared to the original
LuxAm bioreporter.44 However, this is largely attributable to
increased translational read-through, as indicated by the
increase in light production seen in the absence of AcK
(Table 1). The analysis of amber context motifs that promote
ribosome stallingKDP, PP and KDPPrevealed a strong
decrease in luminescence, which was unaffected by the presence
of AcK. This decrease is presumably the result of the
recruitment of ribosome rescue systems, such as tmRNA,
which ultimately lead to abortion of translation.49 Of the three
arrest motifs tested, only the PP motif present in the LuxPP(Am)
reporter had a significant effect on amber suppression. In this
case, the addition of AcK to the growth medium was correlated
with an increase of >6-fold in luminescencethe highest
relative change observed with any of the motifs tested. Thus, a
diprolyl amber context would appear to be especially beneficial
in experiments where coupling with transcriptional regulation
must be avoided.
A Diproline Amber Context Allows Tight Regulation
of β-Galactosidase Protein Levels. We next tested whether
the integration of an amber stop codon into the bacterial
chromosome might allow for tighter regulation of protein
production in E. coli. For these experiments, we chose the β-
galactosidase LacZ, which cleaves the disaccharide lactose into
D-galactose and D-glucose. This enzyme is essential for growth
of E. coli cells on lactose as sole carbon source. We constructed
two E. coli strains, bearing either an Am (TAG) or a PP(Am)
(CCG CCG TAG) insertion after the ninth codon in the lacZ
Table 1. Influence of the 5′ Amber Context on
Luminescence Productiona
motif AcK (1 mM) mean × 103/SD × 103 (RLU)
Lux+ − 7165 ± 392
Lux+ + 7252 ± 486
LuxAm − 689 ± 26
LuxAm + 2406 ± 77
Lux2Am − 0
Lux2Am + 0
LuxRA(Am) − 919 ± 68
LuxRA(Am) + 3400 ± 22
LuxDA(Am) − 194 ± 33
LuxDA(Am) + 496 ± 51
LuxHH(Am) − 1434 ± 21
LuxHH(Am) + 3717 ± 633
LuxKDP(Am) − 20 ± 5
LuxKDP(Am) + 35 ± 26
LuxPP(Am) − 112 ± 35
LuxPP(Am) + 691 ± 72
LuxKDPP(Am) − 3 ± 3
LuxKDPP(Am) + 78 ± 7
aCells harboring the corresponding Lux reporter plasmid in
combination with pACYCDuet-AcKRST were grown in LB
supplemented with 0.2% L-arabinose overnight and luminescence
production was monitored in response to AcK and is given in relative
light units (RLU).
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coding sequence (Figure 3A). Similar to LuxC, our decision for
the insertion position was based on a lack of structural elements
as well as comparatively low sequence conservation in the first
ten N-terminal amino acids of LacZ.54 In addition to the
resulting strains LF1-LacZ(Am) and LF1-LacZ-PP(Am) and to
further exclude any effects on protein activity we engineered
two strains containing a lysine codon instead of TAG for use as
positive controls (LF1-LacZ-K and LF1-LacZ-PPK). These two
strains were compared with wildtype MG1655 cells and found
to be phenotypically indistinguishable with respect to both
growth on lactose and β-galactosidase activity (data not
shown). By contrast, both LF1-LacZ(Am) and LF1-LacZ-
PP(Am) exhibited strongly diminished LacZ production
(Figure 3B). Moreover, whereas β-galactosidase activity was
still detectable in LF1-LacZ(Am) in the absence of AcK (141
MU; MU = Miller Units), only background levels (55 MU)
were measured in strain LF1-LacZ-PP(Am). As expected,
addition of 1 mM AcK to the medium increased LacZ
production in both cases, to 468 MU (LF1-LacZ(Am)) and
111 MU (LF1-LacZ-PP(Am)), respectively. In agreement with
our previous finding for the luminescence reporter LuxPP(Am),
the PP(Am) context resulted in a more pronounced decrease in
translational output, confirming that it further reduces leakiness
in the system. The virtually complete abrogation of LacZ
production is further illustrated by the fact that the color
change from white to blue of E. coli colonies encoding LacZ-
PP(Am) is strictly dependent on AcK (Figure 3C). In contrast,
the LF1-LacZ(Am) strain turns blue when grown on LB/X-Gal
agar plates containing the lacZ inducer IPTG (Figure 3C).
Furthermore, LF1-LacZ-PP(Am) containing AcKRST was only
able to grow on lactose when AcK was concomitantly supplied,
while the residual β-galactosidase activity in LF1-LacZ(Am)
cells (Figure 3B) was sufficient to promote growth even in the
absence of AcK (Figure 3D). Thus, these data further
corroborate our findings with the Lux reporters (Figure 2C,
D; Table 1).
The ability to tightly control LacZ synthesis in this way
demonstrates the potential of our system for AcK-dependent
translational regulation of essential genes with a specific amber
context.
Chromosomal Integration of AcKRS Enhances Regu-
lated Amber Suppression. Having shown that amber
suppression is a potent molecular tool for the regulation of
translational output, we set out to engineer E. coli in such a way
that it can serve as a host for investigation of the function of
essential genes in an AcK-dependent manner. In a previous
publication we reported the construction of a strain named
LF1, into which we had inserted a kanamycin resistance
cassette and a wildtype copy of rpsL (conferring streptomycin
sensitivity) into the lac locus.55
The two genes are flanked by FRT sites that mediate Red/
ET (Gene Bridges) recombination, which permits scarless
insertion of any DNA sequence of interest within 1 day. We
used this method to integrate pylS*/pylT into the LF1 strain.
While pylS was set under the control of Plac, pylT (tRNACUA)
expression was kept constitutively expressed employing PproK.
The genomic context of the resultant insert in the new strain
LF1-AcKRST is depicted in Figure 4A. To test amber
suppression in E. coli LF1-AcKRST, the cells were transformed
with pBAD/HisA-Lux(Am), and luminescence was monitored
in response to the external supply of IPTG and AcK. As
expected, no luminescence was detectable in the absence of
both substances. Similarly, supplementation with 1 mM AcK
alone did not lead to any measurable light production, while
addition of IPTG to the medium on its own resulted in only
very weak luminescence of approximately 1.0 × 104 RLU. In
stark contrast, the simultaneous presence of AcK and IPTG
Figure 3. Regulation of LacZ levels in E. coli by amber suppression.
(A) Genetic organization of the lacZ gene in E. coli LF1-LacZ strains.
E. coli LF1 strains were constructed by inserting either an amber (LF1-
LacZ(Am)) or PP amber sequence (LF1-LacZ-PP(Am)) after the
ninth codon of the lacZ gene. Corresponding lysine codon insertions
served as positive controlsLF1-LacZ-K and LF1-LacZ-PPK,
respectively. (B) Quantitative analysis of amber suppression of β-
galactosidase LacZ. To measure the β-galactosidase activity, cells were
grown in LB overnight and reporter activity was determined according
to Miller,52 in the presence/absence of the amber suppression
machinery (AcKRST). Cells were incubated with IPTG, AcK or a
combination of both substances. The activity is given in Miller Units
(MU). (C) Qualitative analysis of amber suppression of LacZ. E. coli
LF1 strains described in (A) were grown on LB agar supplemented
with 80 μM X-Gal, 1 mM IPTG and 1 mM AcK as indicated. (D)
Growth analysis of E. coli LF1 strains with lactose as sole carbon
source. LF1 strains with and without AcKRST were grown in M9
minimal medium53 supplemented with 20 mM lactose in the
presence/absence of 1 mM AcK in microtiter plates.
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increased the light intensity to about 3.7 × 105 RLU. Thus, the
E. coli strain LF1-AcKRST provides an on/off switch for the
production of specific proteins. It should be noted that 0.2%
Ara was always added to the medium, so that the luxCDABE
operon was fully induced under all conditions tested. Recall
that when pylS*/pylT was provided in trans (pACYCDuet-
AcKRST) significant luminescence was observed in the absence
of AcK (Figure 2C). Thus, the reduction in pylS*/pylT copy
number from about 20−30 in the plasmid-based system56 to
one in the chromosome almost completely abolishes
mischarging of tRNACUA. Furthermore, the coupling of
chromosomal integration of the amber suppression machinery
(AcKRST) with IPTG-inducible expression of pylS* eliminates
the physiological burden that goes along with the constitutive
expression of orthogonal tRNAs and aminoacyl tRNA
synthetases57 (Supplementary Figure S4).
To proof functionality of the parental strain E. coli LF1-
AcKRST in regulating the expression of essential gene
products, we aimed to generate a mutant with a defect in cell
wall biosynthesis. For this purpose, we chose the gene encoding
dihydrodipicolinate synthase DapA, being crucial for the
generation of meso diaminopimelic acid (DAP).58 Accordingly,
a dapA deletion causes DAP auxotrophy. To this end the E. coli
strain LF1-AcKRST/dapA:camr was generated using Red/ET
(Gene Bridges) recombination. As expected LF1-AcKRST/
dapA:camr (DAP−) can only grow in LB supplemented with as
little as 75 μM DAP (Supplementary Figure S5).
To trace the observed auxotrophy back to the deletion of
dapA we constructed a plasmid pBAD/HisA-dapA coding for
an N-terminal His6-tagged copy of DapA. Ectopic expression of
His6-DapA in LF1-AcKRST/dapA:cam
r permitted growth in
the absence of DAP after induction with 0.2% Ara (Figure 5A).
Beside the fact, that this result clearly links the observed
phenotype to the gene deletion, it also demonstrates that the
N-terminal extension of the protein sequence does not interfere
with the enzymatic activity of DapA. Consequently, a plasmid
pBAD/HisA-dapA(Am) was derived from pBAD/HisA-dapA.
This daughter plasmid deviates from the parental only by an
amber motif as a third codon in the original dapA ORF which
in turn follows a 39 amino acids (aa) long N-terminal extension
encoded in the pBAD/HisA backbone.
We investigated the power of coupled transcriptional and
translational regulation by controlling the growth of the DAP−
Figure 4. E. coli LF1-AcKRST. (A) Genetic organization of the E. coli
strain LF1-AcKRST. Nε-acetyl lysyl-tRNA-synthetase (pylS*) was
cloned under the control of the IPTG-inducible lac promoter (Plac),
while the cognate tRNACUA (pylT) was placed under the control of the
constitutive promoter PproK. (B) AcK-dependent amber suppression in
E. coli LF1-AcKRST. Cells were transformed with the Lux-amber
reporter (LuxAm). The resulting strains were then grown overnight in
LB, and luminescence development was recorded in response to IPTG
and AcK. The maximal luminescence normalized to the OD600 from a
16 h time course experiment is depicted. Error bars represent the
standard deviation of data from three different experiments.
Figure 5. Transcriptional and translational control of DAP auxotrophy. Growth analysis of the LF1-AcKRST/dapA:camr strain harboring the pBAD/
HisA-dapA or pBAD/HisA-dapA(Am) plasmid. Cells were grown in a microtiter plate over a time course of 22h in LB with the indicated
supplements. Afterwards pictures of the bacterial cultures were taken. (A) Growth curve and picture of the LF1-AcKRST/dapA:camr strain harboring
a plasmid borne copy of dapA (pBAD/HisA-dapA), or the empty vector e.v. (pBAD/HisA) as negative control, in response to 0.2% (w/v) L-
arabinose (Ara), 0.2% (w/v) D-glucose (Gluc) or 75 μM diaminopimelic acid (DAP). Ara and DAP growth curves are depicted as triplicates, Gluc
growth curves are depicted as single measurements. (B) Growth curve and picture of the LF1-AcKRST/dapA:camr strain harboring the empty vector
(e.v.) as negative control or pBAD/HisA-dapA(Am) (DapAAm) containing a plasmid borne copy of DapA with an inserted amber codon, in response
to Ara, DAP, Gluc, Nε-acetyl-L-lysine (AcK) and isopropyl β-D-1-thiogalactopyranoside (IPTG) as indicated. Error bars in the growth curve represent
the standard deviation of data from three different experiments.
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strain in the presence of a plasmid borne gene copy. Therefore,
the E. coli DAP− strain LF1-AcKRST/dapA:camr was trans-
formed with pBAD/HisA-dapA and pBAD/HisA-dapA(Am),
respectively and cells were initially cultivated overnight in LB
supplemented with 75 μM DAP. The next day cells were
inoculated into LB + 0.2% D-glucose (Gluc) (to catabolically
repress PBAD induction), LB + 75 μM DAP and LB + 0.2% Ara
(to induce PBAD induction). Growth of the strain harboring the
pBAD/HisA-dapA(Am) was additionally monitored in LB + 1
mM IPTG (to induce expression of Plac regulated AckRS), in
LB + 1 mM IPTG + 1 mM AcK (to allow Amber suppression)
and ultimately in LB containing a combination of all three
components (0.2% Ara, 1 mM IPTG and 1 mM AcK) (Figure
5B). As expected, this coupling of AcK dependent amber
suppression with Ara induced transcriptional activation
permitted growth in the absence of DAP. Notably, growth
behavior of cells cultivated with 0.2% L-Ara, 1 mM IPTG and 1
mM AcK was beside a short lag-phase almost identical to what
we observed for cells that were supplemented with 75 μM of
DAP (Figure 5B). On the other hand, we could not detect an
increase in OD600 in the cultures lacking either DAP or 0.2%
Ara. However, the sole addition of Ara was sufficient to
promote overnight growth of LF1-AcKRST/dapA:camr with
pBAD/HisA-dapA(Am). Compared to cultures containing all
three supplements (Ara, IPTG and AcK) we observed an
extended lag phase and even an initial drop in the starting
OD600 (Figure 5B). The latter might be explained by cell lysis
due to instability of the bacterial cell wall, whereas the first 10 h
without any significant change in OD600 indicates the
development of a suppressor mutation that promotes growth
even under translationally repressing conditions. Similar results
were observed when monitoring the growth of cells containing
pBAD/HisA-dapA in which PBAD dependent gene expression
was catabolically repressed59 (+0.2% Gluc) (Figure 5A).
Thus, the coupling of transcriptional and translational
regulation does not only allow a tunable protein output over
several orders of magnitude but also prevents a fast develop-
ment of suppressor mutation in cases where prolonged
incubation is necessary.
Four Broad-Host-Range Cloning Vectors Allow Amber
Suppression in Diverse Bacterial Species. The demon-
stration that amber suppression permits tight regulation of
protein output in E. coli raised the question of the system’s
transferability to other bacteria. To answer this question, we
made use of the various pBBR1MCS-X derivatives available,60
bearing resistance cassettes for kanamycin, tetracycline,
ampicillin and gentamycin, respectively.61 The pBBR1 origin
of replication present in these plasmids is recognized in a wide
range of bacterial hosts, and they are also mobilizable for
conjugational transfer.60
Moreover, the vectors do not belong to the Inc.P, Inc.Q or
Inc.W incompatibility group, and can therefore be coinherited
with p15A- or ColE1-dependent replicons.61 Consequently, we
cloned the genes of the amber suppression machinery into
pBBR1MCS-2 to 5, keeping the original multiple cloning sites
intact, and retaining the potential for blue/white screening
Figure 6. A set of broad-host-range cloning vectors for amber suppression in diverse bacteria. (A) Maps of pBBR1MCS-X AcKRST derivatives. The
pylS*/pylT cassette was integrated adjacent to the multiple cloning site in the available broad-host-range plasmids pBBR1MCS-2 to 5. (B) Analysis
of amber suppression in cells bearing the pBBR1MCS-X AcKRST derivatives. pBBR1MCS-X AcKRST vectors were transferred into E. coli BW25113
together with the Lux-amber reporter (LuxAm) or Lux reporter (Lux+), as positive control. The resulting strains were grown overnight in LB and
luminescence development was recorded in response to Ara and AcK. The maximal luminescence normalized to the OD600 from a 16 h time course
experiment is depicted. Error bars represent the standard deviation of data from three different experiments.
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(Figure 6A). The function of the resulting derivatives was
validated by transformation of E. coli with the LuxAm reporter
and subsequent analysis of AcK-dependent amber suppression
(Figure 6B).
Next we cloned a copy of the NanoLuc luciferase (Nluc) into
pBBR1MCS-2 AcKRST (Figure 7A) under the control of the
PBAD promoter. The plasmids generated in this way
(pBBR1MCS-2 AcKRST Nluc, pBBR1MCS-2 AcKRST Nluc-
(Am), pBBR1MCS-2 AcKRST Nluc PP(Am)) were then
transferred into Salmonella enterica LT2 and Vibrio cholerae El
Tor C6706 cells, and the wildtype NanoLuc was used as the
positive control (Nluc). AcK-dependent amber suppression was
analyzed with a NanoLuc variant, containing a UAG as third
codon (NlucAm). Again, a position close to the protein start was
selected because the enzyme reportedly tolerates N-terminal
fusions.62 In addition, we constructed a variant with PP amber
context (NlucPP(Am)) (Figure 7A). The dependence of
luminescence production in S. enterica and V. cholerae cells
on supplementation with Ara and/or AcK was then analyzed.
As expected, cells encoding a NanoLuc without any amber
insertion emit luminescence when grown in the presence of Ara
(Figure 7B, C). In contrast, significant luminescence
production by cells harboring the NlucAm or NlucPP(Am)
reporter required the simultaneous addition of Ara and AcK.
As in E. coli, the PP(Am) context further diminished the low
level of light production seen in the absence of AcK. Thus, our
results are 1:1 transferable from E. coli to S. enterica and
V. cholerae and with this, amber suppression is applicable to
diverse bacteria.
■ CONCLUDING REMARKS
In the present study we investigated the application of AcK-
dependent amber suppression for the regulation of translational
outputs. We showed that coupling of transcriptional and
translational regulation is an effective way to fully switch off the
synthesis of specific proteins. Manipulation of the concen-
trations of both the transcriptional inducer and AcK permits
gradual adjustment of the protein output. Furthermore, and in
line with previous reports, we observed that the incorporation
of an amber stop codon into a plasmid-borne gene copy
resulted in a measurable level of protein synthesis by
translational read-through (Figure 2C), which can be
modulated by changing the amber context43,46,49 (Table 1).
Such read-through might be beneficial when reduced levels of
an essential gene product are needed to maintain viability, but
nevertheless cause a mutant phenotype. If necessary, the
translational output can be further increased by ectopic
expression of the pylS*/pylT amber suppression system. It
should be noted that in our system mischarging becomes
virtually irrelevant when pylS*/pylT was integrated in the
chromosome and combined with inducible expression. This is
exemplified by the fact that E. coli LF1-AcKRST cells encoding
a LuxAm reporter remain completely dark in the absence of
IPTG (Figure 4). Only the concomitant presence of IPTG and
AcK allowed efficient amber suppression. Thus, chromosomal
incorporation of the amber suppression machinery might
generally increase specificity for ncAAs.
Altogether, our analyses of AcK-dependent amber suppres-
sion as a means of regulating protein production provide the
basis for use of the system as a versatile translational control
mechanism for investigation of the function of essential genes.
Thus, the components available in this molecular toolbox
enable fine-tuning of protein synthesis, not only in E. coli but
also in other Gram-negative bacteria such as S. enterica or
V. cholerae.
■ MATERIALS AND METHODS
Bacterial Stains, Oligonucleotides and Plasmids.
Strains, primers and plasmids used in this study are listed in
Supplementary Tables S1−S3. All oligonucleotides used for
PCR amplification and sequencing were synthesized by Sigma-
Aldrich. The sequences of all constructed plasmids were
verified by Sanger sequencing.
Molecular Biological Methods. E. coli, S. enterica and
V. cholerae cells were routinely grown in LB and where
indicated in M9 minimal medium.63 Solidification of the
medium was achieved by adding 1.5% (w/v) Agar−Agar (Carl
Roth). If necessary, media were supplemented with antibiotics
at the following concentrations: ampicillin sodium salt (100
μg/mL), chloramphenicol (30 μg/mL), kanamycin sulfate (50
μg/mL), tetracycline hydrochloride (15 μg/mL), gentamycin
sulfate (15 μg/mL), and streptomycin sulfate (50 μg/mL). For
blue-white selection, LB-agar plates were additionally supple-
mented with 80 μM 5-bromo-4-chloro-3-indolyl β-D-galacto-
Figure 7. Amber suppression in Salmonella enterica and Vibrio cholerae.
(A) An amber (NlucAm) or PP amber motif (NlucPP(Am)) was inserted
after codon 2 of the NanoLuc gene and cloned into the pBBR1MCS-2
AcKRST backbone. A vector bearing the wildtype NanoLuc gene
served as the positive control (Nluc). pBBR1MCS-2 AcKRST Nluc,
pBBR1MCS-2 AcKRST Nluc(Am) and pBBR1MCS-2 AcKRST Nluc
PP(Am) were transferred into Vibrio cholerae (B) and Salmonella
enterica (C). Luminescence was measured from overnight cultures
using the Nano-Glo luciferase assay system. Error bars represent the
standard deviation of data from three different experiments.
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pyranoside (X-Gal) (Sigma-Aldrich) and 1 mM isopropyl β-D-
1-thiogalactopyranoside (IPTG) (Sigma-Aldrich) to induce the
lac promoter Plac. Unless indicated otherwise, 0.2% (w/v) L-
arabinose was added to induce the PBAD promoter.
All enzymes and kits were used according to the
manufacturers’ directions. DNA fragments were purified from
agarose gels using a high-yield PCR cleanup and gel extraction
kit (Sued-Laborbedarf). Restriction endonucleases were
purchased from New England Biolabs. Sequence amplifications
were performed by PCR using Phusion high-fidelity DNA
polymerase (Finnzymes) or Taq DNA polymerase (New
England Biolabs). All mutants were constructed by one- or
two-step PCR using mismatched primer pairs.64
β-Galactosidase activity assays were performed as essentially
described previously.55
Plasmid and Strain Construction. pACYCDuet-AcKRST
was constructed as follows: A PCR fragment containing the
respective mutations in the pylS gene was generated as
described previously by Umehara et al. 20127 and cloned into
pACYCDuet-PylRST using the internal XhoI and NotI
restriction sites (Supplementary Table S2, Supplementary
Table S3).
LuxCDABE-containing pBAD/HisA constructs were gener-
ated as follows: The luxCDABE operon from Photorhabdus
luminescens was amplified from pBBR1MCS-5 TT-RBS-lux,65
and then cloned into pBAD/HisA (Invitrogen) using NcoI and
KpnI as restriction sites. The resulting vector pBAD/HisA-Lux
served as a template for all other luxCDABE-bearing plasmids
used in this study. To construct luxC amber versions we used
mismatched primer pairs (Supplementary Table S3) for
overlap-extension PCR and cloned the resulting fragments
into pBAD/HisA-Lux using NcoI and BsrGI, thereby replacing
the parental luxC fragment. The resulting plasmids, pBAD/
HisA-Lux(Am), pBAD/HisA-Lux(2Am), pBAD/HisA-Lux-RA-
(Am), pBAD/HisA-Lux-DA(Am), pBAD/HisA-Lux-HH(Am),
pBAD/HisA-Lux-KDP(Am), pBAD/HisA-Lux-PP(Am) and
pBAD/HisA-Lux-KDPP(Am) are listed and described in
Supplementary Table S2.
The constructs pBAD/HisA-dapA and pBAD/HisA-dapA-
(Am) were generated as follows: From genomic E. coli DNA,
dapA was amplified and the amber motif was introduced using a
mismatched primer (Supplementary Table S3). The resulting
fragments were than cloned into the pBAD/HisA backbone
using XhoI and EcoRI as restriction sites. The resulting plasmids
are listed in Supplementary Table S2.
To generate pBAD/HisA-Kan and plasmid derivatives
(Supplementary Table S2) the ampicillin resistance cassette
was replaced by nptI, which was amplified from pBBR1MCS-2
(Supplementary Table S3). The PCR fragment was introduced
restriction-free into pBAD/HisA as described.66
The broad-host-range cloning vectors containing pylS*/pylT
were constructed as follows: pylS*/pylT was amplified from
pACYCDuet-AcKRST and the resulting PCR fragment was
cloned into pBBR1MCS-2 to 5 plasmids using either the NsiI
or the AgeI restriction site (Supplementary Table S2,
Supplementary Table S3).
The Nluc reporter plasmids were generated by amplifying
the sequence encoding NanoLuc luciferase from pNL1.1
(Promega). The respective amber motifs were introduced
using mismatched primer pairs in a standard PCR (Supple-
mentary Table S3). The fragments obtained were each
combined with the arabinose-inducible PBAD promoter frag-
ment (amplified from pBAD/HisA, via overlap-extension
PCR), and cloned into pBBR1MCS-2 AcKRST using XbaI
and KpnI restriction sites. The resulting plasmids, pBBR1MCS-
2 AcKRST Nluc, pBBR1MCS-2 AcKRST Nluc(Am), and
pBBR1MCS-2 AcKRST Nluc PP(Am) are listed in Supple-
mentary Table S2.
E. coli LF1-LacZ-K, LF1-LacZ(Am), LF1-LacZ-PPK, and
LF1-LacZ-PP(Am) strains, as well as LF1-AcKRST, were
constructed essentially as described previously by Fried et al.55
and are listed in Supplementary Table S1.
E. coli LF1-AcKRST/dapA:camr was generated by using the
pRed/ET recombination technology in accordance to the
technical protocol of the Quick & Easy E. coli Gene Deletion
Kit (Gene Bridges) and is listed in Supplementary Table S1.
Lux-Based Luminescence Activity Assay. Single colo-
nies were transferred into LB supplemented with the
appropriate antibiotics, and grown aerobically overnight at 37
°C. On the next day, cells were inoculated at an OD600 of 0.01
into fresh LB supplemented with the corresponding antibiotics.
Cells were then grown aerobically at 37 °C in a microtiter plate
in a Tecan Infinite F500 system (TECAN) and luminescence
development in response to AcK and Ara was monitored at 10
min intervals over the course of 16 h. Light units were
normalized to OD600 and are thus expressed in relative light
units (RLU). Subsequently RLUs were background corrected
by subtracting the luminescence level detected in cells
containing a vector without a luxCDABE operon. Each
measurement was performed in triplicate.
The luminescence assay for the E. coli LF1-AcKRST strain
was performed as described above but with the difference that
the cells on the second day were inoculated in LB, containing
besides the antibiotic additionally 0.2% Ara (w/v). Sub-
sequently, luminescence development in response to 1 mM
AcK and 1 mM IPTG was detected as described before.
NanoLuc Luciferase Assay in S. enterica and V. chol-
erae. Single colonies of S. enterica and V. cholerae were
transferred into LB supplemented with kanamycin sulfate (50
μg/mL) and grown overnight aerobically at 37 °C. On the next
day, these cultures were used to inoculate the main cultures to
an OD600 of 0.01. To determine AcK- and Ara-dependent
luminescence development, all main cultures were grown
aerobically overnight at 37 °C in LB supplemented with
kanamycin sulfate (50 μg/mL) and containing either 1 mM
AcK, 0.2% Ara (w/v), or a combination of both compounds. A
culture grown in the absence of both served as negative control.
OD600 was determined from overnight cultures and the Nano-
Glo luciferase assay reagent (Promega) was prepared according
to manufacturer’s instructions. Then, the experimental cultures
were mixed 1:1 with Nano-Glo luciferase assay reagent,
transferred into a 96-well microtiter plate, and luminescence
was determined 5 min later with a Tecan Infinite F500 system
(TECAN). Light units were normalized to OD600 and
expressed in relative light units (RLU). Each measurement
was performed in triplicate.
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6 Concluding discussion 
Protein-glycosylation is a universal strategy for post-translational modification and has 
been linked to numerous processes that are important for bacterial physiology and 
pathogenicity (71, 100). These capacities are mediated by the considerable structural and 
functional changes that can result from carbohydrate linkage to polypeptides (16). Almost all 
reported cases of nitrogen-linked glycosylation (N-glycosylation) occur on asparagine (65). 
The EF-P specific rhamnosyltransferase EarP is one of only two known glycosyltransferases 
linked to arginine N-glycosylation. Both of these enzymes are involved in mediating bacterial 
pathogenicity (113, 114, 116). Moreover, arginine rhamnosylation has so far not been 
detected in humans (126) Therefore, this process offers opportunities for application as an 
orthologous protein glycosylation platform in synthetic biology and as an efficient 
antibacterial target in medicine. However, understanding of the molecular mechanism of the 
glycoconjugate biosynthesis must precede application. 
The structural and biochemical data presented here substantially contributes to a better 
understanding of arginine glycosylation and allows us to derive a mechanistic model of EarP 
mediated EF-P modification (Figure 6). In a first step, the nucleotide sugar donor 
TDP-β-L-rhamnose is bound and oriented in the C-terminal domain of the GT-B 
glycosyltransferase EarP by the concerted action of several highly conserved amino acids 
(Chapter 3, Figure 6B). Subsequently, structural elements of the KOW-like EF-P N-domain 
are recognized and bound by the N-terminal EarP domain, thereby occluding the active site 
from the environment (Chapters 3, 4 and (127)). By a mechanism that is so far not fully 
understood, the negatively charged side chains of two aspartates activate the acceptor 
arginine, which in turn engages in a nucleophilic attack onto the anomeric carbon of the 
nucleotide sugar (Chapter 3, Figure 6C). This reaction results in the formation of 
α-rhamnosyl-arginine on the protein acceptor, thus representing an inverting mode of 
glycosyl transfer (Chapter 2). Finally, the products are released from the active site and EarP 
engages in another cycle of rhamnosylation (Figure 6A).  
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Figure 6. Proposed glycosylation mechanism of the rhamnosyltransferase EarP from P. putida. A) Ground 
state; both the donor and acceptor binding site of EarP (orange and green) are unoccupied. B) Donor-bound 
state; TDP-β-L-rhamnose (TDP-Rha, red) is bound and oriented within the binding pocket in the C-terminal 
domain. C) Catalytic state; The putative catalytic amino acids D13 and D17 facilitate the nucleophilic attack onto 
the anomeric centre of TDP-β-L-rhamnose by activating the arginine 32 guanidinium of EF-P (yellow and blue). 
Binding and dissociation events are indicated by arrows: 1. TDP-Rha binding; 2. EF-P binding; 3. EF-P, rhamnose 
and TDP dissociation.  
 
6.1 EarP is a GT-B fold glycosyltransferase 
Crystal structure analysis identified EarP as a GT-B fold glycosyltransferase (Chapter 3). 
Enzymes of this fold consist of two physically separate domains that are connected by a 
flexible linker (42). Canonically, the N-terminal domain is involved in acceptor binding, 
whereas the nucleotide sugar binding pocket is localized in the C-terminal domain (26). 
Accordingly, EarP binds its donor substrate TDP-β-L-rhamnose in a highly conserved pocket 
in the protein C-domain (Chapter 3, Figure 6B). Here, the aromatic side chains of F191, F252 
and F258 surround and coordinate the thymine moiety of the substrate. The deoxyribose is 
specifically recognized by hydrogen bonds with Q255. A hydrogen bonding network 
established by the side chains of R271 and Y193, as well as the backbone amides of E273 
and D274 orient the phosphate. The side chain of R271 is localized in a position suitable to 
neutralize the developing negative charges on the phosphate upon transfer and thus to 
stabilize the deglycosylated dinucleotide product (31, 42) (Chapter 3, Figure 6B). This donor 
binding site architecture is broadly observed for the GT-B fold, which generally exhibits a 
high degree of structural conservation in the nucleotide sugar binding domain (26).  
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In contrast, the N-terminal acceptor binding domain is structurally more diverse, most 
likely reflecting the capability of GT-B fold glycosyltransferases to adapt to a wide variety of 
different acceptor substrates such as carbohydrates, lipids or proteins (26). Structural 
analysis of the EF-P-EarP complex from Neisseria meningitidis (PDB: 5WXK) confirmed that 
the N-terminal domain of EarP is responsible for binding of the acceptor substrate (127). 
Thus, the general principles that are observed for GT-B protein-glycosyltransferases with 
respect structure and substrate binding also apply for EarP (27). Conversely, the molecular 
targets of the rhamnosyltransferase are quite unusual. EarP is so far the only known 
glycosyltransferase that activates a cytosolic protein and the sugar that is transferred in order 
to confer this activity is rarely used in protein glycosylation (65, 116). In addition, EarP also 
represents the first example of GT-B mediated arginine glycosylation. As the chemical nature 
of the arginine guanidinium is different from the asparagine amido group, the mechanism for 
activation of this side chain remains to be conclusively determined.  
6.2 EarP is an inverting glycosyltransferase 
NMR analysis of in vivo modified EF-P of P. putida demonstrated that the product of the 
rhamnosylation reaction is α-rhamnosyl-arginine (Chapter 2). As the nucleotide sugar donor 
substrate for the glycosylation reaction was previously identified to be TDP-β-L-rhamnose 
(116), these results unambiguously identified EarP as an inverting glycosyltransferase. Wang 
and colleagues later confirmed our findings using an alternative approach. They used 
chemical synthesis to generate peptides that correspond to the P. aeruginosa EF-P acceptor 
loop and carried either α- or β-mono-rhamnosyl-arginine (128). The elution profiles of these 
glycopeptides during nano-UHPLC analyses were compared to the one of the corresponding 
native peptide released from purified EF-P after Lys-C digest. As the native peptide co-eluted 
with the synthesized α-rhamnosyl-arginine containing glycopeptide, the inversion of the 
anomeric configuration during transfer was confirmed. The specific stereochemical outcome 
of the glycosylation reaction is a key characteristic of a given glycosyltransferase (27). 
Inversion and retention result from fundamentally different reaction mechanisms which are in 
turn based on the microenvironment within the active site (129). Structural comparison of 
glycosyltransferases that result in the same stereochemical outcome can therefore be 
utilized in order to deduce the underlying molecular mechanism (Chapter3). 
A well-studied and structurally supported mechanism for bacterial N-glycosylation is that 
of the inverting asparagine olygosaccharyltransferase PglB of C. lari (52, 54). This enzyme 
catalyzes the transfer of a preassembled glycan from a lipid donor to a multitude of 
periplasmic acceptor proteins (130). The catalytic activity of GTs mainly includes activation of 
the acceptor substrate, which in turn attacks the anomeric carbon (29, 42). Therefore, this 
mechanism of activation provides valuable information despite the utilization of a chemically 
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distinct donor substrate (131). In PglB, two negatively charged amino acids are responsible 
for activation of the acceptor asparagine. These side chains form hydrogen bonds with the 
amido group. Thereby the partial double-bond character is abolished and the acceptor is 
activating by a twisted amide mechanism. The necessary interactions are further stabilized 
by a coordinated divalent cation and additional side chain hydrogen bond interactions (52, 
54) (Figure 7A).  
Bioinformatic and structural analyses of EarP led to the identification of two invariant 
aspartate residues (D13 and D17 in P. putida EarP) that are located within the active site of 
the rhamnosyltransferase (Chapter 3). The side chains of these amino acids might exert a 
similar function as the catalytically important amino acids in PglB (Figure 7A and 7B). 
Substitution of either of these amino acids to alanine leads to inactivation of EarP. 
NMR-analysis confirmed that the corresponding protein variants are correctly folded and 
capable of binding the sugar substrate. Additional bacterial two-hybrid based protein-protein 
interaction studies showed that interaction with the acceptor substrate is not inhibited by 
these mutations either (Chapter 3). Based on these results, we suggest a PglB-like 
mechanism for the activation of arginine (Figure 7). In this model, D13 and D17 form 
hydrogen bond interactions with the acceptor. These interactions in turn abolish electron 
delocalization on the guanidinium, yielding a lone electron pair on the nitrogen that is capable 
of a nucleophilic attack onto the anomeric carbon (Figure 7B).  
As GT-B glycosyltransferases are in general functionally independent of divalent cations, 
involvement of charged metal ions seems unlikely. Instead, an extended hydrogen bond 
network based on side chain interactions could be compensating for the lack of the positive 
charge. Due to low electron density of structural elements of the EarP N-terminal domain, the 
position of the catalytically relevant amino acid side chains of D13 and D17, but not of the 
surrounding and possibly supporting residues, could be derived from the crystal structure 
(Chapter 3). Thus it remained unclear, whether the EarP active site is suitably organized to 
coordinate a twisted amide-like mechanism of activation.  
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Figure 7. Chemical structures of the PglB, EarP and PRMT1 catalytic sites. Amino acids involved in building 
the active site are indicated by single letter code specifiers. Hydrogen bonds are indicated by dashed lines. 
Hydrogen atoms of the acceptor substrates that are engaging in hydrogen bond interaction with the 
corresponding modification enzyme are highlighted by a red background. Oxygen atoms of the modification 
enzyme that are engaging in hydrogen bond interaction with the acceptor substrate are highlighted by a green 
background. A) PglB of C. jejuni as described in (52). The position of the divalent metal ion (M
2+
) is indicated by a 
grey sphere. The amido group of the acceptor asparagine is highlighted by a grey backdrop. B) EarP of 
N. meningitidis as described in (127). The guanidinium of the acceptor arginine is highlighted by a grey backdrop. 
C) PRMT1 of Rattus norvegicus (right) as described in (132). The guanidinium of the acceptor arginine is 
highlighted by a grey backdrop. 
 
The two aspartates D16 and D20 of N. meningitidis EarP (corresponding to D13 and D17 
of P. putida EarP) are located in close proximity of the acceptor arginine and form salt bridge 
interactions with the amino groups of the guanidinium (127). Together with additional side 
chain interactions, these negatively charged amino acids comprise the main site of contact. 
Based on this structure, D20 was suggested to act as catalytic base that deprotonates one of 
the amino groups in order to activate the acceptor arginine. This mechanism is orthologous 
to the one that is generally accepted to be utilized by most inverting O-glycosyltransferases 
and has also been proposed for N-linked glycosylation (29, 62, 133, 134) (Figure 4D).  
In the case of asparagine modification by PglB, the specific architecture of the active site, 
the involvement of a divalent cation, as well as the orientation of the acceptor substrate seem 
to favor the twisted amide mechanism over acid/base catalyzed activation (52, 54). The 
structural information on N. meningitidis EarP confirms that the rhamnosyltransferase does 
not coordinate a divalent cation and reveals that there are no obvious interactions with 
positively charged amino acid side chains that could compensate for the lack of this cofactor 
(127). Therefore, EarP lacks a structural feature that is considered to be important for 
catalysis by the twisted amide mechanism. The acid/base activation on the other hand has 
been shown to involve a proton donor that is part of the Asn-X-Ser/Thr glycosylation motif on 
the acceptor substrate. Neither the protein acceptor EF-P, nor the glycosyltransferase EarP 
exhibit an appropriate polar residue that reaches into vicinity of the active site and could fulfil 
this function (127). Additionally, the high pKa value of the guanidinium (pKa = 12.10) raises 
the question, how deprotonation by the weak base aspartate would occur under physiological 
conditions.  
Catalytic deprotonation of arginine by negatively charged amino acids was originally 
proposed for the Rattus norvegicus protein-arginine-methyltransferase 1 (PRMT1) but later 
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shown not to play a role in promoting this transfer reaction (132, 135). Interactions similar to 
those that are associated with the twisted amide mechanism were instead proposed to 
properly align the substrate (Figure 7C). These interactions abolish the planarity of the 
guanidinium in order to prime it for the nucleophilic attack (136). The orientation of the 
catalytically important amino acids relative to the acceptor arginine in PRMT1 is highly similar 
to that in EarP, suggesting that a shared mechanism for substrate activation might be 
possible (Figure 7B and 7C). Specifically, localization and hydrogen bond formation of D16, 
D20 and Y288 in EarP of N. meningitidis are essentially mimicked by E144, E153 and Y35 in 
PRMT1 (127, 132, 136) (Chapter 3). While this similarity again indicates that a twisted 
amide-like mechanism for activation might be viable for the rhamnosyltransferase EarP, 
experimental evidence for this hypothesis is lacking. 
Taken together, the functional importance of several amino acid side chains has been 
demonstrated (Chapter 3). However, their exact molecular role in activation of the acceptor 
substrate has not yet been conclusively determined. Comparison with reported mechanisms 
of N-linked post-translational modification provides theoretical insights (Figure 7). However, 
further experimental analyses will ultimately have to prove, whether a twisted amide-like 
mechanism or acid/base activation is used to prime arginine for glycosylation.  
6.3 Rhamnosyl-arginine is a novel bacterial glycoconjugate 
EarP is an inverting glycosyltransferase that mediates the formation of α-rhamnosyl-
arginine on the protein acceptor EF-P. Based on this information, polyclonal antibodies 
targeting this modification were raised in rabbits (Chapter 2, 3). Single mono-rhamnosyl-
arginine containing peptide haptens fused to bovine serum albumin were used as 
immunogens. The purified anti-rhamnosyl-arginine antibodies (anti-ArgRha) sensitively and 
specifically bind rhamnosylated EF-P (EF-PRha), while showing no cross-reactivity with the 
unmodified elongation factor (Chapter 2, 3). As EF-P rhamnosylation is found in clinically 
relevant bacteria such as P. aeruginosa and N. meningitidis (116, 127), antibodies with this 
specificity could be used in diagnostic applications in order to detect these pathogens.  
As a biochemical tool, anti-ArgRha allows for detection of product formation during in vitro 
rhamnosylation reactions. This enables both the determination of kinetic parameters and the 
quantification of intracellular TDP-β-L-rhamnose concentrations (Chapter 3). E. coli, P. putida 
and P. aeruginosa cells contain high micromolar concentrations of this nucleotide sugar. This 
is in line with previous studies reporting a TDP-β-L-rhamnose concentration of 1 mM in the 
Gram-positive lactic acid bacterium Lactococcus lactis (137). Gram-positive bacteria have 
been shown to exhibit L-rhamnose containing cell wall polysaccharides that are critical for 
both pathogenicity and cell viability (138-140). These polymers are synthesized using 
TDP-β-L-rhamnose as a sugar donor (126), which explains the high demand of this 
 
79 
 
metabolite within the cells. The O-antigen and the outer core oligosaccharide region of 
lipopolysaccharide (LPS) of several pathogenic Gram-negative bacteria also contain 
L-rhamnose derived from this precursor (Figure 8). Besides this, the γ-proteobacterium 
P. aeruginosa is considered to be the most prominent producer of rhamnolipids (126). Due to 
this frequent use of L-rhamnose in various molecular contexts, it is conceivable that 
P. aeruginosa has a high demand for the activated sugar precursor. Interestingly, E. coli and 
P. putida do not produce rhamnolipids and have not been shown to contain L-rhamnose in 
their LPS. Yet, these bacteria exhibit levels of TDP-β-L-rhamnose that are comparable or 
even higher than those of P. aeruginosa (Chapter 3). The biosynthesis of this metabolite is 
energy-intensive and involves the subsequent action of RmlA, RmlB, RmlC and RmlD (126, 
138) (Figure 8). Due to this elaborate biosynthesis pathway, an important cellular function 
can be assumed. The high levels of TDP-β-L-rhamnose might not only be necessary to 
supply for the synthesis of cell wall components or secondary metabolites, but also for the 
glycosylation of so far unknown protein targets.  
 
Figure 8. TDP-β-L-rhamnose biosynthetic pathway. Chemical structures of the metabolites used and 
generated during TDP-β-L-rhamnose biosynthesis are shown. The biosynthesis enzymes RmlA (glucose-1-
phosphate thymidyltransferase), RmlB (dTDP-D-glucose-4,6-dehydratase), RmlC (dTDP-4-keto-6-deoxy-D-
glucose 3,5-epimerase) and RmlD, (dTDP-4-keto-6-deoxy-L-mannose reductase) are indicated by yellow 
background. The chemical changes occurring during each reaction are indicated by red backgrounds at the 
corresponding positions. Rhamnose is transferred onto membrane components and proteins and used in the 
synthesis of secondary metabolites such as streptomycin and vancomycin.  
 
Two distinct pathways for arginine linked N-glycosylation have been identified (113, 114, 
116, 117). The effector glycosyltransferase NleB1 of enteropathogenic E. coli is injected into 
the host cell via a type III secretion system and inhibits the innate immune response (113, 
114). Specifically, the protein target TRADD is modified with a GlcNAc moiety at a highly 
conserved arginine and thereby inactivated. Conversely, the rhamnosyltransferase EarP 
activates its acceptor substrate EF-P by transferring a rhamnose moiety onto the arginine 
guanidinium (116, 117). These two cases exemplify that the molecular role of arginine 
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glycosylation is functionally diverse. Consequently, glycosylated arginine residues might be 
involved in various cellular processes such as stabilization of tertiary structures or even cell-
cell recognition that are to date believed to be modulated only by asparagine linked N-
glycosylation (100). 
In eukaryotes, all N-linked glycoproteins are initially modified with a core polysaccharide 
(67, 141). While this glycan is certainly modified to yield vastly different mature 
polysaccharide modifications, the glycan-peptide linkage will almost inevitably remain 
asparagine-GlcNAc. In bacteria, asparagine has been observed to be directly linked to 
diNAcBac, GlcNAc, galactose or glucose (142), therefore exhibiting a higher degree of 
structural diversity. A similar observation can be made for arginine-linked glycans that have 
been shown to encompass both GlcNAc and rhamnose modifications (113, 114, 116). 
GlcNAc is a ubiquitously used sugar that is - among involvement in other processes – not 
only essential for synthesis of the bacterial cell-wall but also as a component and precursor 
of the most widespread carbohydrate-asparagine linkages (141, 143). Conversely, rhamnose 
is so far considered as a rare sugar in protein glycosylation (65). This deoxyhexose has been 
shown to constitute the main component of the asparagine glycosylated platelet aggregation 
associated protein (PAAP) of Streptococcus sanguinis. However, the direct linkage to the 
amino acid occurs via GlcNAc (144). Thus, arginine glycosylation by EarP results not only in 
the formation of a novel glycoconjugate (Chapter 3), but also represents the first 
experimentally verified example of nitrogen-linked rhamnosylation. Considering the functional 
diversity of arginine glycosylation and the high concentration of TDP-β-L-rhamnose within 
bacterial cells, it seems likely, that both rhamnosyl-arginine and other arginine-linked 
glycoconjugates are also involved in other cellular processes.  
6.4 EF-P-EarP interaction is sequence and structure dependent 
The KOW-like EF-P N-domain is sufficient for rhamnosylation by the glycosyltransferase 
EarP. NMR titration and biochemical analyses suggest that most of the binding events occur 
around the EF-P acceptor loop that protrudes from the β-strands β3 and β4 (Chapter 3) 
(Figure 9 A and B). Besides the main contacts established by the catalytically relevant 
aspartates D16 and D20 further contacts were derived from the structure of the 
N. meningitidis EarP-EF-P complex. Specifically, K36 and K55 of N. meningitidis EF-P form 
salt bridges with E114 and E89 of EarP (127). Interestingly, position equivalent residues are 
missing in EF-P of P. putida. Moreover, the EarP homologue of P. putida interacts both with 
its cognate EF-P as well as with the non-cognate orthologue of E. coli (Chapter 4). The 
orthologous elongation factors exhibit a sequence identity of only ~30 % and E. coli EF-P 
does not contain lysine residues corresponding to those that were proposed to play a role in 
protein-protein interaction (Chapter 4). As these amino acids are neither universally 
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conserved in their corresponding homologues nor necessary for interaction, it seems that the 
observed contacts are specific for the N. meningitidis EarP-EF-P pair. Their role might 
therefore be to support and enhance a general and sequence-independent mode of EF-P 
recognition and binding by EarP.  
The target site of the bacterial AIDA-associated heptosyltransferase (Aah) was identified 
as a “short β-strand–short acceptor loop–short β-strand” (145). Similarly, the acceptor loop of 
elongation factor P is bracketed by two β-strands and thus exhibits a structurally reminiscent 
architecture (123, 127, 146) (Figure 9 A and B). As EarP can bind and potentially even 
modify sequentially different EF-Ps (Chapter 4), substrate recognition based mainly on 
overall structure seems plausible. This mode of acceptor binding is in line with the co-
evolution of specific interactions that support the general, structure-based protein-protein 
interaction. The structure-dependent substrate specificity of Aah was assessed using short 
peptide stretches with varying sequence and conserved structure (145). Similar experiments 
conducted on EarP might lead to the identification of a minimal binding motif. Additionally, 
the positional constraints on the acceptor arginine within the loop could be assessed by 
locating the acceptor amino acid to different positions within the unstructured region. These 
experiments could provide further insights into the mechanism of substrate recognition and 
the architecture of the EarP active site.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Natural and unnatural strategies for post-translational activation of P. putida and E. coli EF-P. 
All EF-P homologues exhibit an unstructured loop region that is bracketed by the β-strands β3 and β4. This 
acceptor loop harbors an invariant amino acid that is post-translationally modified. Modified amino acids are 
shown in single letter code in yellow (R - arginine) and green (K - lysine) spheres. The acceptor loop regions are 
magnified. Covalent modifications are depicted as chemical structures. A) α-rhamnosylation of arginine on 
P. putida EF-P (orange). B) (R)-β-lysylation of lysine on E. coli EF-P (green). C) α-rhamnosylation of arginine on 
an E. coli / P. putida EF-P hybrid containing the P. putida acceptor loop and the E. coli body.  
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6.5 The role of glycosylation in EF-P evolution 
The bacterial elongation factor EF-P is orthologous to the eukaryotic/archaeal e/aIF5A. 
The cognate modification enzyme deoxyhypusine synthase is strictly conserved in 
eukaryotes and archaea (125). By contrast, the modifications that activate the bacterial 
elongation factor are chemically diverse and species-specific. Beside arginine 
rhamnosylation two further modes of EF-P activation – β-lysylation of lysine e.g. in E. coli 
and 5-aminopentanolylation e.g. in B. subtilis – are known (116, 119, 147). Interestingly, 
minor sequential changes in E. coli EF-P (including the modification site) are sufficient to 
switch the mode of activation from lysine lysylation to arginine rhamnosylation. Specifically, 
the substitution of the lysine containing E. coli acceptor loop by the homologous P. putida 
loop is sufficient to enable in vitro rhamnosylation and in vivo activation of the resulting EF-P 
hybrid (Chapter 4) (Figure 9C). Thus, we provide first insights into the evolution of EF-P and 
its cognate modification system. However, the driving force behind this process is unknown. 
Deletion of efp in E. coli severely impairs biosynthesis of polyproline-containing peptides 
and results in reduced growth (116, 117). These deficiencies can be fully complemented by 
heterologous co-expression of arginine type efp and the corresponding modification system 
earP (116). Consequently, the core function of ribosome rescue can be fulfilled by both EF-P 
isoforms, independent of the chemically distinct modifications. Nevertheless, miniscule 
variances between different EF-P types might provide an evolutionary advantage. Bacterial 
genomes encode for a species-specific assortment of polyproline-containing proteins that 
varies in number (125) and possibly also stalling motif composition. It is conceivable that 
different motifs form structurally different stalling complexes. Based on the structure of the 
modification these events could be rescued with varying efficiency. An elongation factor that 
is – for example due to its modification – more suitable to rescue critical stalling complexes 
could therefore displace another one. Thus, an adaptation of the modification to the 
polyproline-proteome could drive evolution.  
EF-P recruitment to a stalled ribosome requires the simultaneous presence of prolyl-tRNA 
(148). Moreover, cryo-EM structures of ribosomes with bound EF-P suggest that interaction 
with the mRNA might also play a role in this process (149). As proline is encoded by four 
canonical codons (CCA, CCG, CCT, CCC) that are differently recognized by the three 
cognate tRNAs proK, proL and proM (150), the codon context might play a role in defining 
EF-P efficiency for certain stalling motifs. Future experiments will show, which of the 
differently modified elongation factors performs better in different amino acid and codon 
contexts. Taken together, this data will ultimately allow conclusions on the selective benefit of 
either modification type over the other and maybe even the engineering of bacterial strains or 
elongation factors with improved capabilities with respect to production of 
polyproline-containing peptides.  
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6.6 EarP-mediated arginine rhamnosylation and its application in 
synthetic biology 
The comprehensive understanding of EarP-mediated arginine rhamnosylation lays the 
ground for the application of this cytosolic rhamnosyltransferase in synthetic biology and 
medicine (Chapters 2, 3 and 4). In a cellular context, directed modification of proteins could 
be used to fine-tune transcriptional or translational output by targeting corresponding 
regulatory proteins (15, 116). In a clinical context, selective glycosylation could be used to 
improve the pharmacokinetic properties of protein therapeutics (151).  
The development of a synthetic glycosyltransferase, that could be tailored to modify a 
soluble protein of choice with a given carbohydrate, would therefore allow for a wide variety 
of applications. The prerequisite to generate such a synthetic glycosyltransferase is the 
possibility to modulate enzyme specificity with respect to both the donor and the acceptor 
substrate (152). Our data provides a structural and biochemical framework for the 
engineering of such a glycosynthase (Chapter 3). With the construction of the first unnatural 
acceptor for EarP we made an initial step in identifying a minimal structural recognition motif 
(Chapter 4). After further characterization, this structure could be implemented into other 
proteins or recreated using existing structural prerequisites in order to allow specific 
rhamnosylation by EarP. In combination with our highly sensitive anti-ArgRha, the modification 
could also be used as an affinity tag for protein purification (Chapters 2 and 3).  
Complementarily, our data on binding of the nucleotide sugar (Chapter 3) provides the 
basis for rational mutagenesis of the TDP-β-L-rhamnose binding pocket in order to allow for 
enhanced donor substrate promiscuity or even a switch in specificity. Initially, the natural 
substrate specificity needs to be assessed in order to determine structural prerequisites for 
sugar binding. A subsequent switch of the nucleotide donor to UDP-GlcNAc could be used to 
synthesize N-actetylglucosaminyl-arginine. The ubiquitous eukaryotic initial linkage between 
N-actetylglucosamine and asparagine has been used as a precursor for synthesis of 
homogenous N-linked glycopeptides via transglycosylation (153). An engineered EarP 
variant could not only allow for direct synthesis of a mono-GlcNAc precursor but also provide 
the basis for an orthologous pathway. Here, not asparagine but arginine-linked glycans could 
be specifically glycosylated to yield clinically relevant glycoproteins such as humanized 
antibodies. If EarP could be further engineered to modify asparagine residues, the resulting 
variant could likely lead to even more applications.  
The modular architecture of EarP and GT-B glycosyltransferases in general allows the 
generation of chimeric enzyme variants (154). Combination of the N-terminal EF-P binding 
domain of EarP with the C-terminal GlcNAc binding domain of a structurally related enzyme 
like MurG could potentially generate a functional glycosyltransferase with entirely new 
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properties. Similarly, other combinations could be engineered in order to design a modular 
platform for glycosylation of various target proteins with a wide variety of carbohydrates.  
Many approaches in glycoengineering are focusing on the ingenious synthesis of novel 
lipid-linked oligosaccharides (LLOs) that can be transferred onto proteins using the natural 
substrate promiscuity of oligosaccharyltransferases (155, 156). While this approach has 
already been successfully applied, it faces certain constraints with respect to function and 
subcellular localization. As the name suggests, OSTs catalyze the transfer of 
oligosaccharides. Many applications are however depending on a monoglycosylated 
precursor that can be further modified by transglycosylation. Thus an additional step of 
polysaccharide trimming is necessary (153). Additionally, as OSTs are localized in the 
periplasm, both the donor LLOs and the target protein have to be translocated to the 
intermembrane space. The possibility of site-specific monoglycosylation of soluble proteins 
by a modified variant of the cytosolic enzyme EarP would therefore increase the range of 
possible targets and at the same time facilitate further processing by transglycosylation.  
The virulence of several clinically relevant bacteria has been shown to be dependent on 
EarP activity (116, 157). The design of compounds that selectively inhibit this reaction might 
therefore be a promising route to develop novel antibiotics (116). Targeted inhibitor design 
depends on structural information and will therefore be facilitated by our data.  
Taken together, our analysis has not only allowed comprehensive insights into the 
structural and biochemical mechanism of EF-P glycosylation but also made the 
rhamnosyltransferase EarP accessible for other fields of research including synthetic biology 
and medical application. 
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6.7 Outlook 
The novel rhamnosyltransferase EarP was characterized with respect to its structure, 
substrate binding and catalytic activity. Future perspectives for research on this exceptional 
enzyme lie mostly in the application for synthetic biology and medical endeavors. Further 
characterization of the donor and acceptor substrate specificity will provide an understanding 
of the fundamental prerequisites that determine recognition and binding events. The 
synthesis of artificial mono-rhamnosylated and potentially cyclized acceptor peptides could 
greatly help in determining a minimal binding motif and the associated structural constraints 
in target recognition. Similarly, the chemical or enzymatic synthesis of nucleotide sugars that 
are structurally related to TDP-β-L-rhamnose will yield information on the natural selectivity of 
the glycosyltransferase. This information will in turn enable approaches to ultimately enhance 
or switch the spectrum of usable substrates in EarP-mediated protein glycosylation. In 
parallel, the feasibility of generating chimeric glycosyltransferases has to be investigated. In 
a first step, chimeras of sequentially distinct EarP variants will be constructed in order to 
determine optimal cleavage sites for hybrid-fusions. Thorough understanding of the structural 
prerequisites for EarP-mediated arginine glycosylation will ultimately also facilitate the 
rational design of specific inhibitors and thus enable the synthesis of a new class of 
species-specific antibiotics.  
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1. General Information
1.1 Materials
All reagents and solvents were purchased from Acros Organics, Alfa Aesar or Sinopharm 
Chemical Reagent Co. Ltd and were purified when necessary. THF was distilled from 
sodium/benzophenone ketyl before use. DMF was distilled under reduced pressure from 
sodium sulfate and stored in flask containing 4 Å molecular sieves. Et3N and CH2Cl2 were 
distilled from calcium hydride immediately prior to use. All organic extracts were dried over 
sodium sulfate and concentrated under rotary evaporator. All other commercially obtained 
reagents and solvents were used directly without further purification. TLC was performed on 
plates pre-coated with silica gel 60 F254 (250 layer thickness). Flash column chromatographic 
purification of products was finished using forced-flow chromatography on Silica Gel (300-
400 mesh). Visualization was accomplished with 5% (v/v) H2SO4 in EtOH, UV light, and/or 
phosphomolybdic acid (PMA) solution.
1.2 HPLC
Protein A chromatography was carried out on an ÄKTA Explorer chromatographic system 
from Amersham Biosciences with built-in UV, pH and conductivity detectors to monitor 
column effluent.
Analytical HPLC was run on a SHIMADZU (Prominence LC-20AD) instrument using an 
analytical column (Grace Vydac “Protein & Peptide C18”, 250 X 4.6 mM, 5 μm particle size, 
flow rate 1.0 mL/min, rt). Analytical injections were monitored at 214 nm, 254 nm. Semi 
preparative HPLC was run on a SHIMADZU (LC-6A) instrument using a semi preparative 
column (Grace Vydac “Peptide C18”, 250 X 10 mM, 10 μm particle size, flow rate 4 
mL/min). Solution A was 0.1% TFA in water, and solution B was 0.1% TFA in MeCN. 
Gradient A: A linear gradient of 10% to 10% B over 2 min, then a linear gradient of 10% to 
90% B over 25 min. Gradient B: A linear gradient of 1% to 1% B over 3 min, then a linear 
gradient of 1% to 35% B over 25 min. 
1.3 Mass spectrometry and NMR of small moleculars
1H-NMR and 13C-NMR spectra were obtained on a Bruker Avance 300 MHz or 600 MHz 
NMR Spectrometer. The chemical shifts of protons are given on the δ scale, ppm, with 
tetramethylsilane (TMS) as the internal standard. HR-Q-TOF-MS was measured on an 
Agilent 6538 UHD Accurate Mass Q-TOF LC/MS mass spectrometer.
2. Nuclear magnetic resonance spectroscopy 
In order to determine the configuration of rhamnose when bound to EF-P, the rhamnosylated 
protein was expressed in M9 minimal medium with 13C-Glucose and 15N-ammonium chloride 
as sole carbon and nitrogen source, respectively. Triple resonance experiments1 were used to 
assign backbone chemical shifts of the protein. The rhamnose moiety was assigned, using a 
sensitivity-enhanced 13C-edited NOESY-HSQC with simultaneous evolution of 13C and 15N 
during t22. Three undecoupled, sensitivity-enhanced 13C-HSQC3 were acquired to obtain the 
1JCH coupling of the anomeric carbon to its proton (H1’-C1’). One without 13C decoupling in 
the 1H direct dimension during acquisition to obtain the 1JCH coupling constant resolved in the 
1H dimension with 4096 points (160 ms acquisition time) for sufficient resolution to allow 
reliable fitting of the coupling constant. The second and third without 1H decoupling during 
13C chemical shift evolution to resolve the 1JCH coupling in the 13C indirect dimension was 
acquired with 3584 points (63.6 ms) to obtain sufficient resolution and with 600 points (10.7 
ms) to not resolve 13C-13C coupling (see figure 2c). In order to acquire the 13C dimension 
with large spectral width to include the methyl, aliphatic, sugar, and aromatic regions with 
sufficient carbon decoupling, but without sideband artifacts we employed low-power 
broadband heteronuclear decoupling based on optimal control theory4. All spectra were 
processed using NMRPipe5 with a gaussian window function and zero filling. Peak detection 
and fitting of the coupling constant has been used with in-built functions in NMRPipe 
(nlinLS) using gaussian fitting. The coupling constants derived from fitting the three spectra 
are consistent.
3. Chemical synthesis
3.1 2,3,4-Tri-O-acetyl-6-deoxy-α-L-mannopyranosyl chloride (3)
Acetyl chloride (60.0 mL, 843.6 mmol) was added dropwise into a round flask containing L-
Rhamnose (2, 25.0 g, 152.4 mmol). The mixture was stirred for 48 h under Ar. 
Dichloromethane (300 mL) was added and the organic layer was washed with water (3*100 
mL) and then saturated sodium bicarbonate (3*100 mL). The organic layer was dried over 
sodium sulfate and concentrated. The residue was purified by column chromatography 
eluting with 4/1 petroleum ether/ethyl acetate to give 3 as a white foam (39.9 g, 85 %). 1H 
NMR (300 MHz, CDCl3): δ 5.91 (d, J = 0.8 Hz, 1 H), 5.56 (dd, J = 10.2 Hz, 4.2 Hz, 1 H), 
5.37 (q, J = 1.7 Hz, 1 H), 5.15 (t, J = 10.1 Hz, 1 H), 4.17- 4.08 (m, 1 H), 2.15 (s, 3 H), 2.06 (s, 
3 H), 1.98 (s, 3 H), 1.26 (d, J = 6.4 Hz, 3H). 13C NMR (75 MHz, CDCl3): δ 169.9, 169.8, 
169.7, 89.0, 71.9, 70.3, 69.4, 67.7, 20.8, 20.8, 20.6, 17.1.
3.2 2,3,4-Tri-O-acetyl-6-deoxy-α-L-mannopyranosyl isothiocyanate (4)
A mixture of tetrabutylammonium iodide (9.18 g, 25.0 mmol), KSCN (4.85 g, 50.0 mmol), 
and molecular sieve (4 Å, 20 g) in dry acetonitrile (200 mL) was stirred at room temperature 
under argon for 2 h. Then compound 3 (7.70 g, 25.0 mmol) was added to the solution and the 
mixture was refluxed for another 3 h. Then the mixture was filtered, and the filtrate was 
concentrated under vacuum. The residue was purified by column chromatography with 4/1 
petroleum ether/ethyl acetate to yield compound 4 ( 5.80 g, 70 %) as a white solid. 1H NMR 
(300 MHz, CDCl3): δ 5.46 (d, J = 1.0 Hz, 1 H), 5.29- 5.24 (m, 2 H), 5.10- 5.03 (m, 1 H), 
4.01- 3.96 (m, 1 H), 2.15 (s, 3 H), 2.06 (s, 3 H), 1.99 (s, 3 H), 1.26 (d, J = 6.2 Hz, 3 H). 13C 
NMR (75 MHz, CDCl3): δ 170.8, 170.6, 170.6, 169.2, 143.3, 82.8, 77.2, 74.0, 71.7, 67.9, 
61.7, 56.1, 23.3, 20.7, 20.6, 20.6. HR-Q-TOF-MS: calcd. for C13H17NNaO7S+ [M+Na]+ m/z, 
354.0618; found, 354.0620.
3.3 N-(2,3,4-Tri-O-acetyl-6-deoxy-α-L-mannopyranos -1-yl) thiourea (5)
Gaseous ammonia was passed through a solution of 4 ( 3.31 g, 10 mmol) in anhydrous THF 
(50 mL) for 1 h. Compound 5 was obtained as a white solid after removal of solvent in 
vacuum ( 3.3 g, 99 %) and used in the next step without further purification. 1H NMR (300 
MHz, CDCl3): δ 7.72 (s, 1 H), 6.86 (s, 2 H), 5.45-5.29 (m, 3 H), 5.08 (t, J = 9.5 Hz, 1 H), 
3.91-3.86 (m, 1 H), 2.14 (s, 3 H), 2.03 (s, 3 H), 1.99 (s, 3 H), 1.22 (d, J = 6.2 Hz, 3 H). 13C 
NMR (75 MHz, CDCl3): δ 184.4, 170.1 (2 C), 167.0, 80.9, 70.5, 68.7, 67.8, 65.9, 20.9, 20.8, 
20.8, 17.4. HR-Q-TOF-MS: calcd. for C13H20N2NaO7S+ [M+Na]+ m/z, 371.0883; found, 
371.0887.
3.4 1-(tert-Butoxycarbonyl)-3-(2,3,4-Tri-O-acetyl-6-deoxy-α-L-mannopyranos -1-yl) -2-
ethylisothiourea (6)
 A solution of 5 (2.8 g, 8.0 mmol) and EtI (0.76 mL, 9.6 mmol) in 40 mL of anhydrous 
CH3OH was stirred under reflux for 4 h. The solvent was removed in vacuo and the residue 
was desolved in dry DCM (50 mL) by adding Et3N (2.24 mL, 16.0 mmol), (Boc)2O (1.96 g, 
9.0 mmol) and catalytic amount of DMAP. After the mixture was stirred at room temperature 
overnight, it was washed with water and brine. The organic layer was dried by Na2SO4 and 
concentrated under vacuum. The residue was purified by flash chromatography eluting with 
5:1 petroleum ether/acetone and further crystallized from ether to yield compound 6 ( 2.86 g, 
75 %) as a white solid. 1H NMR (600 MHz, CDCl3): δ 5.39 (s, 1 H), 5.17 (s, 1 H), 5.04- 5.01 
(m, 2 H), 3.62- 3.57 (m, 1 H), 3.13- 3.02 (m, 2 H), 2.24 (s, 3 H), 2.05 (s, 3 H), 1.98(s, 3 H), 
1.45 (s, 9 H), 1.30- 1.25 (m, 6H). 13C NMR (150 MHz, CDCl3): δ 170.3, 170.2, 169.9, 80.1, 
79.3, 72.1, 71.1, 70.0, 69.4, 28.1 (3 C), 25.5, 20.8 (2 C), 20.6, 17.5, 13.9. ESI MS: calcd. for 
C20H33N2O9S+ [M+H]+ m/z, 477.1901; found, 477.1909.
3.5 Synthesis of the title hapten glycopeptide 1 
After a mixture of 2-Cl-trityl-Cl resin (400.0 mg, active Cl, 0.20 mmol), Fmoc-Leu-OH ( 
354.0 mg, 1.0  mmol) and DIEA (365.0 μL) in DMF (5 mL) was shaken on a vortex mixer at 
rt overnight, the resin was filtered off and washed several times with MeOH, DCM and DMF. 
The Leu-linked resin was then used for the construction of full length peptide/glycopeptides. 
The protocols employed were: deprotection of Fmoc with 20% piperidine in DMF (15 min) 
and peptide coupling using 5 eq. of amino acid, 4.5 eq. of HCTU and 10 eq. of DIEA. All 
coupling reactions were set to perform 1 h at rt. Amino acids Fmoc-Gly-OH, Fmoc-Orn(Aloc)-
OH, Fmoc-Gly-OH, Fmoc-Cys-OH, and AcOH were sequentially installed to construct 
peptide after removal of allyloxycarbonyl group on the resin. Then, a solution of compound 6 
(3 eq.), Et3N (10 eq.) and AgNO3 (3 eq.) in 5 mL of anhydrous DMF was added into the resin. 
After the mixture was shaken for 8 h in the dark, the resultant mixture was filtered and the 
resin was washed thoroughly with DMF, MeOH, and DCM to compound 8. To remove the 
acetyl groups from the glycopeptide on the resin, the peptide-loaded resin was treated with a 
mixture of NH2-NH2 in DMF (5 %, 10 mL) for 10 h at rt. The resin was filtered off and 
washed thoroughly with DMF, H2O, MeOH, and DCM. Then, the peptide-loaded resin was 
treated with a mixture of TIPS/TFA (5:95, 10 mL) for 2 h at rt. The resin was filtered off and 
washed with TFA. The washings were combined and condensed in vacuum to give crude 1. 
The crude product was dissolved in water and purified by HPLC (conditions: Grace Vydac 
“Peptide C18”, 250 X 10 mM, 10 μm particle size, suitable ratio of acetonitrile-0.1%TFA in 
water-0.1%TFA, 4 mL/min) to give 1 (18.0 mg, isolated yield 27 %) as a white solid. 1H 
NMR (600 MHz, DMSO-d6) : δ 8.29-7.40 (signal of amide protons), 5.33 (s, 1 H), 4.84 (d, J 
= 9.2 Hz, 1H), 4.34- 4.21 (m, 3H), 3.75- 3.73 (m, 4H), 3.67 (s, 1H), 3.28- 3.25 (m, 3 H), 
3.17- 3.12 (m, 3H), 2.79- 2.76 (m, 1 H), 2.71- 2.67 (m, 1 H), 2.46 (t, J = 6.4 Hz, 1H), 1.89 (s, 
3 H), 1.76- 1.70 (m, 1 H), 1.64- 1.55 (m, 1 H), 1.55- 1.45 (m, 5H), 1.13 (d, J = 6.1 Hz, 3 H), 
0.89 (d, J = 6.6 Hz, 3 H), 0.84 (d, J = 6.6 Hz, 3 H). 13C NMR (150 MHz, DMSO-d6): δ 173.9, 
171.3, 170.4, 169.8, 168.7, 168.5, 155.4, 78.2, 73.6, 72.8, 71.2, 69.9, 55.4, 52.1, 50.2, 42.1, 
41.5, 10.1, 29.0, 25.8, 24.6, 24.2, 22.8, 22.5, 21.3, 17.7. HR-Q-TOF-MS: calcd. for 
C27H49N8O11S+ [M+H]+ m/z, 693.3236; found 693.3246.
Fig S1 Analytical HPLC traces of synthetic intermediates and title compounds about 
gylcopeptide 1 respectively. All products were detected after TIPS/TFA cleavage of the resin. 
a) Full protected peptide b); Peptide 7; c) Glycosylation of amino group of Orn with 
6/TEA/AgNO3/DMF; d) NH2NH2 mediated removing of Ac groups, e) Analytic trace of the 
purified gylcopeptide 1. Analytical HPLC was run on a SHIMADZU (Prominence LC-20AD) 
instrument using an analytical column (Grace Vydac “Protein & Peptide C18”, 250 X 4.6 
mM, 5 μm particle size, flow rate 1.0 mL/min, rt). Solution A was 0.1% TFA in water, and 
solution B was 0.1% TFA in MeCN. Gradient for a-e: A linear gradient of 10% to 10% B 
over 2 min, then a linear gradient of 10% to 90% B over 25 min.
3.6 X-ray crystallography of compound 5 
Single crystal of compound 5 was obtained by slow evaporation of dichloromethane/n-
hexane solution of 5 at room temperature. The X-ray single crystal diffraction data for 5 was 
collected on Bruker APEX DUO diffractometers with M Kα radiation ( = 0.71073 Å) at 
298  2 K in the -2scanning mode. The structures were solved by direct methods using the 
SHELXS-97 program6 and refined by full-matrix least-squares techniques (SHELXL-97) on 
F2. 
Anisotropic thermal parameters were assigned to all non-hydrogen atoms. The organic 
hydrogen atoms were generated geometrically. CCDC-1469830 contains the supplementary 
crystallographic data for this paper. These data can be obtained free of charge from the 
Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data_request/cif.
Fig S2 Single-crystal structure of Compound 5. 
4. Methods for antibody generation and purification
4.1 Conjugation of glycopeptides to BSA
Glycopeptides were conjugated with Bovine serum albumin (BSA) for inoculation and 
ELISA analysis, respectively, using Sulfo-GMBS as the crosslinker by following the 
manufacturer's instruction. BSA was mixed with indicated peptides at a molecular ratio of 1:1.
4.2 Rabbit immunization 
Two rabbits (male, 2- 2.5 Kg) were immunized three times at three-week intervals. P1(Rha)-
BSA was injected together with the complete and incomplete form of Freund's adjuvant for 
the 1st and 2nd/3rd immunization, respectively. For each immunization 2 mg peptide was 
used. Serum samples were collected prior to immunization (pre-bleed) and 1 week after the 
final immunization for subsequent analyses.
4.3 Affinity purification of antibody 
Firstly, the crude anti sera were purified over Protein A Sepharose 4B fast flow. Protein A 
chromatography was carried out on a 1.1 cm D × 10 cm H column. The column was 
equilibrated with 25 mM PBS, 150 mM sodium chloride, pH 7.2 buffer, washed with 
equilibration buffer, and eluted with 100 mM glycine-HCl, pH 2.8. The eluate was collected 
and neutralized with 1 M tris base. Turbidity and protein concentration were determined 
following neutralization of the elution pool. Next our anti sera were further purified with 
BSA Sepharose 4B Fast Flow & naked peptide-BSA Sepharose 4 Fast Flow. Affinity resin 
consisting of BSA and naked peptide-BSA immobilized onto agarose were prepared by 
covalently attaching BSA and naked peptide-BSA to agarose beads using CNBr-activated 
Sepharose 4B (GE Healthcare) according to the manufacturer’s instructions. Eluting 
procedure was same as that of the Protein A purification. Fractions containing 
rhamnosylarginine antibody were determined by SDS-PAGE and ELISA analysis.
4.4 ELISA of crude anti-Arg-Rha anti sera and purified antibody 
BSA or BSA-peptides (5 μg/mL) were dissolved in coating buffer (0.032 M Na2CO3 and 
0.068 M NaHCO3, pH 9.6). 100 µL of each sample containing 0.5 µg of protein was added to 
a Nunc-Immuno Maxisorp 96-well plate. The plate was incubated at 4C overnight on a 
nutator. The wells were then washed three times with wash buffer (phosphate buffer solution 
supplemented with 0.05% Tween-20) and blocked with 10% Fetal Bovine Serum (FBS) in 
the wash buffer (200 µL/well) for 120 min at 37C. After removing the blocking solution, 
crude anti sera (including the neutralized anti sera) or purified antibody diluted in wash buffer 
were added to the wells (100 µL/well) and incubated for 60 min at 37C. The neutralized 
crude anti sera were prior incubated with BSA for 60 min at 37C before adding to the wells. 
The wells were then washed three times with the wash buffer. Goat-anti rabbit-HRP 
secondary antibody (1:5,000 dilution) was added to the wells (100 µL/well) and incubated for 
60 min at 37C. After extensive wash, 100 µL of fresh ELISA substrate solution (4.86 mL of 
0.1 M citric acid and 5.14 mL of 0.2 M Na2HPO4 supplemented with 4 mg o-
phenylenediamine and 15 µL of H2O2) was added to each well and incubated for 5-10 min at 
room temperature followed by addition of 50 µL of 2 M H2SO4 to quench the reaction. The 
absorbance at 490 nm was measured on a BioRad microplate reader.
Fig S3 Anti-ArgRha crude sera immunized by BSA-glycoconjugate can recognize the arginine 
rhamnosylated BSA with high affnity. ELISA analysis of two batches of anti-sera immunized 
by glycopeptide 1. Anti-serum 1# and anti-serum 2# were diluted 128,000 fold and subjected 
to indirect ELISA experiments against BSA-glycoconjugate or independent BSA. BSA-1: 
BSA-ArgRha, *: The anti-sera were neutralized with BSA when detecting immune reactivity. 
Absorbance at 490 nm is shown.
Fig S4 SDS-PAGE of the crude antibody. M: Marker, 1: Crude Anti-serum：20ul (4 mg/ml), 
BSA：20ug.
Fig S5 SDS-PAGE of the antibody after affinity purification. M: Marker, 1: Anti-Arg-Rha 
Rabbit IgG after specific purification：20ul (4 mg/ml), BSA：20ug.
Fig S6 Purified anti-ArgRha antibody immunized by BSA-glycoconjugate can recognize the 
BSA-glycoconjugate with high affinity and specificity. purified anti-ArgRha antibody were 
diluted 8,000 fold  and subjected to indirect ELISA experiments against BSA-glycoconjugate, 
BSA-non-glycoconjugate and independent BSA.  BSA-1: BSA-ArgRha (BSA-glycoconjugate), 
BSA-naked: BSA-Arg (BSA-non-glycoconjugate). Absorbance at 490 nm is shown.
5. Specificity of the anti-ArgRha for EF-PRha
5.1 Bacterial strains and growth conditions 
Strains and plasmids used in this study are listed in Table S1. P. aeruginosa, S. oneidensis 
MR-1 and E. coli were routinely grown in Lysogeny broth (LB) according to Miller at 30°C 
(for S. oneidensis) and 37°C (for E. coli and P. aeruginosa). When required, media were 
solidified by using 1.5% (w/v) agar. The optical density at 600 nm (OD600) of cultures was 
monitored. If necessary, media were supplemented with 30 µg/ml chloramphenicol, 50 µg/ml 
kanamycin sulfate, and/or 100 µg/ml ampicillin sodium salt. For promoter induction from 
plasmids pET SUMO, paCYC-DUET1 and derivatives 1 mM Isopropyl-β-D-
thiogalactopyranosid (IPTG) was added to liquid medium.
5.2 Construction of plasmids for protein overproduction 
Genes and gene fragments to be overexpressed were amplified from template S. oneidensis 
genomic DNA. The resulting PCR products for efp and earP were ligated into pET SUMO 
(Invitrogen) and pACYC-DUET1 respectively resulting in an N-terminal SUMO-tag fusion 
for EF-P (pET SUMO-efpS.o.) and a His6-tag fusion for EarP (paCYC-Duet1-earPS.o.). 
Routinely, chemically competent E. coli as strain for high-efficiency transformation7.
5.3 Production and purification of unmodified and rhamnosylated EF-P 
N-terminal His6-SUMO-tagged EF-PS.o. was overproduced in E. coli BL21 (DE3) by addition 
of 1 mM IPTG to exponentially growing cells. After induction, cells were incubated at 16 °C 
overnight. Rhamnosylated EF-PS.o.(EF-PRha) was produced by co-overexpression of paCYC-
Duet1-earPS.o.. Cells were lysed by sonication and His6-tagged protein was purified using Ni-
NTA (Qiagen) and 250 mM imidazole. The His6-SUMO-tag. was removed by incubation 
with 1 u/mg His6-ulp18 for 16 h and pure EF-P variants were collected in the flowthrough 
after repeated metal chelate affinity chromatography. For use in later experiments and NMR 
spectroscopy, proteins were dialyzed against storage buffer. Protein concentrations were 
determined as described by Bradford9. 
5.4 Immunodetection analysis of S. oneidensis EF-P
Electrophoretic separation of proteins was carried out using SDS-PAGE as described by 
Laemmli10. Separated proteins were visualized in-gel using 0.5 % (v/v) 2-2-2-trichloroethanol 
11 and transferred onto nitrocellulose membrane by vertical Western blotting. Antigens were 
detected by 0.2 µg/ml Anti-EF-P or 2 µg/ml or dilutions of Anti-ArgRha respectively. Primary 
antibodies (rabbit) were targeted by 0.2 µg/ml alkaline phosphatase conjugated Anti-
RABBIT IgG (H&L) (GOAT) antibody (Rockland) and target proteins were visualized by 
addition of substrate solution (50 mM sodium carbonate buffer, pH 9.5, 0.001% (w/v) Nitro-
Blue-Tetrazolium, 0,045% (w/v) 5-Bromo-4-chloro-3-indolylphosphate).
To assess the specificity of Anti-ArgRha towards rhamnosyl arginine, 0.5 µg of purified, 
unmodified and modified (rhamnosylated) EF-P (EF-PRha) were subjected to SDS-PAGE and 
Western Blot analysis as described above and targeted by 0.2 µg/ml Anti-EF-P and Anti-
ArgRha respectively. 
Minimal Anti-ArgRha concentrations for detection of EF-P were determined by employing 0.5 
µg of EF-PRha and decreasing amounts of Anti-ArgRha (2 µg/ml, 1 µg/ml, 0.4 µg/ml, 0.2 
µg/ml, 0.1 µg/ml, 0.04 µg/ml, 0.02 µg/ml) for detection. 
Antigen detection limits were determined by subjecting decreasing amounts of EF-PRha (0.5 
µg, 0.25 µg, 0.125 µg, 62.5 ng, 31.25 ng, 15.6 ng, 7.8 ng, 3.9 ng) to SDS-PAGE and Western 
Blot analysis as described above and detection with 2 µg/ml and 0.2 µg/ml Anti-ArgRha 
respectively.
To investigate cross-reactivity of Anti-ArgRha against free L-arginine, L-fucose or L-rhamnose, 
varying concentrations of EF-PRha (0.015 µM, 0.15 µM, 1.5 µM 15 µM) and putative 
competitors (15 µM, 1 mM 5 mM, 15 mM) were preincubated with Anti-ArgRha prior to EF-
PRha detection. 
In vivo detection of EF-P and EF-PRha was carried out using total cell lysates of Pseudomonas 
aeruginosa PAO1 wildtype, Shewanella oneidensis MR-1 wildtype as well as S. oneidensis 
mutant strains carrying markerless inframe deletions12 in efp (Δefp), earP (ΔearP) and rmlC 
(ΔrmlC). Cells were grown to an OD600 of 1. About 15 µg total protein were subjected to 
SDS-PAGE and Western Blot analysis as described above. EF-P and EF-PRha were detected 
using 0.2 µg/ml Anti-EF-P and 2 µg/ml Anti-ArgRha respectively. 
Table S1: Strains and plasmids used for EF-P detection
Plasmid Features
pET SUMO Expression vector, Kanr cassette, pBR322 origin, SUMO 
coding sequence, lacI coding sequence, ROP coding sequence, 
IPTG inducible lac operator
Invitrogen
pET SUMO-efpS.o. C-terminal His6-Tag efp from S. oneidensis in pET SUMO This study
paCYC-Duet1 Expression vector, Camr cassette, P15A replicon, lacI coding 
sequence, IPTG inducible lac operator
Novagen
paCYC-Duet1-earPS.o. earP from S. oneidensis in paCYC-Duet1 This study
Strain Genotype Purpose Reference
E.coli DH5pir recA1 gyrA (lacIZYA-argF) (80d lac [lacZ] 
M15) pir RK6
[14]
E. coli BL21 (DE3) fhuA2 [lon] ompT gal (λ DE3) [dcm] ΔhsdS 
λ DE3 = λ sBamHIo ΔEcoRI-B 
int::(lacI::PlacUV5::T7 gene1) i21 Δnin5
Overproduction 
of EF-P
[15]
P. aeruginosa PAO1 Pseudomonas aeruginosa PAO1 wildtype
S. oneidensis MR-1 Shewanella oneidensis MR-1 wildtype in vivo detection 
of EF-P
[16]
S. oneidensis MR-1 Δefp efp  (SO_2328) in vivo detection 
of EF-P
[13]
S. oneidensis MR-1 ΔearP earP (SO_2329) in vivo detection 
of EF-P 
[13]
S. oneidensis MR-1 ΔrmlC rmlC  (SO_3160) in vivo detection 
of EF-P
[13]
 
Fig S7 Detection of purified EF-P with Anti-ArgRha. Cross-reactivity analysis of Anti-ArgRha 
against L-rhamnose, L-fucose, L-arginine or L-lysine. 0.5 µg of purified EF-PRha were 
subjected to SDS-PAGE and subsequent Western Blot analysis using 0.2 µg/ml Anti-ArgRha. 
Anti-ArgRha was incubated with varying concentrations of EF-PRha, L-rhamnose, L-fucose, L-
arginine and L-lysine. Buffer only served as control.
6. NMR spectrum
1H-NMR of compound 1 (DMSO-d6)
13C-NMR of compound 1 (DMSO-d6)
HR-Q-TOF-MS of compound 1
1H-NMR of compound 3 (CDCl3)
13C-NMR of compound 3 (CDCl3)
1H-NMR of compound 4 (CDCl3)
13C-NMR of compound 4 (CDCl3)
HR-Q-TOF-MS of compound 4
1H-NMR of compound 5 (CDCl3)
13C-NMR of compound 5 (CDCl3)
HR-Q-TOF-MS of compound 5
1H-NMR of compound 6 (CDCl3)
13C-NMR of compound 6 (CDCl3)
HR-Q-TOF-MS of compound 6
Table S2 Crystal data and structure refinement for compound 5.
Identification code a51230b
Empirical formula C13H20N2O7S
Formula weight 348.37
Temperature 298(2) K
Wavelength 0.71073 Å
Crystal system Orthorhombic
Space group P 21 21 21
Unit cell dimensions a = 8.984(5) Å α = 90°.
b = 10.648(6) Å β = 90°.
c = 18.894(10) Å γ = 90°.
Volume 1807.5(17) Å3
Z 4
Density (calculated) 1.280 Mg/m3
Absorption coefficient 0.213 mm-1
F (000) 736
Crystal size 0.660 x 0.200 x 0.150 mm
Theta range for data collection 2.156 to 26.979 °
Index ranges -10<=h<=11, -13<=k<=13, -18<=l<=23
Reflections collected 8825
Independent reflections 3845 [R (int) = 0.0627]
Completeness to theta = 25.242° 99.7 % 
Absorption correction Semi-empirical from equivalents
Max. and min. transmission 1.000 and - 0.009
Refinement method Full-matrix least-squares on F2
Data / restraints / parameters 3845 / 8 / 224
Goodness-of-fit on F2 0.841
Final R indices [I>2 sigma(I)] R1 = 0.0410, wR2 = 0.0809
R indices (all data) R1 = 0.0624, wR2 = 0.0860
Absolute structure parameter 0.03(6)
Extinction coefficient n/a
Largest diff. peak and hole 0.146 and -0.193 e.Å-3
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Supplemental figures 
 
 
Figure S1. (A) Specificity of anti-Arg
Rha
 antibodies. One point five micrograms of unmodified EF-P (EF-P
−
) and 
0.5 µg modified EF-P (EF-P
Rha
) were subjected to SDS-PAGE and transferred to a nitrocellulose membrane by 
horizontal Western blotting. The membrane was cut, and the halves were used to detect EF-PPpu using 0.2 µg/ml 
anti-EF-P and EF-P
Rha
 using 0.25 µg/ml anti-Arg
Rha
 antibodies. (B) In vivo functionality analysis of EarPPpu single-
amino-acid exchange variants. (Top) β-Galactosidase activity in E. coli MG1655 PcadBA::lacZ Δefp upon 
expression of EF-PPpu and EarPPpu and coexpression of EF-PPpu with EarPPpu and single-amino-acid substitution 
variants. Cells were incubated under cadBA-inducing conditions (LB, pH 5.8) at 30°C o/n (17). Data are mean 
values from three independent replicates ± standard deviations. Asterisks indicate significance. (Middle) The 
presence of heterologously expressed His6-tagged EF-PPpu was verified using 0.1 µg/ml anti-His6 tag (Abcam, 
Inc.). (Bottom) Rhamnosylation of EF-PPpu in MG1655 cells coexpressing EF-PPpu and its EarPPpu single-amino-
acid exchange variants was assessed by Western blotting and detection of EF-P
Rha
 using 0.25 µg/ml anti-Arg
Rha
. 
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Figure S2. (A) Time-dependent in vitro rhamnosylation of EF-PPpu by EarPPpu. Fixed amounts of EF-PPpu 
(2.5 µM), EarPPpu (0.1 µM), and TDP-Rha (500 µM) were incubated at 30°C in 100 mM NaPi, pH 7.6, for various 
amounts of time. Measurements were performed in technical duplicates. Standard errors are shown. A 
representative SDS-PAGE gel and Western blot used for generation of the time course curve are shown. 
Rhamnosylated EF-PPpu (EF-P
Rha
) was detected using 0.25 µg/ml anti-Arg
Rha
. Band intensities were quantified 
using ImageJ (76). (B) TDP-Rha saturation curves of EarPPpu single-amino-acid exchange variants. Fixed 
amounts of EF-PPpu (2.5 µM) and the respective EarPPpu single-amino-acid exchange variants (0.1 µM) were 
incubated with various concentrations of TDP-Rha at 30°C in 100 mM NaPi, pH 7.6. In the cases of the F191A
EarP
 
and Y1931A
EarP
 variants, 0.5 µM concentrations were used. Suitable incubation times were determined by time 
course experiments prior to determination of kinetic parameters (data not shown). Representative SDS-PAGE 
gels and Western blots used for generation of the TDP-Rha saturation curves are depicted underneath the 
corresponding graphs. Rhamnosylated EF-PPpu was detected after Western blotting using 0.25 µg/ml anti-Arg
Rha
. 
Band intensities were quantified using ImageJ (76). Km and kcat were calculated using SigmaPlot. Standard errors 
are shown when measurements were performed in technical duplicates 
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Figure S3. (A) Fold recognition models of EarP from P. putida. (Top) Structural models of EarP from P. putida 
were generated using Phyre
2
 (orange), the I-TASSER server (white), and SWISS-MODEL (blue). Model coverage 
and scoring is shown underneath the respective model structures. (Bottom) Overlay of structural models from 
Phyre
2
 and I-TASSER (left), I-TASSER and SWISS-MODEL (middle), and SWISS-MODEL and Phyre
2
 (right). 
Root mean square deviations of atomic positions are shown underneath the respective structural overlays. All 
illustrations and overlays were generated using UCSF Chimera and the UCSF Chimera MatchMaker (82). (B) B-
factors are plotted on the crystal structure of EarP. Several regions in the N-domain show significantly higher B-
factors than in the C domain, suggesting the mobile nature of this region. (C) Electron density of TDP-Rha in the 
donor binding pocket. TDP-Rha is depicted as sticks. Sigma-Aldrich weighted 2mFo-DFc map of TDP-Rha 
contoured at 1 σ is depicted as grey mesh. (D) SAXS analysis of free EarP and EarP bound to TDP-Rha. The two 
experimental small-angle X-ray scattering curves of free EarP (black) and EarP plus TDP-Rha (blue) do not 
exhibit any significant changes. Thus, it can be concluded that there are no major conformational changes upon 
ligand binding. The crystal structure and monomeric states of the protein are also validated in solution, as the 
back-calculated scattering densities (red line) fit well with the experimental data (χ2 = 1.96). The deviation at the 
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low Q range is due to aggregation and/or interparticle interaction. (E) Secondary structure of EF-P from P. putida. 
The secondary structures of individual amino acids are indicated as a propensity to form either α-helix (red) or β-
strand (green). The amino acids with a propensity to adopt a random coil or lacking information about secondary 
structure were assigned zero values in the plot. The propensity values were obtained from Cα, Cβ, and C′ 
secondary chemical shifts using CcpNmr Analysis (106). (F) Secondary structure of EF-P from P. aeruginosa 
(PDB accession number 3OYY) (45). Red ribbons indicate α-helices; green arrows indicate β-strands. 
 
 
Figure S4. (A) Stereo view of the EarP–TDP-Rha complex. Electron density is shown. (B and C) Electron 
densities for the N- and C-terminal domains, respectively. The N-terminal domain shows several disconnected 
blobs of electron density currently modeled with water, and some regions are entirely missing.  
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Figure S5. (A) STD NMR 
at a 1:100 ratio of protein to 
ligand shows several 
signals from the TDP but 
no signal from the sugar 
region of the TDP-Rha, 
thus confirming the crystal 
structure where the sugar 
is solvent exposed, and 
does not show extensive 
contacts with the protein. 
(B) STD NMR with a low 
excess of TDP-Rha (1:7 
ratio of protein to ligand) 
clearly shows the signal for 
the methyl group of the 
thymidine ring, confirming 
the interaction between 
TDP-Rha and EarP under 
conditions used for SAXS 
data collection. (C) STD 
NMR experiments with 
E273 variants showing that 
the mutation of E273 to 
alanine, glutamine, or 
aspartate does not affect 
the binding of TDP-Rha to 
EarP. 
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Figure S6. (A) SDS-PAGE gels and Western blots for determination of the intracellular TDP-Rha concentration in 
E. coli MG1655 (top), P. putida KT2440 (middle), and P. aeruginosa (bottom). Purified EF-PPpu (2.5 µM) and 
EarPPpu (0.1 µM) were incubated with increasing concentrations of TDP-Rha or lysates from ~10
7
 and ~10
8
 cells 
(sample volume, 20 µl; 100 mM NaPi [pH 7.6]; 20 s; 30°C). Samples containing cell lysates were incubated in the 
presence and absence of EarPPpu. Rhamnosylated EF-P (EF-P
Rha
) was detected using 0.25 µg/ml anti-Arg
Rha
. For 
E. coli and P. aeruginosa, experiments were performed as biological triplicates. (B) Representative calibration 
curves calculated from relative Western blot band intensities in samples containing increasing TDP-Rha 
concentrations. Band intensities were quantified using ImageJ (76). TDP-Rha concentrations in samples 
containing ~10
8
 lysed cells (triangles) were calculated from the slope of the calibration curve and are indicated by 
dashed lines. Band intensities from samples containing no EarPPpu were subtracted from those containing EarPPpu 
to correct for background signal. (C) Equations used to calculate average TDP-Rha concentrations in single cells. 
For calculation of average TDP-Rha concentrations in E. coli cells, an average cell volume of 3.9 fl was assumed 
(84). For calculation of average TDP-Rha concentrations in P. putida and P. aeruginosa cells, an average cell 
volume of 2.1 fl was assumed (85). 
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Figure S7. Assessing 
folding state of EarPPpu 
variants. To check whether 
a given variant is properly 
folded, a 
1
H-
15
N HSQC of 
15
N-labeled variants was 
recorded (colored) and 
overlaid with a spectrum of 
wild-type protein (grey). 
Note that the mutant 
spectra were recorded with 
a small number of scans. 
Spectra of all variants 
except the D274A variant 
overlap well with the wild-
type spectrum and show 
well-dispersed peaks (an 
indicator of a stable 
secondary structure), 
confirming that the single-
amino-acid substitutions do 
not influence proper folding 
of EarP. In contrast, the 
D274A variant is in large 
part unfolded. 
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Supplemental figures 
 
Figure S1, related to Figure 1 & 2 (A) Phylogenetic tree built from the EF-P KOW-like N-domain I. The tree is 
colored according to the 34
th
 position in the multiple sequence alignment and annotated according to the co-
occurrence with EpmABC and EarP. (B) Venn diagram of modification proteins that co-occur with EF-P/IF5A. (C) 
(D) Phylogenetic trees of the EF-P KOW-like N-domain I, with reconstructed state of the modification system (C) 
and the 34
th
 position (D).  
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Figure S2, related to Figure 3 & 4 (A) β-galactosidase activity in the ∆epmA reporter strain (E. coli MG-CL-12-
yjeA) harboring either a plasmid borne copy of epmA (pBAD33-epmA) or efp (pBAD24-efpEco) (B) Effect of the 
hybrid EF-PEco loopPpu on different polyproline containing stalling motifs. Measurements were performed in E. coli 
∆efp cells (JW4107), harboring plasmid encoded different stalling motifs followed by the lacZ reporter 
(pBBR1MCS-3 XPPX lacZ). (C) In vivo rhamnosylation and functionality analysis of hybrid EF-Ps coexpressed 
with EarP from P. putida (light grey) or EarP from Shewanella oneidensis MR-1 (blue). The measurements were 
performed in the reporter strain were efp was deleted (E. coli MG-CR-efp-KanS). β-galactosidase activity is given 
in Miller units and reflects the degree of EF-P functionality. Production and rhamnosylation of EF-P was verified 
by Western blot analysis. (D) Single colonies of E. coli BTH101, DHM1 and KV1 cotransformed with variants of 
pUT18C (T18) and pKT25 (T25) were inoculated in 2 ml of LB medium supplemented with 50 μg/ml kanamycin 
sulfate and 100 µg/ml carbenicillin and grown at 30 °C under agitation over night. On the next day the cells were 
harvested by centrifugation, and the β-galactosidase activities were determined. (E) Isoelectric focusing of E. coli 
EF-P, either overproduced in E. coli epmA
-
 (BW25113-epmA), in which epmA is chromosomally deleted, or in E. 
coli wild type cells (BW25113). Furthermore, EF-P was overproduced in combination with its PTM proteins EpmA 
and EpmB in E. coli wild type (BW25113). Production of EF-P was verified by Western blot analysis. 
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Figure S3, related to Figure 3 & 4 (A) Left: Analysis of EarPPpu kinetic parameters. 0.5 µg of EF-PPpu and 0.05 
µg of EarPPpu were subjected to SDS-PAGE after in vitro rhamnosylation (see methods) for 20 seconds at varying 
TDP-rhamnose concentrations. Proteins were transferred to nitrocellulose membrane by horizontal Western 
blotting. Rhamnosylated EF-PPpu was detected using 0.25 µg/ml of Anti-Arg
Rha
. Right: TDP-rhamnose saturation 
curve of EarPPpu. Band intensities on nitrocellulose membrane were quantified using ImageJ and relative band 
intensities were plotted against TDP-rhamnose concentration. (B) Timecourse analysis of various EF-PPpu and 
EF-PEco variants. 0.5 µg of EF-PPpu and 0.05 µg of EarPPpu were subjected to SDS-PAGE after in vitro 
rhamnosylation at a TDP-rhamnose concentration of 50 µM for varying timespans. Band intensities on 
nitrocellulose membrane were quantified using ImageJ and relative band intensities were plotted against time. 
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Figure S4, related to Figure 4 (A) 
1
H-
15
N HSQC titrations of EF-PEco and EF-PEco loopPpu with EarPPpu is shown 
along with the backbone assignments. Both proteins show a decrease in intensity upon titration with EarPPpu 
indicating their interaction with EarPPpu. (B) Intensity ratio of all the EF-PEco mutants on titration with EarPPpu is 
shown. (C) The correlation time (c) for EF-PEco and its variants along with (D) R1, (E) R2 rates and (F) hetNOE 
are shown.  
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Table S1: Distribution of EF-P, EpmA, EpmB, EpmC and EarP homologs 
Supplemental online material 
 
Table S2: Strains used in this study 
Strain Genotype Reference 
DH5αλpir recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 ∆lacZYA-argF U169 ɸ80dlacZ∆M15 λpir (1) 
LMG194 
F
-
 ΔlacX74 galE galK thi rpsL ΔphoA (PvuII) 
Δara714 leu::Tn10 (2) 
BL21(DE3) F
-
 ompT gal dcm lon hsdSB(rB
-
 mB
-
) λ(DE3) (3) 
DHM1 
F
-
 cya-854 recA1 endA1 gyrA96 (NalR) thi1 
hsdR17 spoT1 rfbD1 glnV44(AS) 
(4) 
BTH101 
F
-
 cya-99 araD139 galE15 galK16 rpsL1 (StrR) 
hsdR2 mcrA1 mcrB1 additional relA1 mutation 
reported by (Battesti and Bouveret, 2012) 
Euromedex 
JW4107 
Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, rph-
1, Δ(rhaD-rhaB)568, Δefp-772::kan, hsdR514 (5) 
KV1 MG1655 rpsL150 ΔcyaA Plac::luxCDABE-lacZ This study 
LF1 
MG1655 rpsL150 Plac::rpsL-neo-kan::lacZ
Δ1–100 
bp;Kan
R
 Strp
S
 
(6) 
MG-CR-efp 
MG1655 ΔlacZ::tet rpsL150 efp::npt ΔcadBA 
PcadBA::lacZ 
(7) 
MG-CR-efp-KanS 
MG1655 ΔlacZ::tet rpsL150 Δefp ΔcadBA 
PcadBA::lacZ 
This study 
MG-CR-efp-epmA-
KanR 
MG1655 ΔlacZ::tet rpsL150 Δefp ΔcadBA 
epmA::npt PcadBA::lacZ 
This study 
MG-CL-12-yjeA 
MG1655 ∆lacZ::tet rpsL150 yjeA::npt ∆cadBA 
cadBA::lacZ 
(8) 
BW25113 
∆(araD-araB)567, ∆lacZ4787(::rrnB-3),  
λ-, rph-1, ∆(rhaD-rhaB)568, hsdR514 (9) 
BW25113-epmA 
∆(araD-araB)567, ∆lacZ4787(::rrnB-3),  
λ-, rph-1, ∆(rhaD-rhaB)568, hsdR514, ΔepmA This study 
JW4116 
F
-
, Δ(araD-araB)567, ΔlacZ4787(::rrnB-3), λ-, 
rph-1, Δ(rhaD-rhaB)568, ΔpoxA782::kan, 
hsdR514 
(5) 
KanR: kanamycin resistance, StrepS: streptomycin sensitive 
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Table S3: Plasmids used in this study 
Plasmid Features Reference 
Plasmids for strain construction 
pRED/ET® Amp λ-RED recombinase in pBAD24; AmpR GeneBridges,  
Germany 
FRT-PGK-gb2-neo-
FRT  
template DNA 
PCR-template (plasmid DNA) for generating a FRT-
flanked PGK-gb2-neo cassette, Kan
R
 
GeneBridges,  
Germany 
709-FLPe, amp 
Plasmid for removal of FRT flanked resistance cassette, 
Supplier ID: A106 
GeneBridges,  
Germany 
pBAD/HisA-Lux 
Contains the luxCDABE operon from Photorhabdus 
luminescens 
(10) 
Plasmids for mutational analysis of the E. coli loop and for overproduction 
pBAD24 
Amp
R
-cassette, pBBR322 origin, araC coding 
sequence, ara operator 
(2) 
pBAD24-efpEco 
C-terminal His6-tagged E. coli efp amplified from 
pBAD33-efpE.c.-His6 (Lassak et al., 2015) using P1/P2 
this study 
pBAD24-efpEco P32G 
C-terminal His6-tagged E. coli efp substitution variant 
P32G. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P16 and P2/P15 
this study 
pBAD24-efpEco P32S 
C-terminal His6-tagged E. coli efp substitution variant 
P32S. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P18 and P2/P17 
this study 
pBAD24-efpEco G33A 
C-terminal His6-tagged E. coli efp substitution variant 
G33A. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P20 and P2/P19 
this study 
pBAD24-efpEco G33S 
C-terminal His6-tagged E. coli efp substitution variant 
G33S. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P22 and P2/P21 
this study 
pBAD24-efpEco K34A 
C-terminal His6-tagged E. coli efp substitution variant 
K34A. Amplified from pBAD33-efpE.c.-His6-K34A 
(Lassak et al., 2015) using P1/P2 
this study 
pBAD24-efpEco K34M 
C-terminal His6-tagged E. coli efp substitution variant 
K34M. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P24 and P2/P23 
this study 
pBAD24-efpEco K34N 
C-terminal His6-tagged E. coli efp substitution variant 
K34N. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P26 and P2/P25 
this study 
pBAD24-efpEco K34Q 
C-terminal His6-tagged E. coli efp substitution variant 
K34Q. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P28 and P2/P27 
this study 
pBAD24-efpEco K34R 
C-terminal His6-tagged E. coli efp substitution variant 
K34R. Amplified from pBAD33-efpE.c.-His6-K34R 
(Lassak et al., 2015) using P1/P2 
this study 
pBAD24-efpEco G35N 
C-terminal His6-tagged E. coli efp substitution variant 
G35N. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P30 and P2/P29 
this study 
pBAD24-efpEco Q36S 
C-terminal His6-tagged E. coli efp substitution variant 
Q36S. Overlap PCR fragment was amplified from 
pBAD24-efpEco using P1/P32 and P2/P31 
this study 
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Plasmids for mutational analysis of the P. putida loop and for overproduction 
pBAD24-efpPpu 
C-terminal His6-tagged P. putida efp amplified from 
Pseudomonas putida KT2440 using P1/P2 
this study 
pBAD24-efpPpu K29A 
C-terminal His6-tagged efp P. putida substitution variant 
K29A. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P36 and P2/P35 
this study 
pBAD24-efpPpu K29R 
C-terminal His6-tagged P. putida efp substitution variant 
K29R. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P37 and P2/P35 
this study 
pBAD24-efpPpu S30A 
C-terminal His6-tagged P. putida efp substitution variant 
S30A. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P38 and P2/P35 
this study 
pBAD24-efpPpu S30G 
C-terminal His6-tagged P. putida efp substitution variant 
S30G. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P39 and P2/P35 
this study 
pBAD24-efpPpu S30P 
C-terminal His6-tagged P. putida efp substitution variant 
S30P. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P40 and P2/P35 
this study 
pBAD24-efpPpu G31A 
C-terminal His6-tagged P. putida efp substitution variant 
G31A. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P41 and P2/P35 
this study 
pBAD24-efpPpu G31S 
C-terminal His6-tagged P. putida efp substitution variant 
G31S. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P42 and P2/P35 
this study 
pBAD24-efpPpu R32K 
C-terminal His6-tagged P. putida efp substitution variant 
R32K. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P44 and P2/P43 
this study 
pBAD24-efpPpu N33D 
C-terminal His6-tagged P. putida efp substitution variant 
N33D. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P46 and P2/P45 
this study 
pBAD24-efpPpu N33G 
C-terminal His6-tagged P. putida efp substitution variant 
N33G. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P47 and P2/P45 
this study 
pBAD24-efpPpu S34A 
C-terminal His6-tagged P. putida efp substitution variant 
S34A. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P48 and P2/P45 
this study 
pBAD24-efpPpu S34Q 
C-terminal His6-tagged P. putida efp substitution variant 
S34Q. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P49 and P2/P45 
this study 
pBAD24-efpPpu A35S 
C-terminal His6-tagged P. putida efp substitution variant 
A35S. Overlap PCR fragment was amplified from 
pBAD24-efpPpu using P1/P50 and P2/P45 
this study 
pBAD33 
Cm
R
-cassette, p15A origin, araC coding sequence, ara 
operator 
(2) 
pBAD33 PP1857-
His6 
C-terminal His6-Tag earP version from P. putida 
KT2440 
(11) 
  
 
142 
 
Plasmids for cross modification/actication and overproduction 
pBAD24-efpEco  
domainI-efpPpu 
C-terminal His6-tagged E. coli efp where the first 65 
amino acids (domainI) were substituted by the first 65 
amino acids from P. putida efp. Overlap PCR fragment 
was amplified from pBAD24-efpPpu using P1/P52 and 
pBAD24-efpEco P2/P51 
this study 
pBAD24-efpEco  
loop-efpPpu 
C-terminal His6-tagged E. coli efp P32S K34R G35N 
Q36S multiple amino acid substitution variant, 
corresponding to EF-P of E. coli carrying the acceptor 
loop of EF-P from P. putida. Overlap PCR fragment was 
amplified from pBAD24-efpEco using P1/P54 and P2/P53 
this study 
pBAD24-efpEco  
P32S K34R 
C-terminal His6-tagged E. coli efp substitution variant 
P32S K34R. Overlap PCR fragment was amplified from 
pBAD24-efpEco K34R using P1/P56 and P2/P55 
this study 
pBAD24-efpEco  
K34R G35N 
C-terminal His6-tagged E. coli efp substitution variant 
K34R G35N. Overlap PCR fragment was amplified from 
pBAD24-efpEco K34R using P1/P58 and P2/P57 
this study 
pBAD24-efpEco  
K34R Q36S 
C-terminal His6-tagged E. coli efp substitution variant 
K34R Q36S. Overlap PCR fragment was amplified from 
pBAD24-efpEco K34R using P1/P60 and P2/P59 
this study 
pBAD24-efpEco  
P32S K34R G35N 
C-terminal His6-tagged E. coli efp substitution variant 
P32S K34R G35N. Overlap PCR fragment was 
amplified from pBAD24-efpEco P32S K34R using P1/P62 
and P2/P61 
this study 
pBAD24 -efpEco  
P32S K34R Q36S 
C-terminal His6-tagged E. coli efp substitution variant 
P32S K34R Q36S. Overlap PCR fragment was 
amplified from pBAD24-efpEco P32S K34R using P1/P64 
and P2/P63 
this study 
pBAD24-efpEco  
K34R G35N Q36S 
C-terminal His6-tagged E. coli efp substitution variant 
K34R G35N Q36S. Overlap PCR fragment was 
amplified from pBAD24-efpEco K34R using P1/P66 and 
P2/P65 
this study 
pBAD33-earPSo 
earP from Shewanella oneidensis MR-1 amplified from 
pBAD24-earPS.o.-His6 (Lassak et al., 2015) using 
P1/P67 
this study 
Plasmids for XPPX assay 
p3LC-TL30-APP p3LC-TL30 + sequence encoding Ala-Pro-Pro (12) 
p3LC-TL30-PPD p3LC-TL30 + sequence encoding Pro-Pro-Asp (12) 
p3LC-TL30-PPP p3LC-TL30 + sequence encoding Pro-Pro-Pro (Ude et al., 2013) 
p3LC-TL30-DPP p3LC-TL30 + sequence encoding Asp-Pro-Pro (12) 
p3LC-TL30-PPG p3LC-TL30 + sequence encoding Pro-Pro-Gly (12) 
p3LC-TL30-PPN p3LC-TL30 + sequence encoding Pro-Pro-Asn (12) 
Plasmids used in the reporter strain MG-CL-12-yjeA 
pBAD33-epmA epmA from E. coli, amplified using P72/P75 this study 
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Plasmids for protein overproduction (NMR) 
pET SUMO 
pBR322 origin, lacI, T7 lac promoter, N-terminal His6 
tag,  
SUMO coding sequence, Kan
R
, Supplier ID: K300-01 
Invitrogen 
pET SUMO-efpEco 
C-terminal genetic fusion of efp from E. coli to His6-
SUMO-tag. Amplified from pBAD24-efpEco using 
P68/P69 
this study 
pET SUMO-efpPpu 
C-terminal genetic fusion of efp from P. putida KT2440 
to His6-SUMO-tag 
(11) 
pET SUMO-efpEco 
P32S 
C-terminal genetic fusion of efp from E. coli substitution 
variant P32S to His6-SUMO-tag. Overlap PCR fragment 
was amplified from pET SUMO-efpEco using P5/P18 and 
P6/P17 
this study 
pET SUMO-efpEco 
K34R 
C-terminal genetic fusion of efp from E. coli substitution 
variant K34R to His6-SUMO-tag. Overlap PCR fragment 
was amplified from pET SUMO-efpEco using P5/P71 and 
P6/P70 
this study 
pET SUMO-efpEco 
P32S K34R 
C-terminal genetic fusion of efp from E. coli substitution 
variant P32S K34R to His6-SUMO-tag. Overlap PCR 
fragment was amplified from pET SUMO-efpEco using 
P5/P56 and P6/P55 
this study 
pET SUMO-efpEco 
loopPpu 
C-terminal genetic fusion of efp from E. coli substitution 
variant P32S K34R G35N Q36S to His6-SUMO-tag. 
Overlap PCR fragment was amplified from pET SUMO-
efpEco using P5/P54 and P6/P53 
this study 
Plasmids for bacterial two-hybrid (BTH) 
pUT18-zip 
N-terminal genetic fusion of the leucine zipper from 
GCN4 to the T18 fragment of CyaA 
Euromedex 
pKT25-zip 
C-terminal genetic fusion of the leucine zipper from 
GCN4 to the T25 fragment of CyaA 
Euromedex 
pUT18C-PP1858 
C-terminal genetic fusion of efp from Pseudomonas 
putida to the T18 fragment of CyaA 
(11) 
pKT25-PP1857 
C-terminal genetic fusion of earP from Pseudomonas 
putida to the T25 fragment of CyaA 
(11) 
pUT18C-efpEco 
C-terminal genetic fusion of efp from Escherichia coli to 
the T18 fragment of CyaA. PCR fragment was amplified 
from pBAD24-efpEco using P80/P81 
this study 
pUT18C-efpEco K34R 
C-terminal genetic fusion of efp from Escherichia coli to 
the T18 fragment of CyaA. K34R single amino acid 
exchange variant. PCR fragment was amplified from 
pBAD24-efpEco K34R using P80/P81 
this study 
pUT18C-efpEco P32S 
K34R 
C-terminal genetic fusion of efp from Escherichia coli to 
the T18 fragment of CyaA. P32S K34R double amino 
acid exchange variant. PCR fragment was amplified 
from pBAD24-efpEco P32S K34R using P80/P81 
this study 
pUT18C-efpEco 
loopPpu 
C-terminal genetic fusion of efp from E. coli to the T18 
fragment of CyaA. P32S K34R G35N Q36S multiple 
amino acid exchange variant, corresponding to EF-P of 
E. coli carrying the acceptor loop of EF-P from P. 
putida. PCR fragment was amplified from pBAD24-
efpEco loopPpu using P80/P81 
this study 
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Plasmids for isoelectric focusing 
pBAD33-efp-His6 
C-terminal His6-Tag efp version from E. coli into 
pBAD33 
(7) 
pBAD33-efp-His6-
epmAB 
C-terminal His6-tagged efp and epmAB from E. coli. 
Overlap PCR fragment was amplified using P73/P76, 
P72/P75 and P74/P77  
this study 
AmpR, CmR, KanR: ampicillin, chloramphenicol, kanamycin resistance. 
 
Table S4: Primers used in this study 
Identifier Oligonucleotide Sequence (5' - 3') Restriction  
site 
Reference 
Primers for sequencing and cloning     
P1 Seq33 fw GGC GTC CAC ACT TTG CTA TGC   (13) 
P2 pBAD HisA rev CAG TTC CCT ACT CTC GCA TG   (13) 
P3 epmA chk fw 
TAG GTA CAA CAG TAT AGT CTG ATG 
GAT AA 
  this study 
P4 epmA chk rev 
TGA GGC ATG AAA CCA TCC TTC ATT 
TC 
  this study 
P5 T7 Prom TAA TAC GAC TCA CTA TAG G     
P6 T7 Term TAT GCT AGT TAT TGC TCA G     
Primers for strain construction of KV1 
P7 LacI-583-fw 
GTC TGC GTC TGG CTG GCT GGC 
ATA 
  (6) 
P8 LuxC-OL-rev 
TAG TGC CCA TAG CTG TTT CCT 
GTG TGA AAT TGT TAT CC 
  this study 
P9 LuxC-OL-fw 
GGA AAC AGC TAT GGG CAC TAA 
AAA AAT TTC ATT CAT TAT TAA CGG 
  this study 
P10 
LuxE-OL-sRBS-
lacZ-rev 
AAT GTA CCT CCT TAC TTT ATT TAT 
TGT ATT TGT TTA GCT ATC AAA CGC 
TTC GGT TAA GCT C 
  this study 
P11 
OL-sRBS-lacZ-
fw 
ACA AAT ACA ATA AAT AAA GTA AGG 
AGG TAC ATT ATG ACC ATG ATT ACG 
GAT TCA CTG GCC G 
  this study 
P12 lacZ 500bp anti 
CGA CTG TCC TGG CCG TAA CCG 
ACC 
  (6) 
P13 delta CyaA fw 
GTT GGC GGA ATC ACA GTC ATG 
ACG GGT AGC AAA TCA GGC GAT 
ACG TCT TGA ATT AAC CCT CAC TAA 
AGG GCG 
  this study 
P14 delta CyaA rev 
TCC GCT AAG ATT GCA TGC CGG 
ATA AGC CTC GCT TTC CGG CAC 
GTT CAT CAT AAT ACG ACT CAC TAT 
AGG GCT C 
  this study 
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Primers E. coli loop mutation and overproduction constructs 
P15 
EF-P Eco P32G 
fw 
GTA AAA GGC GGT AAA GGC CAG G   this study 
P16 
EF-P Eco P32G 
rev CCT GGC CTT TAC CGC CTT TTA C 
  this study 
P17 
EF-P Eco P32S 
fw 
CGT AAA ATC GGG TAA AGG CCA GG   this study 
P18 
EF-P Eco P32S 
rev CCT GGC CTT TAC CCG ATT TTA CG 
  this study 
P19 
EF-P Eco G33A 
fw 
TAA AAC CGG CGA AAG GCC AGG   this study 
P20 
EF-P Eco G33A 
rev CCT GGC CTT TCG CCG GTT TTA 
  this study 
P21 
EF-P Eco G33S 
fw 
GTA AAA CCG TCG AAA GGC CAG G   this study 
P22 
EF-P Eco G33S 
rev 
CCT GGC CTT TCG ACG GTT TTA C 
  this study 
P23 
EF-P Eco K34M 
fw 
GTA AAA CCG GGT ATG GGC CAG 
GCA TTT 
  this study 
P24 
EF-P Eco K34M 
rev 
AAA TGC CTG GCC CAT ACC CGG 
TTT TAC 
  this study 
P25 
EF-P Eco K34N 
fw 
GTA AAA CCG GGT AAC GGC CAG 
GCA TTT 
  this study 
P26 
EF-P Eco K34N 
rev 
AAA TGC CTG GCC GTT ACC CGG 
TTT TAC 
  this study 
P27 
EF-P Eco K34Q 
fw 
GTA AAA CCG GGT CAG GGC CAG 
GCA TTT 
  this study 
P28 
EF-P Eco K34Q 
rev 
AAA TGC CTG GCC CTG ACC CGG 
TTT TAC 
  this study 
P29 
EF-P Eco G35N 
fw 
CCG GGT AAA AAC CAG GCA TTT GC   this study 
P30 
EF-P Eco G35N 
rev GCA AAT GCC TGG TTT TTA CCC GG   this study 
P31 
EF-P Eco Q36S 
fw 
GGG TAA AGG CAG CGC ATT TGC   this study 
P32 
EF-P Eco Q36S 
rev 
GCA AAT GCG CTG CCT TTA CCC 
 
this study 
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Primers P. putida loop mutation and overproduction constructs 
P33 
NheI-NRBS-
PP_1858-fw 
GCA CTA GCT AGC CGC GGC CTC 
GAT TTT TAT AAA TCC 
NheI this study 
P34 
XbaI-PP_1858-
GS-His6-rev 
CGT CTA GAT TAG TGA TGG TGA 
TGG TGA TGC GAG CCC TTC TTG 
GAG CGG CCT TTG AA 
XbaI this study 
P35 
EF-P Ppu 29 30 
31 OL fw 
CGT AAC AGC GCG ATC ATG AAG 
ACC 
  this study 
P36 
EF-P Ppu K29A 
OL rev 
CAT GAT CGC GCT GTT ACG GCC 
CGA CGC GGT GAA CTC AGC   
this study 
P37 
EF-P Ppu K29R 
OL rev 
CAT GAT CGC GCT GTT ACG GCC 
CGA GCG GGT GAA CTC AGC 
  this study 
P38 
EF-P Ppu S30A 
OL rev 
CAT GAT CGC GCT GTT ACG GCC 
CGC CTT GGT GAA CTC AGC   
this study 
P39 
EF-P Ppu S30G 
OL rev 
CAT GAT CGC GCT GTT ACG GCC 
GCC CTT GGT GAA CTC AGC 
  this study 
P40 
EF-P Ppu S30P 
OL rev 
CAT GAT CGC GCT GTT ACG GCC 
CGG CTT GGT GAA CTC AGC   
this study 
P41 
EF-P Ppu G31A 
OL rev 
CAT GAT CGC GCT GTT ACG CGC 
CGA CTT GGT GAA CTC 
  this study 
P42 
EF-P Ppu G31S 
OL rev 
CAT GAT CGC GCT GTT ACG GCT 
CGA CTT GGT GAA CTC   
this study 
P43 
EF-P Ppu R32K 
fw 
ACC AAG TCG GGC AAG AAC AGC 
GCG ATC 
  this study 
P44 
EF-P Ppu R32K 
rev 
GAT CGC GCT GTT CTT GCC CGA 
CTT GGT   
this study 
P45 
EF-P Ppu 33 34 
35 OL fw 
ATC ATG AAG ACC AAG CTG AAG 
AAC CTG 
  this study 
P46 
EF-P Ppu N33D 
OL rev 
CTT CAG CTT GGT CTT CAT GAT CGC 
GCT ATC ACG GCC CGA CTT   
this study 
P47 
EF-P Ppu N33G 
OL rev 
CTT CAG CTT GGT CTT CAT GAT CGC 
GCT GCC ACG GCC CGA CTT 
  this study 
P48 
EF-P Ppu S34A 
OL rev 
CTT CAG CTT GGT CTT CAT GAT CGC 
CGC GTT ACG GCC CGA   
this study 
P49 
EF-P Ppu S34Q 
OL rev 
CTT CAG CTT GGT CTT CAT GAT CGC 
CTG GTT ACG GCC CGA 
  this study 
P50 
EF-P Ppu A35S 
OL rev 
CTT CAG CTT GGT CTT CAT GAT GCT 
GCT GTT ACG GCC   
this study 
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Primers cross modification/activation and overproduction 
P51 
EF-P Eco 
domainI Ppu OL 
fw 
AAG CTG GAC GAC GTG ATC CTG 
GAT ATG AAC CTG ACT TAC CTG 
  this study 
P52 
EF-P Eco 
domainI Ppu OL 
rev 
CAG GTA AGT CAG GTT CAT ATC 
CAG GAT CAC GTC GTC CAG CTT   
this study 
P53 
EF-P Eco loop 
Ppu OL fw 
AAG TCG GGC CGT AAC AGC GCG 
TTT GCT CGC GTT AAA CTG CGT 
  this study 
P54 
EF-P Eco loop 
Ppu OL rev 
CGC GCT GTT ACG GCC CGA CTT 
TAC GAA TTC ACT CGC TTC AAC   
this study 
P55 
EF-P Eco P32S 
K34R OL fw 
GAA TTC GTA AAA AGC GGT CGC 
GGC CAG GCA TTT 
  this study 
P56 
EF-P Eco P32S 
K34R OL rev 
AAA TGC CTG GCC GCG ACC GCT 
TTT TAC GAA TTC   
this study 
P57 
EF-P Eco K34R 
G35N OL fw 
CCG GGT CGC AAC CAG GCA TTT 
GCT CG 
  this study 
P58 
EF-P Eco K34R 
G35N OL rev 
CGA GCA AAT GCC TGG TTG CGA 
CCC GG   
this study 
P59 
EF-P Eco K34R 
Q36S OL fw 
CGC GGC AGC GCA TTT GCT CGC 
GTT A 
  this study 
P60 
EF-P Eco K34R 
Q36S OL rev 
TAA CGC GAG CAA ATG CGC TGC 
CGC G   
this study 
P61 
EF-P Eco P32S 
K34R G35N OL 
fw 
AGC GGT CGC AAC CAG GCA TTT 
GCT CG 
  this study 
P62 
EF-P Eco P32S 
K34R G35N OL 
rev 
CGA GCA AAT GCC TGG TTG CGA 
CCG CT 
  
this study 
P63 
EF-P Eco P32S 
K34R Q36S OL 
fw 
AGC GGT CGC GGC AGC GCA TTT 
GCT CG 
  this study 
P64 
EF-P Eco P32S 
K34R Q36S OL 
rev 
CGA GCA AAT GCG CTG CCG CGA 
CCG CT 
  
this study 
P65 
EF-P Eco K34R 
G35N Q36S OL 
fw 
GGG TCG CAA CAG CGC ATT TG   this study 
P66 
EF-P Eco K34R 
G35N Q36S OL 
rev 
CAA ATG CGC TGT TGC GAC CC 
  
this study 
P67 EarP So rev 
GCG GTA CCC GAT TTT CTA TTT CAG 
CGC AGC AT 
KpnI this study 
Primers pET SUMO constructs 
P68 
EF-P Eco-
SUMO-fw 
ATG GCA ACG TAC TAT AGC AAC 
GAT TTT 
  this study 
P69 
EF-P Eco-
SUMO-rev 
TTA GTG ATG GTG ATG GTG ATG 
GCT 
  this study 
P70 
EF-P Eco K34R 
OL fw 
GTA AAA CCG GGT CGC GGC CAG 
GCA TTT 
 this study 
P71 
EF-P Eco K34R 
OL rev 
AAA TGC CTG GCC GCG ACC CGG 
TTT TAC 
 this study 
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Primers isoelectric focusing and pBAD33-epmA  
P72 
efp-yjeA-OL-
XbaI-fw 
CGT GAA GTA ATC TAG ATT GTC AAA 
AAC TGG AGA TTT AAC TAT GAG C 
XbaI this study 
P73 
efp-yjeA-OL-
XbaI-rev 
TTT TTG ACA ATC TAG ATT ACT TCA 
CGC GAG AGA CGT ATT CA 
XbaI this study 
P74 
yjeA-yjeK-OL-
PstI-fw 
GCA TAA CTG CAG GGT AGC TAA 
GCC ACA AAA TGG CG 
PstI this study 
P75 
yjeA-yjeK-OL-
PstI-rev 
GCT ACC CTG CAG TTA TGC CCG 
GTC AAC GCT AAA G 
PstI this study 
P76 SacI-RBS-efp-fw 
GCG ATG AGC TCA ATT AAC AAA TTT 
CAG AGG GCC TTA TGG 
SacI this study 
P77 SphI-yjeK-rev 
GCA TCG CAT GCT TAC TGC TGG 
CGT AGC TGG AG 
SphI this study 
Primer for strain construction of MG-CR-efp-epmA-KanR 
P78 epmA fw CAC CGC TGT TTG ATT CCT GCG T   this study 
P79 empA rev GCT ACA GAA TGG CGC TTA TCA CG   this study 
Primer for for bacterial two-hybrid (BTH) 
P80 
XbaI-EF-
PEcoFW 
GTA TCG TCT AGA GGC AAC GTA 
CTA TAG CAA CGA TTT TCG TG 
XbaI this study 
P81 
XmaI-EF-
PEcoRev 
GTA TCG CCC GGG ACT TCA CGC 
GAG AGA CGT ATT CAC C 
XmaI this study 
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Supplemental Experimental Procedures 
Molecular biological techniques 
All kits and enzymes were used according to manufacturers instructions. Plasmid DNA was 
isolated using the Hi Yield® Plasmid Mini Kit from Süd Laborbedarf. DNA fragments were 
purified from agarose gels using the Hi Yield® Gel/PCR DNA fragment extraction from Süd 
Laborbedarf. All restriction enzymes, DNA modifying enzymes and the Q5® high fidelity DNA 
polymerase for PCR amplification were purchased from New England BioLabs. 
SDS-PAGE and Western blotting 
Cells were subjected to 12 % (w/v) sodium dodecyl sulfate (SDS) polyacrylamide gel 
electrophoresis (PAGE) as described by Laemmli (14). To visualize and confirm protein 
separation, 2,2,2-trichloroethanol was incorporated into the polyacrylamide gels (15) and 
detected within a Gel DocTM EZ gel documentation system (Bio-Rad). Afterwards the 
proteins were transferred onto nitrocellulose membranes (Whatman) which were then subject 
for immunoblotting. The membranes were in a first step incubated either with 0.1 µg/mL Anti-
His6 antibody (Abcam, Inc.) to detect EF-P, or with 0.25 µg/ml Anti-Arg
Rha antibody (11) to 
detect rhamnosylation of EF-P. These primary antibodies (rabbit) were then targeted with 0.2 
µg/ml Anti-rabbit phosphatase-conjugated secondary antibody (Rockland). Localization was 
visualized by adding development solution (50 mM sodium carbonate buffer, pH 9.5, 0.01% 
(w/v) p-nitroblue tetrazolium chloride (NBT) and 0.045% (w/v) 5-bromo-4-chloro-3-indolyl-
phosphate (BCIP)). 
Growth conditions 
E. coli cells were routinely grown in Miller modified LB (16-18) at 37 °C aerobically under 
agitation, if not indicated otherwise. When required, media were solidified by using 1.5% 
(w/v) agar. The medium was supplemented when indicated with antibiotics at the following 
concentrations: 100 μg/ml ampicillin sodium salt, 50 μg/ml kanamycin sulfate, 30 μg/ml 
chloramphenicol, or 15 μg/ml tetracycline hydrochloride. Plasmids carrying the PBAD promoter 
(2) were induced with L-arabinose at a final concentration of 0.2% (w/v). 
β-galactosidase activity assay 
Whenever the plasmid based reporter system pBBR1MCS-3 XPPX lacZ was used, cells 
were grown over night (o/n) in 100 mM sodium-phosphate buffered Miller modified LB (pH 
5.8), aerobically under agitation at 37 °C. Whenever the E. coli ∆epmA reporter strain (MG-
CL-12-yjeA (8)) was used, cells were grown in potassium buffered KE minimal medium (19) 
pH 5.8, supplemented with 10 mM lysine, 0.2% glycerol and antibiotics in the appropriate 
concentrations. In both cases, the cells were harvested by centrifugation on the next day, 
and the β-galactosidase activities were determined as described (20) and are given in Miller 
units (MU) (21). 
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Protein overproduction and purification for NMR studies 
To obtain labeled proteins for NMR studies, overproductions were performed in M9 glucose 
minimal medium (18) containing either 15N-labeled ammonium chloride alone (pET-SUMO-
efpEcoK34R, pET-SUMO-efpEco P32S, pET-SUMO-efpEco P32S K34R, pET-SUMO-efpPpu), or 
15N-labeled ammonium chloride in combination with 13C labeled glucose (pET-SUMO-
efpEco, pET-SUMO-efpEco loopPpu). The overproduction of these N-terminally His6-SUMO 
tagged hybrid EF-P variants was induced in E. coli BL21 (DE3) by the addition of 1 mM 
isopropyl β-D-1-thiogalactopyranoside (IPTG; Sigma Aldrich) during exponential growth. Till 
the induction point the cells were grown at 37 °C, after IPTG induction the temperature was 
shifted to 18 °C and the cells were grown o/n. On the next day, the cells were harvested by 
centrifugation. The resulting pellet was resuspended on ice in dialysis buffer 1 (100 mM 
Na2HPO4/NaH2PO4, pH 6.5, 1 mM DTT). Cells were lysed using a continuous-flow cabinet 
from Constant Systems Ltd. at 1.35 kb, in combination with sonication. The resulting lysate 
was clarified by centrifugation for 40 minutes at 4 °C at 39,810 x g. The His6-SUMO tagged 
proteins were purified in a first step using (Ni-NTA; Qiagen) according to the manufacturers 
instructions, using 20 mM imidazole for washing and 250 mM imidazole for elution. 
Subsequently, imidazole was removed by dialysis o/n at 4 °C in dialysis buffer 1 (100 mM 
Na2HPO4/NaH2PO4, pH 6.5, 1 mM DTT buffer). Afterwards, the His6-SUMO tag was 
cleaved off using His6-Ulp1 protease (22), followed by a second Ni-NTA purification step to 
remove the His6-SUMO tag itself as well as the His6 tagged Ulp1 protease. As a final step, 
the purified protein was dialyzed again o/n at 4 °C in dialysis buffer 1 (100 mM 
Na2HPO4/NaH2PO4, pH 6.5, 1 mM DTT). 
C-terminally His6-tagged EarPPpu for NMR interaction studies was overproduced in E. coli 
LMG194 cells harboring a pBAD33-earPPpu plasmid in Miller modified LB at 37 °C. During 
exponential growth, 0.2% (w/v) L-arabinose was added to induce the protein production. After 
induction, the temperature was shifted to 18 °C, and the cells were grown o/n. On the next 
day, the cells were harvested by centrifugation. The resulting pellet was resuspended on ice 
in dialysis buffer 2 (100 mM Na2HPO4/NaH2PO4, pH 7.5, 50 mM NaCl, 5 mM DTT). Cell lysis, 
clarification of the lysate and the first Ni-NTA purification step was performed as described 
above. In a final step, the purified protein was dialyzed o/n in dialysis buffer 2 (100 mM 
Na2HPO4/NaH2PO4, pH 7.5, 50 mM NaCl, 5 mM DTT) to remove imidazole from the 
purification step. 
Protein overproduction and purification for in vitro studies 
To obtain EF-P variants for in vitro studies, overproductions were performed in E. coli 
LMG194 cells, grown in Miller modified LB, harboring the following C-terminally His6-tagged 
EF-P constructs:  
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EF-PPpu: pBAD24-efpPpu S30P, pBAD24-efpPpu G31A, pBAD24-efpPpu G31S, pBAD24-efpPpu 
R32K, pBAD24-efpPpu N33G, pBAD24-efpPpu S34Q 
EF-PEco: pBAD24-efpEco K34R, pBAD24-efpEco P32S K34R, pBAD24-efpEco K34R G35N, 
pBAD24-efpEco K34R Q36S, pBAD24-efpEco P32S K34R G35N, pBAD24-efpEco P32S K34R 
Q36S, pBAD24-efpEco K34R G35N Q36S 
Furthermore, C-terminally His6 tagged EarPPpu was overproduced in E. coli LMG194 
harboring pBAD33-earPPpu.  
To overproduce proteins, cells with the corresponding plasmids were grown at 37 °C, and 
during exponential growth, 0.2% (w/v) L-arabinose was added to induce protein production. 
After induction, the temperature was shifted to 18 °C, and the cells were grown o/n. On the 
next day, the cells were harvested by centrifugation and the resulting pellet was resuspended 
in buffer 1 (100 mM Na2HPO4/NaH2PO4, pH 7.5, 50 mM NaCl). Cells were than lysed by 
sonication and the resulting cell lysate was clarified by centrifugation for 40 minutes at 4 °C 
at 39,810 x g. The His6 tagged proteins were then purified using Ni-NTA beads (Qiagen) 
according to the manufacturers instructions, whereby 20 mM imidazole was used for washing 
and 250 mM imidazole for elution of the His6 tagged proteins. Subsequently, imidazole was 
removed by dialysis o/n at 4 °C in buffer 1 (100 mM Na2HPO4/NaH2PO4, pH 7.5, 50 mM 
NaCl), followed by a second dialysis step at the next morning for 5 hours, again in buffer 1 
(100 mM Na2HPO4/NaH2PO4, pH 7.5, 50 mM NaCl). The resulting proteins were than used 
for in vitro rhamnosylation assays. 
Determination of kinetic parameters 
Kinetic parameters were determined by varying TDP-rhamnose concentrations while keeping 
concentrations of EarPPpu (0.1 µM) and unmodified EF-PPpu (2.5 µM) constant. A mixture of 
EarPPpu and unmodified EF-PPpu was equilibrated to 30 °C in 100 mM NaPi pH 7.6. The 
reaction was started by the addition of TDP-rhamnose and was stopped after 20 seconds of 
incubation at 30 °C by the addition of one volume 2x Laemmli buffer (14) and incubation at 
95 °C for 5 minutes. Samples were subjected to SDS-PAGE and rhamnosylated EF-PPpu was 
detected using an Anti-ArgRha antibody (11). A secondary FITC coupled Anti-rabbit antibody 
(Abcam, UK) was used to visualize rhamnosylation in a LI-COR Odyssey CLx. Band 
intensities were quantified using ImageJ (23). Km values were determined by fitting relative 
band intensities to the Michaelis-Menten equation using SigmaPlot. The Km of 5 µM 
TDP-rhamnose was determined using commercially available substrate (Carbosynth, UK). 
Previously, we determined a Km of 50 µM using biochemically synthesized TDP-rhamnose 
(11). After rigorous assessment of this discrepancy we found that contaminations with 
ammonium acetate were responsible for a miscalculation of the TDP-rhamnose 
concentration in stock solutions. We further excluded that these contaminations had an effect 
on the in vitro rhamnosylation reaction. 
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In vitro rhamnosylation 
In vitro rhamnosylation of EF-PEco and EF-PPpu variants were conducted in 100 mM NaPi pH 
7.6 containing 50 mM NaCl. A master mix containing 25 µM of the corresponding EF-P 
variant and 100 µM TDP-β-L-rhamnose was prepared in a reaction tube and divided into 10 
µl aliquots. The reaction was started by addition of 10 µl of 0.5 µM EarP solution and stopped 
after distinct time intervals by addition of 20 µl 2x Laemmli buffer and immediate heating to 
95 °C in an Eppendorf ThermoMixer for 2 minutes. All samples were diluted by a factor of 10 
in 1x Laemmli buffer and 20 µl (corresponding to 0.5 µg of EF-P) were subjected to SDS-
PAGE and Western blotting. Rhamnosylated EF-P was detected and visualized using a 
polyclonal rabbit Anti-ArgRha and a fluorescence labeled Anti-rabbit antibody respectively. 
Band intensities were determined using ImageJ (23). Relative rhamnosylation rates were 
calculated by plotting the normalized linear range (intensity tx/intensitymax) of the timecourse 
experiments and determining the slope of the resulting graphs. 
Bacterial two-hybrid analysis 
Protein-protein interactions were detected using the bacterial adenylate cyclase two-hybrid 
system kit (Euromedex) according to the product manual. The E. coli KV1 strain used in this 
study was generated by start to stop deletion of the cyaA gene from E. coli LF1 and 
subsequent incorporation of the lux operon at the lac locus by using described methods (6). 
Chemically competent E. coli KV1 cells were cotransformed with pKT25-EarPPpu and/or 
variants of pUT18C coding for an EF-P isoform (EF-PPpu, EF-PEco, EF-PEco loopPpu, EF-PEco 
domainIPpu) that was to be tested for interaction. Cells were plated on LB medium containing 
50 µg/ml kanamycin sulfate and 100 µg/ml carbenicillin and incubated at 30 °C o/n. 
Transformants carrying leucine-zipper-reporter hybrids (pUT18-zip and pKT25-zip) were 
used as positive controls, whereas transformants containing pUT18C and pKT25 vector 
backbones served as negative controls. For quantification of interaction strength, cells were 
cultivated in 96-well plates, with each well containing 200 µl of LB medium supplemented 
with 0.5 mM IPTG as well as 50 µg/ml kanamycin sulfate and 100 µg/ml carbenicillin. Plates 
were incubated at 30 °C and under moderate agitation (550 rpm in Eppendorf ThermoMixer) 
for 16 hours. On the next morning, Costar 96Well White plates containing 200 µl of LB 
medium (0.5 mM IPTG, 50 µg/ml kanamycin sulfate, 100 µg/ml carbenicillin) in each well, 
were inoculated with 2 µl of o/n culture and luminescence output was monitored every 10 
minutes for 42 hours in a Tecan Spark with 240 rpm at 30 °C. For detection of protein-protein 
interaction on culture plates, cells were plated on LB plates containing 40 µg/ml 5-bromo-4-
chloro-3-indolyl-β-D-galactopyranoside (X-Gal) and 0.5 mM IPTG as well as 50 µg/ml 
kanamycin sulfate and 100 µg/ml carbenicillin after transformation and incubated at 30 °C 
o/n. Liquid cultures containing 50 µg/ml kanamycin sulfate, 100 µg/ml carbenicillin and 0.5 
mM IPTG were inoculated from single colonies and incubated at 30 °C for 8 hours. 2 µl of 
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liquid culture were spotted on LB plates containing 40 µg/ml 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-Gal) and 0.5 mM IPTG as well as 50 µg/ml kanamycin sulfate and 100 
µg/ml carbenicillin. Pictures were taken after 32 hours of incubation at 30 °C. 
Protein overproduction for isoelectric focusing 
C-terminally His6-tagged EF-PEco was overproduced in E. coli BW25113 and E. coli 
BW25113 ΔepmA cells, harboring the pBAD33-efp-His6 plasmid, and were grown in Miller 
modified LB at 37 °C. Furthermore, E. coli BW25113 was transformed with pBAD33-efp-His6-
epmAB to produce post-translationally modified EF-P. During exponential growth, 0.2% (w/v) 
L-arabinose was added to induce protein production and cells were grown o/n at 18 °C. On 
the next day, cells were harvested by centrifugation. The resulting pellet was resuspended 
on ice in HEPES buffer (50 mM HEPES, 100 mM NaCl, 50 mM KCl, 10 mM MgCl2, 5% (w/v) 
glycerol, pH 7.0). Cells were lysed using a continuous-flow cabinet from Constant Systems 
Ltd. at 1.35 kb. The resulting lysates were clarified by centrifugation for 1.5 h at 4 °C at 
234,998 x g. The His6-tagged proteins were purified using Ni-NTA beads (Qiagen) according 
to the manufacturers instructions, using 20 mM imidazole for washing and 400 mM imidazole 
for elution. In a final step, the purified protein was dialyzed o/n in HEPES buffer to remove 
imidazole from the purification step. 
Isoelectric focusing 
For isoelectric focusing 0.5 µg of protein per lane was loaded on a native vertical isoelectric 
focusing gel with a pH gradient range of 4-7 (SERVAGelTM) containing approximately 3% 
(w/v) SERVALYTTM. Prior to loading, samples were mixed with 2x IEF sample buffer 
according to instructions and wells were rinsed with SERVA IEF Cathode buffer. Focusing 
was conducted for one hour at 50 V, one hour at 300 V and finally bands were sharpened for 
30 min at 500 V. Western blotting was conducted as described above using 0.1 µg/ml Anti-
EF-PEco (Eurogentec). 
NMR Experiments 
All 15N NMR relaxation experiments for EF-P and its variants were performed in 100 mM 
Na2HPO4/NaH2PO4, pH 6.5 and 1 mM DTT. NMR data were recorded at 298 K for ~ 0.15-
0.18 mM of EF-PEco and its variants except for EF-PEco P32S for which data was recorded at 
0.09 mM due to low yields of expression. Pulse experiments were performed on an 800 MHz 
Bruker Avance III NMR spectrometer equipped with TXI cryogenic probehead. Amide 15N 
relaxation data of R1, R2, and steady-state heteronuclear {
1H}–15N-NOE experiments were 
performed as described (24, 25) T1 data were measured with 11 different relaxation delays: 
20, 50, 100, 150, 250, 400, 500, 650, 800, 1000, and 1300, where 150 ms was used as 
duplicate. T2 data were determined by using eight different relaxation delays: 16, 32, 48, 64, 
80. 96, 112, and 128 ms using 16 ms as duplicate. Duplicate time points were used for error 
estimation. The correlation time (τc) of the protein molecule was estimated using the ratio of 
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averaged T2/T1 values (24). Steady-state heteronuclear {
1H}–15N-NOE experiments were 
recorded with and without 3 s of 1H saturation. All relaxation experiments were acquired as 
pseudo-3D experiments. The spectra were processed with NMRPipe (26) and peak 
integration and relaxation parameter calculation was performed using PINT (27). 
For the titration of EF-PEco and its variants with 2x EarPPpu, both the proteins were dialyzed 
against 100 mM Na2HPO4/NaH2PO4, pH 7.5, 50 mM NaCl and 1 mM DTT. Experiments were 
recorded on an 800 MHz Bruker NMR spectrometer equipped with a TXI cryogenic 
probehead at 298 K. Protein backbone assignments for EF-PEco and EF-PEco loopPpu were 
obtained from HNCACB, CBCA(CO)NH and HNCA experiments (28). Data analysis was 
performed in CcpNmr Analysis software (29). Resonance assignments of EF-P variants have 
been deposited at the BMRB with the following accession codes: XXX. 
Bioinformatics software 
Multiple sequences alignments (MSA) were built using MAFFT software (version 7.394, 
algorithm “l-ins-i”) (30). HMMER web-server was used to predict domain architecture of the 
proteins (31). Phylogenetic trees were built using FastTree tool (32) with default settings and 
visualized using ggtree package in R (33). Sequence logos were built using ggseqlogo 
package in R (34). 
Collection of the data for evolutionary analysis 
EF-P/IF5A, EpmA, EpmB, EpmC and EarP sequences were collected by extracting 
sequences that belong to specific family from databases and additional filtration. 
Proteins with EF-P_N Superfamily domain were extracted from Pfam database as the initial 
set of EF-P/IF5A (35). We have filtered out sequences that: (1) don’t belong to the fully 
sequenced genomes [ftp://ftp.ncbi.nlm.nih.gov/genomes/GENOME_REPORTS/], (2) are 
marked in UniProtKB (36) as obsolete or fragments, (3) have “Uncertain” protein existence 
levels (UniProtKB notation), (4) have no gene name in their UniProtKB entry, (5) belong to 
the outliers of the lengths distribution in the protein family, (6) are missing the function 
GO:0003746 “translation elongation factor activity”. In some species EF-P has nonfunctional 
paralogous protein - YeiP (Elongation factor P-like protein). All proteins that are encoded by 
‘yeiP’ or ‘elongation factor P-like protein’ genes and sequences that share average identity 
with YeiP proteins more than 0.26 (excluding gaps) were removed. Functional EF-P is known 
to have 2 OB-Fold domain, while functional IF5A should have 1 OB-Fold domain (37). 
Number of OB-Fold domains in the sequences was predicted by hmmscan. All IF5A with no 
predicted OB-domains were removed. IF5A with 2 OB-domains (with exception for those that 
are localized in chloroplasts) also were removed. EF-P containing 1 or 0 OB-domains were 
also removed, except those EF-P that belong to the genomes with a second copy of EF-P 
with 2 OB-domains. Sequences A0A0S8CMN6, Q3Z8J4, Q2Y9K0, A0A0C3RPA1, 
A0A0F7KHW6, A0A0S8CBC3, A0A0S8DH18, C7NBD9, U2STQ5, C9MW58, A0A0X8JVW4, 
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A0A0E3ZAU2, D0GJB3, D1AKL3, D1AYT5, A0A0F9ZIK0, A0A0G0Q7K6 were excluded 
from the data set for weblogo building because of their untypical loop regions that bring gaps 
into the MSA of EF-P_N domains. 
Sequences containing tRNA-synthetase II domain were downloaded from Pfam database, as 
this is the only domain that EpmA proteins are known to have. Sequences were filtered using 
(1) - (5) criteria. MSA and phylogenetic tree for the remaining sequences were built and the 
branch with sequences that are encoded by epmA genes (gene name ‘epmA’, ‘genX’ , ‘yjeA’ 
or ‘poxA’  in UniProtKB) was taken as the set of EpmA proteins. 
EpmB proteins are part of lysine aminomutases (LAMs) family that was downloaded from 
InterPro database (35). Initial filters (1) - (5) were applied to this dataset. Sequences without 
predicted Radical_SAM domain or with predicted full LAM_C domain were removed from the 
data set. 
EpmC and EarP sequences were extracted from Pfam database by EpmC and DUF2331 
domains, correspondingly, and additionally filtered by (1) - (3) criteria. 
Final sets of EF-P/IF5A, EpmA, EpmB, EpmC and EarP count 4421, 858, 4894, 317 and 306 
proteins, respectively (Table S1). 
Evolutionary analysis 
Phylogenetic tree of EF-P/IF5A proteins was built from MSA of the EF-P_N Superfamily 
domain sequences. The belonging of EF-P/IF5A and modification system proteins to the 
same genome was determined by the NCBI Taxonomy IDs corresponding to the sequences. 
EF-P/IF5A, EpmA, EpmB, EpmC and EarP proteins belonged to 4169, 845, 3976, 308 and 
302 genomes, respectively. Among the genomes encoding EF-P/IF5A proteins 808, 773, 300 
and 294 genomes also encoded EpmA, EpmB, EpmC and EarP, respectively (Table S1 and 
Figure S1B). 
Evolutionary reconstruction 
Using the MSA of the EF-P KOW-like N-domain I a rooted phylogenetic tree was built using 
the phylogeny tool from MAFFT online server (UPGMA algorithm with default settings) (30). 
The leafs of the tree were mapped to three states: ’EpmA’, ’EarP’ and ’-’ (no modification 
enzymes), representing the presence/absence of the modification proteins. The evolutionary 
state reconstruction of ancestral states was done using the maximum likelihood (ML) method 
from the phytools R package (38). The phylogenetic tree annotated with the likelihood of 
ancestral states was visualized using phytools. The area of the surface colored with the 
certain color represents the predicted probability of the ancestor to have the certain state. 
Using the same method, an evolutionary reconstruction of the K34R substitution was 
performed. The leafs of the tree were mapped to amino acids observed at the 34th position: 
A, G, H, K, M, N, Q, R and S. E. coli EF-P was used as reference sequence. 
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Supplementary Tables 
Supplementary Table S1. Strains used in this study. 
Stain Relevant genotype or description Reference or source 
E. coli DH5αλpir F
- 
80lacZΦM15 (lacZYA-argF)U196 recA1 hsdR17 deoR 
thi-1 supE44 gyrA96 relA1/pir 
1 
E. coli BW25113 
F
-
 λ - ∆(araD-araB)567 ∆lacZ4787(::rrnB-3) rph-1 ∆(rhaD-
rhaB)568 hsdR514 
2 
E. coli MG1655 wild-type; F- lambda- ilvG rfb50 rph-1 
3 
Salmonella enterica Serovar Typhimurium LT2 ATCC 19585 
Vibrio cholera C6706 
O1 El Tor isolate from Peru Centers for Disease Control and 
Prevention (CDC) 
E. coli LF1 
F
-
 - ilvG rfb50 rph-1 rpsL150 Plac::rpsL-neo-kan::lacZ
∆1-
100bp
, Kan
r
, Strp
s
 
4
 
E. coli LF1-LacZ-K 
Derivative from E. coli LF1, contains an insertion of a 
lysine codon (AAA) after position 9 of the lacZ gene, 
Kan
s
 Str
r
 
this study 
E. coli LF1-LacZ(Am) 
Derivative from E. coli LF-1, contains an insertion of an 
amber codon (TAG) after position 9 of the lacZ gene, 
Kan
s
, Str
r
 
this study 
E. coli LF1-LacZ-PPK 
Derivative from E. coli LF1, contains an insertion of a 
proline-proline-lysine motif (CCG CCG AAA) after 
position 9 of the lacZ gene, Kan
s
, Str
r
 
this study 
E. coli LF1-LacZ-PP(Am) 
Derivative from E. coli LF1, contains an insertion of a 
proline-proline-amber motif (CCG CCG TAG) after 
position 9 of the lacZ gene, Kan
s
, Str
r
 
this study 
E. coli LF1-AcKRST 
Derivative from E. coli LF1, contains the acetyl lysyl-
tRNA-synthetase (AcKRS), a mutated version of the 
PylRS from Methanosarcina mazei towards N
ε
-acetyl 
lysine specificity, according to Umehara et al.
5
 and the 
cognate amber suppressor tRNACUA (pylT), Kan
s
, Str
r
 
this study 
E. coli LF1-AcKRST/dapA:cam
r
 
Derivative from E. coli LF1-AcKRST were the dapA gene 
was replaced by a chloramphenicol resistance cassette 
using λ-RED recombinase, Camr 
this study 
 
  
Supplementary Table S2. Plasmids used in this study. 
Plasmid Features References 
pBBR1MCS-2 Broad-host-range cloning vector, 5.1 kb, ND
a
; Kan
r
 
6
 
pBBR1MCS-3 Broad-host-range cloning vector, 5.2 kb, ND
a
; Tet
r
 
6
 
pBBR1MCS-4 Broad-host-range cloning vector, 5.0 kb, ND
a
; Amp
r
 
6
 
pBBR1MCS-5 Broad-host-range cloning vector, 4.9 kb, ND
a
; Gm
r
 
6
 
pBBR1MCS-2 AcKRST 
Broad-host-range cloning vector, Contains the acetyl lysyl-
tRNA synthetase (pylS*) under control of PglnS and the 
suppressor tRNACUA (pylT) under the control of PproK, inserted 
into the NsiI restriction site, 6.8 kb, ND
a
; Kan
r
 
this study 
pBBR1MCS-3 AcKRST 
Broad-host-range cloning vector. Contains the acetyl lysyl-
tRNA synthetase (pylS*) under control of PglnS and the 
suppressor tRNACUA (pylT) under the control of PproK, inserted 
into the AgeI restriction site, 6.9 kb, ND
a
; Tet
r
  
this study 
pBBR1MCS-4 AcKRST 
Broad-host-range cloning vector. Contains the acetyl lysyl-
tRNA synthetase (pylS*) under control of PglnS and the 
suppressor tRNACUA (pylT) under the control of PproK, inserted 
into the NsiI restriction site, 6.6 kb, ND
a
; Amp
r
 
this study 
pBBR1MCS-5 AcKRST 
Broad-host-range cloning vector. Contains the acetyl lysyl-
tRNA synthetase (pylS*) under control of PglnS and the 
suppressor tRNACUA (pylT) under the control of PproK, inserted 
into the NsiI restriction site, 6.5 kb, ND
a
; Gm
r
 
this study 
pBBR1MCS-5 TT-RBS-lux 
PCR template for the amplification of the lux operon 
luxCDABE from Photorhabdus luminescens, ND
a
; Gm
r
 
7
 
pBAD/HisA 
pBR322-derived expression vector, contains the promotor 
PBAD of the arabinose operon araBAD from E. coli and its 
regulatory gene araC, 4.1 kb, Amp
r
 
Invitrogen 
pBAD/HisA-Lux 
Contains the lux operon inserted into the NcoI / KpnI restriction 
sites, 9.8 kb, Amp
r
 
this study 
pBAD/HisA-Lux(Am) 
Contains the lux operon with an amber codon (TAG) in luxC at 
position 3, inserted into the NcoI / BsrGI restriction sites of 
pBAD/HisA-Lux, 9.8 kb, Amp
r
 
this study 
pBAD/HisA-Lux(2Am) 
Contains the lux operon with two amber codons (TAG) in luxC 
at position 3, inserted into the NcoI / BsrGI restriction sites of 
pBAD/HisA-Lux, 9.8 kb, Amp
r
 
this study 
pBAD/HisA-Lux-RA(Am) 
Contains the lux operon with an arginine alanine amber motif 
(CGG GCT TAG) in luxC at position 3, inserted into the NcoI / 
BsrGI restriction sites of pBAD/HisA-Lux, 9.8 kb, Amp
r
  
this study 
pBAD/HisA-Lux-DA(Am) 
Contains the lux operon with an aspartic-acid alanine amber 
motif (GAT GCT TAG) in luxC at position 3, inserted into the 
NcoI / BsrGI restriction sites of pBAD/HisA-Lux, 9.8 kb, Amp
r
 
this study 
pBAD/HisA-Lux-HH(Am) 
Contains the lux operon with an histidine histidine amber motif 
(CAC CAC TAG) in luxC at position 3, inserted into the NcoI / 
BsrGI restriction sites of pBAD/HisA-Lux, 9.8 kb, Amp
r
 
this study 
pBAD/HisA-Lux-KDP(Am) 
Contains the lux operon with an lysine aspartic-acid proline 
amber motif (AAA GAT CCG TAG) in luxC at position 3, 
inserted into the NcoI / BsrGI restriction sites of pBAD/HisA-
Lux, 9.8 kb, Amp
r
 
this study 
pBAD/HisA-Lux-PP(Am) 
Contains the lux operon with an proline amber motif (CCG 
TAG) in luxC at position 3, inserted into the NcoI / BsrGI 
restriction sites of pBAD/HisA-Lux, 9.8 kb, Amp
r
 
this study 
pBAD/HisA-Lux-KDPP(Am) 
Contains the lux operon with an lysine aspartic acid proline 
proline amber motif (AAA GAT CCG CCG TAG) 
in luxC at position 3, inserted into the NcoI / BsrGI restriction 
sites of pBAD/HisA-Lux, 9.8 kb, Amp
r
 
this study 
pNL1.1 
PCR template for amplification of NanoLuc® (Nluc), 3.1 kb, 
Amp
r
 
Promega 
pBBR1MCS-2 AcKRST Nluc 
Derived from pBBR1MCS-2 AcKRST, contains Nluc under 
control of PBAD inserted into the XbaI / KpnI restriction sites, 
8.7 kb, Kan
r
 
this study 
pBBR1MCS-2 AcKRST 
Nluc(Am) 
Derived from pBBR1MCS-2 AcKRST, contains Nluc under 
control of PBAD inserted into the XbaI / KpnI restriction sites, 
insertion of an amber codon in Nluc at position 3, 8.7 kb, Kan
r
 
this study 
pBBR1MCS-2 AcKRST Nluc 
PP(Am) 
Derived from pBBR1MCS-2 AcKRST, contains Nluc under 
control of PBAD inserted into the XbaI / KpnI restriction sites, 
insertion of an proline proline amber motif in Nluc at position 3, 
8.7 kb, Kan
r
 
this study 
pBAD/HisA-Kan 
pBAD/HisA (Invitrogen) derived expression vector, the 
ampicillin resistance cassette (bla) was replaced with a 
this study 
kanamycin resistance cassette from pBBR1MCS-2, 4.2 kb, 
Kan
r
 
pBAD/HisA-Kan Lux 
Derived from pBAD/HisA (Kan), contains the lux operon 
inserted restriction free, 9.8 kb, Kan
r
 
this study 
pBAD/HisA-Kan-Lux(Am) 
Derived from pBAD/HisA (Kan), contains the lux operon 
inserted restriction free, insertion of an amber codon (TAG) in 
luxC at position 3, 9.8 kb, Kan
r
 
this study 
pBAD/HisA-dapA 
Contains dapA inserted between the XhoI / EcoRI restriction 
sites, 5.0 kb, Amp
r
 
this study 
pBAD/HisA-dapA(Am) 
Derived from pBAD/HisA-dapA, contains dapA with an amber 
codon on position 3 of the dapA open reading frame, inserted 
between the XhoI / EcoRI restriction sites, 5.0 kb, Amp
r
 
this study 
pACYCDuet
TM
-1 Standard expression vector, ORI P15A, 4 kb, Cam
r
 Novagen 
pACYCDuet-PylRST 
Contains the pyrrolysyl-tRNA-synthetase (PylRS) / cognate 
amber suppressor tRNACUA (pylT) 
 
pair from Methanosarcina 
mazei, 5.5 kb, Cam
r
 
8
 
pACYCDuet-AcKRST 
Contains the acetyl lysyl-tRNA-synthetase (AcKRS), a mutated 
version of the PylRS from Methanosarcina mazei towards N
ε
-
acetyl lysine specificity, according to Umehara et al.
5
 and the 
cognate amber suppressor tRNACUA (pylT), 5.5 kb, Cam
r 
this study 
pRed/ET λ-RED recombinase in pBAD24; Ampr Gene Bridges 
a
 ND, the incompatibility group of pBBR1 MCS plasmids has not been defined 
9
; compatible with IncP, IncQ and IncW group 
plasmids, as well as ColE1- and P15a-based replicons 
6
. Amp
r
, Cam
r
, Kan
r
, Tet
r
, Gm
r
 and Str
r
 are ampicillin, chloramphenicol, 
kanamycin, tetracycline, gentamycin, and streptomycin resistance, respectively. 
 
  
Supplementary Table S3. Primers used in this study. 
Primer name Sequence Restriction site  Reference 
Sequencing and control primers 
AcKRS chk fw AAT AAG TTC CTC ACA AAG GCA AAC GAA GAC  this study 
pBBR1MCS245 NsiI chk rev CAA GGC GAC AAG GTG CTG ATG  this study 
pBBR1MCS3 AgeI chk rev TGC GAT GAG TGG CAG GGC GGG GC  this study 
Seq33 fw-100 GGC GTC ACA CTT TGC TAT GC  
10
 
AraC chk fw CCT GAC CGC GAA TGG TGA GAT TGA GA  this study 
Ara Prom chk fw CTG ACG CTT TTT ATC GCA ACT CTC TAC TG  this study 
dapA chk fw CAT GAA GCT CCG CAA GCG GT  this study 
dapA chk rev CAC CAG ATA ATG TTG CGA TGA CAGT  this study 
Primers to generate a mutated version of the PylRS from Methanosarcina mazei towards Nε-acetyl lysine specificity 
(AcKRS). Described primers a directly derived from the library primers described by Umehara et al.
5
 
AcKRS L301M Y306L L309A OL fw 
AGA ACT TCT GCC TGA GAC CCA TGA TGG CTC 
CAA ACC TTC TGA ACT ACG CGC GCA AGC TTG 
ACA GGG CCC 
 
this study 
AcKRS L301M Y306L L309A OL rev 
GGG CCC TGT CAA GCT TGC GCG CGT AGT TCA 
GAA GGT TTG GAG CCA TCA TGG GTC TCA GGC 
AGA AGT TCT 
 
this study 
AcKRS C348F OL fw CAT GCT GAA CTT CTT TCA GAT GGG ATC G  this study 
AcKRS C348F OL rev CGA TCC CAT CTG AAA GAA GTT CAG CAT G  this study 
MPYSf TTT CCC TGA ATT CCG GCA AGC  
5
 
AcKRS rev 
ATC GGC GAG AAA GTC AGC AGG CCG CGC GGC 
CGC TTA CAG GTT GGT AGA AAT CCC GTT ATA 
GTA AGA CTC 
 
this study 
Primers for Lux reporter constructs 
KpnI LuxE rev 
GCT TCG AAT TCC CAT ATG GTA CCT TAT CAA 
ACG CTT CGG TTA AGC TCA A 
KpnI this study 
NcoI LuxC-wt fw 
CTA ACA GGA GGA ATT AAC CAT GGG CAC TAA 
AAA AAT TTC ATT CAT TAT TAA CGG CCA G 
NcoI this study 
NcoI LuxC:Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CTA GAC 
TAA AAA AAT TTC ATT CAT TAT TAA CGG CCA 
G 
NcoI this study 
NcoI LuxC:2Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CTA GTA 
GAC TAA AAA AAT TTC ATT CAT TAT TAA CGG 
CCA G 
NcoI this study 
NcoI LuxC:RA Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CCG GGC 
TTA GAC TAA AAA AAT TTC ATT CAT TAT TAA 
CGG CCA G 
NcoI this study 
NcoI LuxC:DA Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CGA TGC 
TTA GAC TAA AAA AAT TTC ATT CAT TAT TAA 
CGG CCA G 
NcoI this study 
NcoI LuxC:HH Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CCA CCA 
CTA GAC TAA AAA AAT TTC ATT CAT TAT TAA 
CGG CCA G 
NcoI this study 
NcoI LuxC:KDP Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CAA AGA 
TCC GTA GAC TAA AAA AAT TTC ATT CAT TAT 
TAA CGG CCA G 
NcoI this study 
NcoI LuxC:PP Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CCC GCC 
GTA GAC TAA AAA AAT TTC ATT CAT TAT TAA 
CGG CCA G 
NcoI this study 
NcoI LuxC:KDPP Am fw 
CTA ACA GGA GGA ATT AAC CAT GGG CAA AGA 
TCC GCC GTA GAC TAA AAA AAT TTC ATT CAT 
TAT TAA CGG CCA G 
NcoI this study 
LuxC rev TCA AAA TCT TTT TTG GCA TTC GGT  this study 
Primers for E. coli LF1 LacZ XXX strain construction and verification 
lacI 583bp sense GTC TGC GTC TGG CTG GCT GGC ATA  
4
 
lacZ 500bp anti CGA CTG TCC TGG CCG TAA CCG ACC  
4
 
lacZ 220bp anti AGC TTT CCG GCA CCG CTT CTG  
4
 
LacZ-K-OL-fw TCA CTG GCC AAA GTC GTT TTA C  this study 
LacZ-K-OL-rev GTA AAA CGA CTT TGG CCA GTG A  this study 
LacZ-PPK-OL-fw TCA CTG GCC CCG CCG AAA GTC GTT TTA C  this study 
LacZ-PPK-OL-rev GTA AAA CGA CTT TCG GCG GGG CCA GTG A  this study 
LacZ-Am-OL-fw TCA CTG GCC TAG GTC GTT TTA C  this study 
LacZ-Am-OL-rev GTA AAA CGA CCT AGG CCA GTG A  this study 
LacZ-PPAm-OL-fw TCA CTG GCC CCG CCG TAG GTC GTT TTA C  this study 
LacZ-PPAm-OL-rev GTA AAA CGA CCT ACG GCG GGG CCA GTG A  this study 
Primers for E. coli LF1-AcKRST strain construction 
Plac-AcKRST-OL-fw GGA AAC AGC TAT GGA TAA AAA ACC ACT AAA  this study 
CAC TCT GAT A 
Plac-AcKRST-OL-rev 
GGT TTT TTA TCC ATA GCT GTT TCC TGT GTG 
AAA TTG TTA TCC 
 
this study 
Plac-OL-sRBS-lacZ-fw 
ACA AAT ACA ATA AAT AAA GTA AGG AGG TAC 
ATT ATG ACC ATG ATT ACG GAT TCA CTG GCC 
G 
 
this study 
Plac-AcKRST-OL-sRBS-lacZ-rev 
AAT GTA CCT CCT TAC TTT ATT TAT TGT ATT 
TGT GCA AAA AAG CCT GCT CGT TGA GC 
 
this study 
Primer for E. coli LF1-AcKRST/dapA:cam
r
 strain construction 
FRT dapA fw 
CCA GGC GCG ACT TTT GAA CAG AGT AAG CCA 
TCA AAT CTC CCT AAA CTT TAA ATT AAC CCT 
CAC TAA AGG GCG 
 
this study 
FRT dapA rev 
CAT ACC AAA CGT ACC ATT GAG ACA CTT GTT 
TGC ACA GAG GAT GGC CCA TGT AAT ACG ACT 
CAC TAT AGG GCT C 
 
this study 
Primers for dapA constructs    
dapA EcoRI fw 
CCG GAA TTC TTA CAG CAA ACC GGC ATG CTT 
AAG 
EcoRI 
this study 
dapA XhoI rev 
CCG CTC GAG ATG TTC ACG GGA AGT ATT GTC 
GCG 
XhoI 
this study 
Amber dapA XhoI rev 
CCG CTC GAG ATG TTC TAG GGA AGT ATT GTC 
GCG 
XhoI 
this study 
Primers for broad-host-range cloning vectors 
AcKRST NsiI fw 
TGC ATG CAT TCA TCA ATC ATC CCC ATA ATC 
CTTG 
NsiI this study 
AcKRST NsiI rev 
TGC ATG CAT GCA AAA AAG CCT GCT CGT TGA 
GCA G 
NsiI this study 
AcKRST BspEI fw 
GGC ATT CTC CGG ATC ATC AAT CAT CCC CAT 
AAT CCT TG 
BspEI this study 
AcKRST BspEI rev 
GGC ATT CTC CGG AGC AAA AAA GCC TGC TCG 
TTG AGC AG 
BspEI this study 
Primers for resistance cassette exchange in pBAD/HisA 
pBAD/HisA amp kan ex fw 
TAT ATG AGT AAA CTT GGT CTG ACA GTC AGA 
AGA ACT CGT CAA GAA GGC GA 
 
this study 
pBAD/HisA amp kan ex rev 
CTT TTT GTT TAT TTT TCT AAA TAC ATA GCT 
TGC AGT GGG CTT ACA TGG CG 
 
this study 
Primers for NanoLuc
®
 reporter constructs 
Ara XbaI fw TGC TCT AGA TTA TGA CAA CTT GAC GGC TAC XbaI this study 
Ara Nluc OL rev CAT GGT TAA TTC CTC CTG TTA GC  this study 
Ara Nluc OL fw 
GCT AAC AGG AGG AAT TAA CCA TGG TCT TCA 
CAC TC 
 this study 
Ara Nluc am OL fw 
GCT AAC AGG AGG AAT TAA CCA TGG GCT AGG 
TCT TCA CAC TCG AAG AT 
 this study 
Ara Nluc am PP OL fw 
GCT AAC AGG AGG AAT TAA CCA TGG GCC CGC 
CGT AGG TCT TCA CAC TCG AAG AT 
 this study 
Nluc KpnI rev CGG GGT ACC TTA CGC CAG AAT GCG TTC KpnI this study 
 
  
Supplementary Table S4. Amber suppression in Salmonella enterica LT2 (A) and Vibrio 
cholerae El Tor C6706 (B). Cells were grown aerobically overnight at 37 °C in LB and on the 
next day, luminescence production in response to Nε-acetyl-L-lysine (AcK) and L-arabinose 
(Ara) was measured for the reporter pBBR1MCS-2 AcKRST Nluc, pBBR1MCS-2 AcKRST 
NlucAm and pBBR1MCS-2 AcKRST NlucPP(Am), using the Nano-Glo® luciferase assay system. 
 
  
Supplementary Figures 
 
Supplementary Figure S1. Influence of Nε-acetyl-L-lysine (AcK) on the doubling time of E. coli 
BW25113 during exponential growth. Cells were grown in LB in the absence (- AcK) and in the 
presence of 1 mM AcK (+ 1 mM AcK). Error bars represent the standard deviation of data from 
three different experiments. 
 
Supplementary Figure S2. Luminescence production of Lux+ (A) and LuxAm (B) in E. coli 
BW25113 in response to L-arabinose (Ara) and of Nε-acetyl-L-lysine (AcK). The maximal 
luminescence normalized to the OD600 from a 16 h time course experiment is depicted in 
response to Ara and AcK for Lux+ (A) and LuxAm (B). Error bars represent the standard deviation 
of data from three different experiments. 
 
 
Supplementary Figure S3. Comparison of PylRS and AcKRS based amber suppression. E. coli 
BW25113 cells were transformed with the Lux-amber reporter (LuxAm) in combination with either 
pACYCDuet-AcKRST (encoding the acetyl lysyl-tRNA synthetase/tRNACUA pair, AcKRST), 
pACYCDuet-PylRST (encoding the pyrrolysyl-tRNA synthase/tRNACUA pair, PylRST) or the 
empty vector (e.v.) as negative control. These cells were grown aerobically in LB supplemented 
with 0.2% (w/v) L-arabinose (Ara) at 37°C in a microtiter plate within a Tecan Infinite® F500 
system (TECAN). The maximal luminescence production in response to Nε-acetyl-L-lysine (AcK) 
and Nε-tert-butoxycarbonyl-L-lysine (BocK) normalized to the OD600 from a 16 h time course 
experiment is depicted. Error bars represent the standard deviation of data from three different 
experiments. 
 
 
Supplementary Figure S4. Influence of the chromosomal integration of the acetyl lysyl-tRNA 
synthetase/tRNACUA pair (AcKRST) on cell growth. E. coli MG1655, LF1 and LF1-AcKRST were 
grown aerobically at 37°C in a microtiter plate within a Tecan Infinite® F500 system (TECAN) in 
LB. Error bars represent the standard deviation of data from three different experiments. 
 
Supplementary Figure S5. Determination of the minimal diaminopimelic acid (DAP) 
concentration required for the growth of the dapA deficient LF1-AcKRST/dapA:camr strain. 
Depicted are cells grown for 16h at 37 °C aerobically in a microtiter plate in LB, supplemented 
with varying DAP concentrations ranging from 600 µM to 0 µM. 
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Tatjana, für die tollen Rahmenbedingungen auf dem ganzen Stockwerk und Grazyna für die 
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Ganz besonders danke ich meiner Familie. Während der gesamten Zeit meines Studiums und meiner 
Promotion konnte ich mir der Unterstützung meiner Eltern Claudia und Ulrich stets sicher sein. 
Meinem Bruder Jonas: Danke, dass man sich auf dich verlassen kann. Meiner Oma Erna: Jetzt ist es 
endlich geschafft, vielen Dank fürs Mitfiebern! Meiner lieben Lisa: Tausend Dank für deine Ruhe und 
deine Geduld, für deine Unterstützung und deine Motivationskünste. Danke, dass du immer für mich 
da bist!   
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